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Abstract 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which has a devastating 
impact on the lives of patients, characterised primarily by the loss of dopamine-producing 
neurons in the brain.  Drug delivery to the mammalian brain is notoriously difficult due to the 
physical and chemical restrictions presented by the blood brain barrier (BBB), a major 
contributing factor to the lack of disease-modifying treatments currently available for PD.  This 
means that recovery from PD is not currently possible and clinical treatment is aimed at 
controlling symptom progression. 
Neurotrophic factors (NTF) are promising treatments for the regeneration of dopaminergic (DA) 
neurons and offer the possibility of functional recovery in PD.  However, the short half-life of NTF 
and invasive means of administration are limiting features in clinical trials of such promising 
treatments.  Endogenous receptors expressed at the BBB and throughout the central nervous 
system (CNS) might present viable targets for achieving highly effective drug delivery to the brain 
in a non-invasive manner via peptide ligand-facilitated transport.  Rabies virus-derived peptide 
(RDP) is a 39-amino acid derivative of the rabies virus glycoprotein (RVG) which has shown 
promise as an in vivo brain targeting ligand.  RDP has gained attention for features such as 
neural cell targeting specificity and in vivo safety, making it an attractive ligand for development 
within brain delivery systems.  
The experimental work reported herein describes the formulation and characterisation of RDP-
conjugated polymeric nanoparticles (NP), which exhibited enhanced payload accumulation in 
neural cell types. It was demonstrated that cellular uptake was mediated by the neuronal nicotinic 
acetylcholine receptor (nAchR) specifically.  RDP optimisation studies lead to the development 
of a smaller 18-amino acid analogue of RDP termed DAS, which showed enhanced serum 
stability whilst retaining neural-specific activity when tested in various cell types in vitro.  A 
human-derived in vitro BBB model was designed and developed using a triple culture of brain 
microvascular endothelial cells (HBMVEC), astrocytes and pericytes. Transport studies using 
this BBB model revealed the significant targeting advantage of both RDP and DAS ligands 
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(compared to the unlabelled NP) in the ability to deliver a payload across this simulated biological 
barrier 
RDP and derivatives such as DAS may offer a solution to the challenge of delivering therapeutics 
across the BBB.  The development of a nanoparticulate drug delivery system decorated with an 
RDP derivative offers specific, non-invasive targeting to the brain alongside protection of 
unstable or sensitive cargo.  Such drug delivery systems may be beneficial for the treatment of 
PD, as a means of depositing regenerative NTF directly to the diseased brain. 
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1.1.  Parkinson’s Disease 
 
1.1.1.  Neurodegeneration in Parkinson’s Disease 
 
In an 1817 essay, James Parkinson described a “shaking palsy” which often started in the hands 
and arms before spreading to the legs (Obeso et al., 2017).  Nowadays, we know this condition 
as Parkinson’s Disease (PD).  In the UK, 1 in 37 people will be diagnosed with PD during their 
lifetime.  Over 135 000 diagnoses of PD were reported for the UK in 2015, however this is 
projected to double by 2065 (Parkinson’s UK, 2017).  PD is more prevalent in the male and 
ageing populations, affecting 2% of those over 60 years old (Kalia & Lang, 2015) and is the 
second most common neurodegenerative disorder after Alzheimer’s Disease (Bauer & 
Przedborski, 2003).  PD affects the central nervous system (CNS), leading to a range of 
complications which progressively worsen with time.   
Primarily characterised by the loss of dopaminergic (DA) neurons in the Substantia Nigra pars 
compacta (SNpc) region of the brain (Dawson & Dawson, 2003), this pathological event results 
in decreased output of the neurotransmitter, dopamine, along the nigrostriatal pathway (Figure 
1.1).  This pathway normally supplies the striatum region of the brain with dopamine, which is 
required for various functions associated with motor control.  The gradual depletion in striatal 
dopamine causes impairment of motor function, resulting in many symptoms which can be 
classified as motor and non-motor symptoms.  The striatum is best known for its essential role 
in voluntary motor control and is the major input source for the basal ganglia.  However, it is also 
responsible for the integration of movement and reward responses in the brain, which can be 
linked to social behaviours (Baez-Mendoza & Schultz, 2013).  Fully functioning striatal neurons 
in the healthy brain enable the planning, initiation and execution of movement in response to 
dopamine input (Tewari et al., 2016), which originates from the large, dopamine-containing 
neurons in the SNpc (Singer et al., 2010).  It is when these cells of the SNpc are progressively 
depleted, that PD onset occurs.  However, clinical manifestation of symptoms does not occur 
3 
 
until 50-70% of SNpc dopaminergic neurons are lost (Cheng et al., 2010).  This greatly limits the 
chance of early detection in patients and is the most important factor for preventing life-
threatening complications of the disease.   
 
 
 
 
Figure 1.1.  Simplified diagram of the human brain showing the anatomical location of the substantia nigra 
pars compacta (SNpc) (red) which is responsible for dopamine input to the striatum via the 
nigrostriatal pathway (green).  Dopamine is a neurotransmitter in the brain involved in 
movement and reward pathways.  Degeneration of dopaminergic (DA) neurons in the SNpc 
results in impaired motor control, the main symptom of Parkinson’s disease. 
 
 
1.1.2.  PD symptoms  
 
The symptoms of PD can be divided into two classes: motor and non-motor.  Impairment of motor 
control, induced by considerable nigrostriatal dopamine depletion, is often the symptom first 
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detected by patients which leads to clinical diagnosis.  This can manifest in several ways, 
including development of symptoms such as tremor, gait difficulties, postural instability, 
bradykinesia, speech impairment, stiffness and muscle rigidity (Lescaudron et al., 2012).  PD is 
well-characterised by these motor symptoms; however non-motor symptoms often precede the 
onset of compromised motor control by many years (Marras & Chaudhuri, 2016).  At some stage 
during their disease progression, 90% of patients experience loss of olfaction (sense of smell) 
as the most common non-movement related symptom (Pfeiffer, 2016).  Other common 
symptoms include severe constipation and sleep disorders.  In addition to this, depression and 
anxiety often occurs as a preceding symptom in around 30% of clinically diagnosed patients 
(Reijinders et al., 2009).  These symptoms are difficult to detect in relation to PD and can quite 
easily be mistaken for many other common clinical conditions.  In late stages of the disease, 
urinary dysfunction and orthostatic hypotension almost universally affect all patients, with a 
further 30-40% experiencing onset of dementia (Poewe, 2008).   
In addition to parkinsonian symptoms, PD patients often suffer many debilitating side effects from 
current first-line treatment options such as hallucinations, psychosis, impulsive behaviours and 
further motor complications such as dyskinesias.  Due to the widespread effects of this 
neurological disease throughout the whole body, quality of life can be severely compromised, 
particularly in the later stages.  All aspects of the disease are difficult to manage, often requiring 
multiple medications for PD symptom control in addition to managing treatment-induced side 
effects.  The use of polypharmacy greatly enhances the risk of adverse drug reactions.  Often, 
risk-benefit approaches must be used to ensure the patient’s quality of life is maintained as far 
as is practicable. Consequently, those responsible for patient care must prioritise treatment of 
different symptoms and patients may be required to tolerate certain side effects to maintain motor 
control. 
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1.1.3.  PD pathology 
 
Currently, the aim is to slow disease progression, however it is not reversible. At the point of 
clinical presentation, disease progression is believed to be too far advanced to benefit from 
neuroprotective treatments (Noyce et al., 2016).   There is a vast range of clinical symptoms 
which PD patients may experience to differing extents and severities, reflecting the rate of 
disease progression which can be different for everyone.  The complexity of this disease and its 
symptoms means that experts are still trying to understand the underlying pathology and what 
this means for patient prognosis.  Recent research has suggested that disease progression may 
not be so random after all, as certain symptoms and factors such as age-onset have been 
grouped and identified to have similarities in relation to patient prognosis (Fereshtehnejad & 
Postuma, 2017).   Developments in PD subtyping could provide better insight into which 
treatments may be successful and ultimately lead to better patient outcomes. 
The detection of Lewy bodies in the cytoplasm of remaining SNpc DA neurons is a distinguishing 
feature in most cases of PD (Lo Bianco et al., 2004).  Lewy bodies are aggregates of amyloid-
like fibrils and cytotoxic α-synuclein protein deposited due to impaired clearance of misfolded 
proteins (Dawson & Dawson, 2003).  Multiple mechanisms have been suggested to explain Lewy 
body formation, however it is generally accepted that the underlying pathology of PD is not yet 
entirely understood.  Many contributory factors have been identified to date, including the 
production of reactive oxygen species (ROS).  Indeed, it has been suggested that multiple 
mechanisms are likely to have a synergistic effect in causing PD (Yacoubain & Standaert, 2009).   
PD pathology can be sporadic or genetic in nature (Timmer at al., 2007), resulting in cell 
apoptosis and Lewy body formation as a sign of defective cellular processes.  Sporadic PD has 
no known cause and accounts for the majority of cases, however 15% of diagnosed patients 
have a family history of the disease (Deng et al., 2018).  Family history is therefore a major risk 
factor for development of PD.   
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The discovery of mutations in the α-synuclein gene, SNCA, was the first indication that PD may 
have a genetic link.  To date, six mutations in the SNCA gene, also known as PARK-1, have 
been identified to cause Lewy body-associated PD, although this only accounts for 2% of all PD 
cases (Rosborough et al., 2017).    A mutation causing genomic triplication of PARK-1, can 
directly lead to α-synuclein accumulation and thus Lewy body formation, causing eventual 
neuronal cell apoptosis (Dawson & Dawson, 2003).  The gene for Parkin (PARK-2) was identified 
second to SNCA or PARK-1 and is an E3 ubiquitin ligase, responsible for ubiquination of cellular 
proteins which determines their cellular fate (Klein & Westenberger, 2012).   These discoveries 
have helped to identify more gene defects responsible for familial PD, such as DJ-1 and PINK-
1.  Mutations in PINK-1 (PTEN- induced kinase 1) or PARK-6, a mitochondrial kinase, can lead 
to loss of enzymatic activity and result in abnormal oxidative stress response (Schapira, 2009).   
Furthermore, PINK-1 protein works alongside Parkin to remove damaged mitochondria 
(Gladkova et al., 2017).  DJ-1 (PARK-7) is a cellular sensor protein of oxidative stress and, along 
with SNCA and PINK-1, is associated with early-onset PD (Deng et al., 2018).   
The aforementioned genes are associated with normal functioning of the ubiquitin-proteasomal 
system (UPS), otherwise known as the cell proteasome.  The UPS is responsible for the 
detoxification and clearance of misfolded and damaged proteins (Lo Bianco et al., 2004).  
Mutations in genes which affect the ability of the UPS to break down protein aggregates in the 
cell cytoplasm, leads to α-synuclein accumulation i.e. Lewy bodies.   
Another major gene associated with risk of familial PD is that for the large 268 kDa protein, 
LRRK2 (leucine-rich repeat kinase 2).  LRRK2 (also known as PARK-8) is an enzyme involved 
in cell signalling with complicated regulation pathways, thought to have multiple cell functions 
(Price et al., 2018).  Understanding of these pathways and events are important advances for 
PD research.  Defects in LRRK2 has been identified as a causative factor in sporadic PD, as has 
UCH-L1 (Ubiquitin carboxy-terminal hydrolase L1), an enzyme which has stabilising functions 
within the UPS (Osaka et al., 2003).   Ongoing enquiry into the genetic causes of PD continues 
to identify new mutations, such as CHCHD2, a gene which encodes a stress-response protein 
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involved in the negative regulation of mitochondria-mediated apoptosis (Puschmann, 2017).  
Indeed, many of the genes contributing to PD pathology previously discussed have also been 
identified in astrocytes, the most abundant glial cell of the brain (Booth et al., 2017).  Further 
studies into the role of astrocytes in PD are required, however early investigations suggest that 
pathological events may occur in more than one cell type. 
Two major pathological events have been identified thus far which are instrumental in causing 
DA neuron degeneration.  Firstly, cytosolic deposits of misfolded or aggregated proteins and 
secondly, mitochondrial dysfunction (Dauer & Przedborski, 2003).  The sequence in which these 
events occur is not clear and therefore it is difficult to identify cellular targets for effective 
treatment.  Oxidative stress due to the production of reactive oxygen species (ROS) is implicated 
as the major cause of neurodegeneration in PD, damaging important cell proteins, DNA and 
organelles such as the mitochondria.  ROS such as hydrogen peroxide and superoxide are 
produced by all tissues of the body as part of the respiratory process and signalling events in the 
mitochondria (Hauser & Hastings, 2013).  In normal circumstances, these oxygen-derived free 
radicals are controlled by endogenous anti-oxidants such as glutathione and thus prevent the 
imbalance which causes oxidative stress (Yuan et al., 2007).  It was reported by Sian et al. (1994) 
that reduced levels of antioxidant molecules were detected in the SNpc of PD patients compared 
to healthy individuals (Sian et al., 1994).  Furthermore, upregulation of DNA repair enzymes has 
been observed in PD patients, possibly triggered due to oxidative damage (Zhang et al., 1999). 
ROS can accumulate from a number of events such as impairment of mitochondrial complex 1 
activity, dopamine metabolism, neuroinflammation, environmental toxins and glutamate 
excitotoxicity (Schapira, 2008).  These pathogenic events which lead to the overproduction of 
ROS may also be caused by some of the genetic mutations previously mentioned.  Oxidative 
stress caused by ROS is therefore implicated in both sporadic and familial forms of the disease.  
Figure 1.2 summarises the different sources of ROS production implicated in PD aetiology. 
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Figure 1.2.  Pathogenic factors influencing the generation of reactive oxygen species (ROS) in Parkinson’s 
disease.  Overproduction of ROS results in oxidative stress, which is harmful to cellular 
organelles and DNA. 
 
 
 
Mitochondrial complex 1 is a major enzyme complex involved in cellular respiration (Mimaki et 
al., 2012).  The mitochondria are responsible for ATP (adenosine triphosphate) synthesis, a 
process which requires oxygen and nutrients (Fukae et al., 2007).  It has been suggested that 
dysfunction of this complex is the major cause of oxidative stress and ROS production in non-
familial sporadic PD (Schapira, 2008).  ROS can induce further mitochondrial complex 1 damage, 
leading to a detrimental cycle of ROS production which ultimately results in cell apoptosis.  
Lysosomal function in neurons might also be affected in this cascade of events, affecting cellular 
enzyme activity (Burbulla et al., 2017).  This makes PD research very challenging, as new 
treatments cannot be developed until these mechanisms are understood. 
Glutamate transmission is responsible for most of the excitatory synaptic activity in the 
mammalian brain and thus is a major source of ROS (Carrillo-Mora et al., 2013).   Glutamate 
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metabolism and ROS production are interrelated as one phenomenon can induce the other, 
leading to a cycling of events resulting in neurodegeneration (Gilgun-Sherki et al., 2001).  
Metabolism of the catecholamine neurotransmitter dopamine generates hydrogen peroxide, 
which in turn can produce cytotoxic hydroxyl ions (Meiser et al., 2013).  It is thought that because 
of this, dopamine-containing neurons of the SNpc are exposed to a higher level of ROS and 
oxidative stress than other brain regions (Yuan et al., 2007).  However, more insight is required 
into how this mechanism of ROS production correlates with PD onset.  Dopamine may be 
oxidised in response to dysfunctional mitochondria, leading to deposits of the dark pigment 
neuromelanin (Rodriguez et al., 2015).  This product of oxidised dopamine, proteins and lipids is 
responsible for the characteristic dark appearance of the SNpc in the mammalian brain (Beach 
et al., 2007), however it has also been implicated as a cause for neuroinflammation.   
High density areas of microglial activation have been identified in the SNpc of both familial and 
sporadic PD patients (Blesa et al., 2015).  Microglia, the resident immune cells of the CNS, 
release ROS in response to environmental stressors and neurotoxins (Block et al., 2007).  
Microglia normally function in a protective capacity, however in circumstances where the 
inflammatory response is amplified neurotoxicity is triggered (Mosley et al., 2006; Goldberg & 
Tansey, 2010).  One cause of neuroinflammation may be the release of neuromelanin from dying 
dopamine-containing neurons (Zucca et al., 2004).  Alternatively, chemical neurotoxins such as 
MPTP and 6-hydroxydopamine (6-OHDA) have been shown to induce similar responses due to 
ROS generation (Tansey & Goldberg, 2010).  Such chemicals have consequently been 
associated with a higher risk of developing PD (Elbaz et al., 2009).  6-OHDA and chemical 
pesticides such as rotenone and paraquat can induce classic parkinsonian symptoms in animal 
models for preclinical studies (Dauer & Przedborski, 2003; Zeng et al., 2018).  In a study by 
Ascherio et al. (2006), a 70% higher incidence of PD was reported in humans who had been 
exposed to pesticides during their lifetime, compared to those who had never been exposed.  
Environmental exposure to pesticides used mainly in cereal and potato crops were reported to 
increase the risk of developing PD in a study by Brouwer et al. (2017). 
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1.2.  PD treatments 
 
  1.2.1.  Current PD treatments 
 
Current pharmacological management of PD is focused on providing symptomatic relief of motor 
symptoms, so that patients can maintain enough functional ability to carry out daily activities.  
Clinical management of PD is not yet at the stage where restoration of neurons or prevention of 
disease progression is possible, however current research is geared towards achieving this.  The 
National Institute for Health and Care Excellence (NICE) advises that dopamine therapy should 
be prescribed as a first line treatment for PD patients with motor symptoms.  This approach which 
aims to replenish striatal dopamine levels has been rather successful in achieving reasonable 
control of motor symptoms in the early to mid-stages of the disease.  NICE clinical guideline 71 
(NICE, 2017) recommends levodopa and if necessary, a dopamine agonist or monoamine 
oxidase-B (MAO-B) inhibitor as an adjunctive treatment for first line therapy for the treatment of 
troublesome motor symptoms.  Levodopa is a prodrug of dopamine, capable of crossing the BBB 
where it is then metabolised to dopamine (Khor & Hsu, 2007).  The most common pharmaceutical 
preparation of levodopa is co-beneldopa, a combination of levodopa and benserazide, a 
peripheral aromatic amino acid decarboxylase inhibitor (Kim et al., 2017). Despite the 
improvement in motor control and ability to carry out daily activities afforded by levodopa therapy, 
it does cause complications with prolonged use (Tomlinson et al., 2010).  Long-term effects of 
levodopa therapy can cause dyskinesias, which are abnormal, repetitive involuntary movements 
commonly affecting the facial, oral and neck muscles (Fox & Lang, 2008).  Dystonic posturing of 
the limbs can often occur during peak concentration of levodopa dose (Jankovic, 2005).  In 
addition to this, impulsive control disorder (Starkstein et al., 2012) and excessive sleepiness 
(Chaudhuri & Logishetty, 2009) are also common side effects.   
Dopamine agonists such as ropinirole and pramipexole activate the dopamine receptor to induce 
the same physiological response as endogenous dopamine (Bonuccelli & Pavese, 2006).  MAO-
11 
 
B inhibitors such as selegiline prevent the breakdown of dopamine in the brain, maximising the 
availability of this neurotransmitter to neurons (Elmer & Bertoni, 2008).  Dopamine agonists and 
MAO-B inhibitors are less likely than levodopa to cause motor complications but are not as 
effective and therefore are rarely sufficient as stand-alone therapies (Gray et al., 2014).       
Side effects of dopamine treatments can range in severity however often require 
pharmacological management.  Psychotic symptoms such as hallucinations, delusions and 
depression occur in many patients (Friedman et al., 2000).  Anti-psychotic drugs such as 
quetiapine and clozapine are recommended by NICE alongside a reduction in any dopamine 
agonist medication.  Anti-psychotic drugs antagonise the D2 dopamine receptor and thus can 
worsen the symptoms of PD (Suchowersky, 2002).  Treatment or a reduction in dopamine 
replacement therapy is also required for symptoms of dementia, sleep disturbance, restless leg 
syndrome and orthostatic hypotension (Pourcher et al., 2010).  The clinical management of this 
disease therefore requires multiple drugs and introduces complex polypharmacy which often 
requires intense monitoring for drug interactions and risk-benefit analysis. 
At late stages of the disease most dopamine replacement strategies are ineffective and cannot 
sufficiently manage debilitating “off periods” to allow initiation of movement on a daily basis.  At 
such times, last resort treatments such as daily infusion of the potent dopamine agonist 
apomorphine is necessary (Salat et al., 2013).  This is inconvenient, restrictive and expensive 
requiring multidisciplinary management.  It is for these reasons, that the aim of current PD 
research is to find preventative and neuroprotective means of managing the disease (Kelly et al., 
2015).  Ultimately, restoration of DA neurons in the SNpc would be the optimal outcome of PD 
treatment.  This novel approach however remains distant from the clinical setting, as significant 
progress in clinical trials is yet to be made. 
 
 
. 
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1.2.2.  Prospective treatments for PD 
 
1.2.2.1.    Antioxidants 
New approaches aiming to preserve neurons in the SNpc and prevent disease progression are 
currently being investigated as an alternative to dopamine replacement initiatives.  Ongoing 
research has identified many potential drug candidates which are targeted towards different 
pathological aspects of the disease.  Due to the major involvement of oxidative stress in DA 
neuron degeneration, antioxidants were explored in the early 1990s as a potential means of 
containing the widespread production of ROS in PD.  In theory, antioxidants may have some 
potential application in the treatment of PD, however clinical data to date has not provided 
enough evidence of efficacy (Chang et al., 2018).  In a pilot study, Fahn (1992) indicated that 
vitamin E supplementation may delay the need for levodopa in PD patients by 2.5 years.  
Following this, the DATATOP trial was set up by The Parkinson Study Group (1993) as an 
investigation into the effect of antioxidant vitamin E.  This trial however, concluded that selegiline 
was effective in delaying PD progression in human participants but antioxidant vitamin E was 
not.  Since then, uric acid and selenium have also been proposed as antioxidants which may 
have some therapeutic benefit in PD (Yacoubian & Standaert, 2009).   
In a study by Gao et al. (2008) a link was reported between high dietary uric acid and a decreased 
risk of PD in men.   A neuroprotective effect from high levels of serum urate has been linked with 
a decrease in PD risk due to its potent antioxidant activity, however results thus far have been 
mixed.  O’Reilly et al. (2010) concluded that high serum urate levels in women was not 
associated with a lower risk of PD.  The use of this antioxidant molecule has been revisited in 
recent studies, showing reduced α-synuclein accumulation in transgenic mice (Sheng et al., 
2017) and association with lower PD risk in both men and women (Cortese et al., 2018).  Due to 
the risk of developing gout and cardiovascular problems from high dietary uric acid intake, Bi et 
al. (2018) aimed to maximise endogenous urate activity through upregulation of the Glut-9 
transporter.  The results from this study supported the action of urate as a neuroprotective agent 
in an animal model of PD.   
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Selenium acts a glutathione promoter and has gained attention for its neuroprotective effects in 
animal models of PD (Zafar et al., 2003).  The antioxidant activity of selenium has also been 
associated with positive effects on co-ordination and speed of tasks in PD patients by Shahar et 
al. (2010).  Dietary sources of selenium may help to reduce PD risk however direct association 
is yet to be established.   
 
1.2.2.2.    Anti-inflammatory agents  
Attempts to reduce neuroinflammation have been made with the use of non-steroidal anti-
inflammatory drugs (NSAIDS) such as ibuprofen, celecoxib, rofecoxib and naproxen with quite 
poor results in animal models of PD (Goldberg & Tansey, 2010; Moore et al., 2010).  The dose 
of NSAID needed to have a significant therapeutic effect in PD may be too high for safe use, 
particularly due to risk of GI and cardiovascular side effects.  The lipophilic tetracycline derivative 
minocycline has gained much attention recently for its positive effects in the SNpc of animals (Du 
et al., 2001; He et al., 2001; Nam et al., 2014).  Recent studies have been promising as 
minocycline has prevented neuronal loss, partially restored neuronal function and reduced 
neuroinflammation in neurotoxin-induced animal models of PD (Cronin & Gready, 2017; Verma 
et al., 2018).  Ongoing investigations using minocycline as a therapeutic agent is certainly 
warranted due to these promising results.  Another molecule which has improved PD-like 
behaviours in MPTP- and rotenone-induced animal models is the plant flavone, baicalein.  The 
neuroprotective effect of baicalein in mice may be due to various mechanisms of action including 
restoration of mitochondrial function (Zhang et al., 2017), reduction of neuroinflammation (Lee et 
al., 2014) and antioxidant activity (Cheng et al., 2008; Mu et al., 2011).  
 
1.2.2.3.    Other neuroprotective agents 
Neuroprotective properties of existing and well-known drugs have been identified as potentially 
useful treatments for PD.  The calcium channel antagonists dihydropyridine and nimodipine have 
been utilised to reduce NMDA receptor-mediated glutamate excitotoxicity in an animal models 
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(Kupsch et al., 1996 & Schapira, 2009).  Furthermore, the adenosine (A2a) receptor antagonist 
caffeine was indicated to preferentially enhance dopamine signalling amongst men, thus 
reducing the incidence of PD (Ascherio et al., 2001).  However, following an extensive review of 
clinical trials by Schapira (2009), it was reported that A2A antagonists in general failed to provide 
sufficient symptom control to be used as effective PD treatments. To date, minimal focus has 
been directed towards the targeting of α-synuclein deposits within DA neurons.  Modulation of 
the stress response which occurs due to α-synuclein may be a promising approach in the 
treatment of PD, as enhanced activation of chaperone molecules such as heat shock protein-70 
(HSP-70) can protect cells from such toxicity (Auluck et al., 2005).  Geldanamycin is such a drug 
which may induce HSP-70 activity and reduce α-synuclein aggregation (McLean et al., 2004). 
The development of these novel approaches has involved targeting many of the major factors in 
PD pathology including oxidative stress and neuroinflammation.  In theory, therapeutic agents 
which target these areas could provide improvement in symptoms, slow disease progression and 
lower overall risk of PD.  The results from these investigations however have been varied, 
preventing progression to large scale clinical trials.  Due to this, the introduction of new and 
effective PD treatments has been hindered in recent years. 
 
 1.2.3.  Neural stem cells  
 
PD therapy could benefit from novel disease-modifying strategies such as DA neuron 
replacement. Cell replacement is the newest approach for overcoming the loss of striatal 
dopamine and preventing disease progression.  Advances in stem cell medicine have 
encouraged this route, as it has been shown that human pluripotent embryonic stem cells can 
be induced to differentiate into motor neurons (Li et al., 2008a) and DA neurons (Stanslowsky et 
al., 2014) in vitro.   Currently human induced pluripotent stem cells are gaining recognition for 
their ability to differentiate into somatic cell types, with the advantage of being derived from adults 
rather than embryos (Appelt-Menzel et al., 2017).  Small molecules such as retinoic acid, 
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purmorphamine, sonic hedgehog and various neurotrophic growth factors can be utilised to 
create the environment required for the differentiation of stem cells to neurons.  Cultured neurons 
derived from stem cell sources may be transplanted into the brain in vivo, however this is invasive 
and would involve major surgery.  Furthermore, difficulties with ethical issues, tumourgenicity 
and unstandardised cultivation methods still surround stem cell transplant initiatives (Coutts & 
Keirstead, 2007).  
The formation and integration of new neurons (neurogenesis) in the brain was once viewed as 
an event which only occurred during the embryonic stages of life.  It is now accepted that new 
neurons are formed during adulthood but only in restricted regions and in response to 
environmental cues (Decimo et al., 2012).  Neural progenitor cells with the ability to proliferate 
and differentiate to form a neuronal phenotype in vitro have been isolated from various areas in 
the brain including the olfactory bulb, hypothalamus, SNpc and the striatum (Lie et al., 2002).  
Despite this, there is no convincing evidence that progenitor cells found in the SNpc produce 
new neurons in situ, even in the healthy brain (Farzanehfar, 2018).  It is therefore likely that the 
in vivo microenvironment inhibits the differentiation of these cells to neurons and thus DA 
neurons are not replaced as a natural response to PD pathology (Van der Berge et al., 2013).  A 
deeper understanding of the nigrostriatal pathway microenvironment in the brain might offer 
useful insight into how the induction of neurogenesis, which has been demonstrated in vitro, 
might be replicated in situ. 
The origins of neural progenitor cells in the human brain are still being uncovered, however two 
of the best characterised areas are the subventricular zone (SVZ) of the lateral ventricle wall and 
the subgranular zone (SGZ) of the hippocampal dentate gyrus (Decimo et al., 2012).  The areas 
where neural stem cells reside are known as niches, where environmental stimuli determine their 
fate.  Neural stem cell populations proliferate to form neural progenitor cells, also known as the 
C cells, which migrate from niches to other areas of the brain (Van der Berge et al., 2013).  
Following proliferation, neural progenitor cells subsequently differentiate into neuroblasts, also 
known as the B cells.  Neuroblast formation and migration has been reported in instances of 
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brain injury, including formation of new neurons in the striatum in response to stroke (Arvidsson 
et al., 2002; Yamashita et al., 2006).  Neurogenesis in the SVZ and SGZ occurs throughout adult 
life, however the natural proliferative potential of these cells is thought to decrease with age 
(Apple et al., 2017).  The ability of the brain to repair is therefore reduced with age, explaining 
the high incidence of neurodegenerative diseases in the elderly population. 
The close anatomical proximity between the SVZ and the striatum may permit the mobilisation 
of neural stem cells in response to certain stimuli and promote the formation of new DA neurons.  
This would be an attractive neurorestorative approach for PD treatment, overcoming many of the 
issues surrounding current treatment modalities.  Naturally occurring neural progenitor cells 
outside the stem cell niches of the SVZ and SGZ do not normally regenerate neurons in response 
to injury or disease, however can produce new glial cells in vivo (Lie et al., 2002).   In a study by 
Ernst et al. (2014), the integration of new neurons in the adult striatum was detected following 
migration from the neighbouring SVZ.  The fact regeneration of neurons can occur in situ 
provides hope that therapeutic stimulation of such processes might prove beneficial in PD 
patients.    
Many studies have shown that in situ neuronal regeneration is possible in response to 
environmental stimuli such as neurotrophic factors (NTF).  Although many NTF are 
endogenously expressed, they may not be released in sufficient quantity to induce regeneration 
of neurons in toxic neurodegenerative conditions (Wang et al., 2004).  Alternatively, the natural 
microenvironment may be inhibiting the secretion of NTF. 
 
1.2.4.  Neurotrophic factors (NTF) 
 
NTF have important functions in the CNS and their use within PD is perhaps one of the most 
exciting new prospects due to positive results in animal models (Kelly et al., 2015).  NTF are 
secretory peptides or small proteins which are involved in the development, differentiation, 
protection and maintenance of neurons to adulthood and thus offer the possibility of neuronal 
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regeneration (Hegarty et al., 2014).  The ability to stop neuronal degeneration and possibly 
restore DA neurons in the SNpc are approaches not possible with the drug candidates discussed 
in section 1.1.5.  NTF describe a subclass of growth factors which exert their action 
predominantly through tyrosine kinase signalling (Huang & Reichardt, 2001). 
 
1.2.4.1.     Recent studies of NTF in animal models 
There has been considerable success in the improvement of PD symptoms following viral vector 
delivery of neurturin (NRTN), platelet-derived growth factor (PDGF), cerebral dopamine 
neurotrophic factor (CDNF) and glial cell-derived neurotrophic factor (GDNF) into the striatum of 
animals (Kelly et al., 2015).  Significant benefit in humans however has yet to be demonstrated 
in clinical trials.  Bartus et al. (2011) reported on the safe and effective administration of NRTN 
with positive outcomes in neurotoxin-induced animal models, which subsequently lead to clinical 
trials involving human participants.  A follow-up phase II clinical trial however failed to provide 
enough evidence of efficacy to reach the primary endpoint of the study, which was to improve 
“motor-off” scores (Bartus et al., 2013).  Despite this, there is still substantial evidence from 
studies in rodents to indicate that NRTN may be a successful treatment option in the future for 
PD (Herzog et al., 2013). 
It was demonstrated by Zachrisson et al. (2011) how intracerebral administration of a PDGF 
isoform (PDGF-BB) resulted in long-term restoration of DA neurons in rodents.  Increased 
expression of dopamine transporter sites and higher levels of tyrosine hydroxylase, the rate-
limiting enzyme in catecholamine synthesis, were detected in the substantia nigra region.  This 
study by Zachrisson et al. (2011) also detected proliferation and mobilisation of neural progenitor 
cells in the sub-ventricular zone of the brain in vivo.  Furthermore, proliferation of non-neuronal 
cell types in the brain following PDGF-BB administration indicated that mobilisation of non-neural 
progenitor cells may have also have protective effects in PD. 
Cordero-Llana et al. (2015) reported on the synergistic effect of cerebral dopamine neurotrophic 
factor (CDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF) after co-
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administration to the substantia nigra of rats.  The combination of both NTF was beneficial for 
improving control of motor symptoms in a rat model. 
GDNF is perhaps the most studied neurotrophic factor with a wealth of positive results in the 
literature reported in animal models for its neuroprotective and restorative effect on DA neurons.  
GDNF has shown efficacy and safety in multiple animal models of PD, increasing dopamine 
levels in the striatum and diminishing motor deficits in some of the earliest investigations into 
NTF (Beck et al., 1995; Bowenkamp et al., 1995; Fox et al., 2001; Emborg et al., 2009).  The 
role of GDNF in PD research has progressed from preclinical studies to clinical investigations 
involving human participants.  A large phase II clinical trial on the use GDNF in idiopathic PD 
was completed in 2017 by the NHS Bristol Trust (TG Study Group, 2017).  The data indicated 
that GDNF was safe and well-tolerated, however failed to show significant therapeutic benefit to 
progress to phase III studies.  This trial was subsequently extended and is currently ongoing.   
Basic fibroblast growth factor (bFGF), also known as FGF-2, is a multifunctional 146-amino acid 
polypeptide native to the CNS, which has an important role in neuronal survival at different stages 
of development from embryogenesis to adulthood (Abe & Saito, 2001).  Endogenous bFGF has 
been found localised to DA neurons and glial cells in the SNpc, which expresses at least three 
high affinity bFGF tyrosine kinase receptors (Claus et al., 2004).  Tooyama et al. (1993) reported 
that approximately 80% of DA neurons express bFGF in the healthy brain.  The expression of 
bFGF in the remaining DA neurons of PD patients however is severely depleted, with only 13% 
of the DA neuronal population expressing this NTF.  Following this, Takayama et al. (1995) 
demonstrated how bFGF could be utilised in vivo to promote the survival of transplanted 
embryonic DA neurons in a mouse.  Since then, bFGF has gained attention for its pro-survival 
and mitogenic effects in regenerative stem cell medicine and in neural progenitor cell populations 
(Jin et al., 2005; Timmer et al., 2006) 
Studies have shown that overexpression of bFGF in animal models can mobilise transplanted 
neural progenitor cells to migrate through injured tissue (Dayer et al., 2007) and directly stimulate 
neurogenesis in the dentate gyrus to form new neuronal populations in situ (Yoshimura et al., 
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2003).  In the adult brain, neurogenesis is unique to the SVZ and hippocampal dentate gyrus, 
however multipotent progenitor cells exist throughout different regions of the brain.  These cells 
can be isolated and respond to environmental cues which induce differentiation.  Palmer et al. 
(1999) induced the differentiation of multipotent progenitor cells from naturally non-neurogenic 
tissue within the CNS into neurons, a response which only occurred in the presence of bFGF.    
Timmer et al. (2007) showed how endogenous bFGF was important for protecting DA neurons 
from neurotoxin injury in mouse models.  Mice deficient in bFGF showed much higher 
susceptibility to the cytotoxic effects of 6-OHDA, illustrating the role of bFGF in neuronal repair 
mechanisms.  A potent inducer of mitosis, bFGF has also shown regenerative potential in the 
peripheral nervous system due to regulation of remyelination and axonal growth of injured 
neurons (Jungnickel et al., 2006).    
The evidence from the literature would suggest that bFGF is an ideal candidate for developing 
into a potential neurorestorative treatment for PD.  It is unlikely that a single NTF provides the 
support required for neuronal replacement and development in the central and peripheral 
nervous systems (Grothe & Timmer, 2007), therefore bFGF could be utilised alongside some of 
the other NTF previously mentioned.  Combinations of NTF such as bFGF and epidermal growth 
factor (EGF) may provide the environmental cues required to upregulate the differentiation 
capacity of native neural stem cell populations (Wang et al., 2004).  For NTF to be successful in 
vivo, they require delivery to the brain via a suitable vehicle or targeted drug carrier to avoid 
peripheral metabolism.   
NTF have a short half-life and are unable to cross the blood brain barrier (BBB).  Most animal 
studies to date have used direct intracerebral infusion, bolus injections and transplant procedures 
as a means of effective administration.  For humans, these methods are invasive, inconvenient 
and have raised concerns on patient safety (Kelly et al., 2015).  It has also been suggested that 
the administration site may have an effect on the activity of GDNF (Sullivan & Toulouse, 2011).  
Lin et al. (2017) recently developed a biological scaffold derived from the extracellular matrix for 
the sustained release of bFGF, which successfully improved PD-like behavioural symptoms in 
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rats.  Invasive transplant into the striatum was still required to overcome the BBB and achieve 
efficient therapeutic levels of bFGF in the brain.  A delivery vehicle permitting sustained release 
of therapeutic agent for neuronal regeneration in the parkinsonian brain is an exciting new 
approach in the search for a PD cure.   
 
1.3.  The blood brain barrier (BBB) 
 
The blood brain barrier (BBB) is the interface between the circulating blood and the brain, which 
tightly regulates the exchange of nutrients, cells, pathogens and metabolites (Wilhelm et al., 
2011).  Essential for normal function of the CNS, the BBB maintains homeostasis of the brain 
microenvironment and protects neural tissue from potentially harmful blood-borne substances 
(Schenk et al., 2016).  The BBB is composed of brain microvascular endothelial cells (BMVEC) 
supported by a capillary basement membrane embedded with pericytes and astrocyte end-feet, 
as shown in Figure 1.3.  Pericytes provide structural support and hence are important for barrier 
integrity (Sweeney et al., 2014).  Astrocytes have roles in the formation, regulation, function and 
permeability of the BBB, cross-communicating with other cells of neurovascular unit (NVU) 
through secretions (Ballabh et al., 2004).  The NVU is the structure formed by the basement 
membrane, BMVEC, neurons, pericytes and glial cells (Banks, 2016).  Cells of the NVU are all 
involved in cross-communication to ensure regular function is maintained within the BBB 
regarding integrity, transport and permeability. 
A healthy BBB typically only permits passive diffusion of small, hydrophobic molecules < 400 Da 
such as oxygen and carbon dioxide (Bhaskar et al., 2010).  Exchange of large or hydrophilic 
molecules across the BBB is limited by the characteristic presence of tight junctions (TJ) between 
BMVEC, unless there is a specific receptor or carrier to mediate their passage.  The highly 
specialised endothelial cells of the BBB uniquely express high levels of mitochondria, lack 
membrane fenestrae typical of peripheral endothelial cells and show low levels of pinocytosis 
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(Bartanusz et al., 2011).  These factors result in high reliance upon energy-dependent 
mechanisms for transport of substances across the BMVEC layer, making delivery of drugs at 
therapeutic concentrations difficult.  The brain endothelium expresses unidirectional protein 
efflux transporters which have been associated with multidrug resistance at the CNS (Shen & 
Zhang, 2010).  P-Glycoprotein encoded by the multidrug resistance-1 (MDR-1) gene is the most 
studied efflux transporter present in many mammalian species (Sun et al., 2003).  There are also 
many more members of the multidrug resistance-associated protein family, collectively known 
as ATP-binding cassette (ABC) transporters, which remove potentially toxic substances from the 
brain (Miller, 2015).   ABC transporters are not unique to the BBB, but expression is much higher 
at the blood-brain interface than in other peripheral tissues.  The protective function of the BBB 
is unable to differentiate between harmful and therapeutic xenobiotics, therefore should drug 
delivery to the brain be achieved, there is a risk it will be removed by such efflux mechanisms 
(Qosa et al., 2015).   
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Figure 1.3.  (A) A representation of the neurovascular unit and blood brain barrier (BBB) structure 
consisting of blood capillary endothelial cells, a basement membrane, pericytes and 
astrocytes.  This specialised structure is responsible for the selective permeability of the brain 
endothelium, controlling the exchange of solutes from blood to brain.  (B)  A close-up 
representation of the BBB showing tight junction protein expression between endothelial 
cells, which are structurally supported by the basement membrane, pericytes and astrocytes. 
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TJ are responsible for high in vivo trans-endothelial electrical resistance or TEER (~1800 Ωcm2) 
of the BBB and hence the physical restriction on paracellular movement of polar and large 
molecules between blood and brain (Abbott et al., 2010).  TJ complexes between endothelial 
cells (Figure 1.4) are formed from various adheren junctions (cadherin proteins), junctional 
adhesion molecules (JAM), claudins, occludins and intracellular scaffold zonula-occludins (ZO) 
proteins (Wolfburg & Lippoldt, 2002; Abbott et al., 2010).  The presence of TJ is essential for a 
functional in vivo BBB and can be used as a marker of BBB properties in endothelial cells of in 
vitro cellular models.   
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Tight junctions between brain microvascular endothelial cells of the blood brain barrier (BBB) 
formed from various proteins such as junctional adhesion molecules (JAM), claudins, occludin 
and zonula occludins (ZO).  Expression of these junctional proteins are unique to the BBB 
structure contributing to the limited permeability of solutes between blood and brain.  Image 
reproduced from Tietz & Engelhardt (2015) with permission of Rockefeller University Press. 
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The physical and chemical defences of the BBB towards foreign blood-borne substances makes 
drug delivery to the CNS extremely difficult.  The protective function of the BBB is essential for 
maintenance of normal homeostasis within the CNS, however it causes many promising drug 
candidates for neurodegenerative conditions to fail in preclinical and clinical in vivo studies.  The 
inability to achieve therapeutic levels of drug accumulation in the brain is a major concern which 
must be overcome in the development of any potential drug candidate for PD.  Aging has been 
strongly associated with the onset of many neurodegenerative conditions and new research is 
beginning to identify how these processes are linked (Xu et al., 2018).  Continuing growth of the 
aging population due to advances in healthcare means that the incidence of PD and other 
neurodegenerative diseases are also set to rise (Aron & Klein, 2011).  Considering this, it is 
essential that suitable solutions are sought to overcome the challenge presented by the BBB in 
drug delivery. 
Invasive means of administration have been utilised to overcome the difficulties presented by the 
BBB for drug delivery.  Trans-cranial delivery by either intra-cerebral injection, infusion or implant 
has been the selected method of administration for clinical studies on NTF such as GDNF 
(Pardridge, 2007).  These methods are extremely invasive and as such are associated with low 
patient acceptance, high cost and adverse events such as infection (Newland et al., 2016).  
Herrán et al. (2014) used a poly(lactic-co-glycolic) acid (PLGA) nanoparticulate delivery vehicle 
loaded with vascular endothelial growth factor (VEGF) and GDNF which was administered to 
rats via direct surgical injection into the striatum.  This NTF delivery system achieved positive 
behavioural test results and increased density of neurons in vivo.  The polymer-based 
nanoparticulate vehicle afforded controlled release and protection of therapeutic payload at the 
target site, despite requiring invasive means of administration.  This neurorestorative effect was 
also observed by Zhao et al. (2014) when treating rats with bFGF-loaded lipid nanocarriers 
administered intranasally.   
Trans-nasal delivery of lipid-soluble molecules is an option for achieving brain delivery of drug, 
however this method is not suitable for larger, hydrophilic molecules unless damage is caused 
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to the nasal mucosa (Merkus et al., 2003).  BBB disruption may be induced with the use of 
hyperosmotic solutions such as mannitol (Sheikov et al., 2004) or ultrasound-induced resonance 
of microbubbles (Chu et al., 2018) to temporarily allow the passage of molecules from blood to 
brain.  These methods are effective, however repeated administration may lead to the toxic 
leakage of plasma proteins into the brain and permanent pathology of the BBB due to damage 
of the brain microvasculature (Pardridge, 2007).  Ongoing studies are uncovering advanced 
methods for achieving effective brain delivery of therapeutic agents which are not invasive and 
consider factors such as susceptibility to enzymatic degradation (Zhou et al., 2018).  
 
1.4.  BBB targeting ligands  
 
The use of targeting ligands to facilitate the cellular uptake of therapeutics is a growing area of 
research across many disease states.  This has been particularly useful in recent times for the 
specific targeting of drugs to the CNS, as certain ligands have the ability to traverse the BBB via 
various mechanisms. 
 
1.4.1.  Cell penetrating peptides (CPP) 
Cell penetrating peptides (CPP) can greatly enhance the intracellular uptake of conjugated cargo 
across biological membranes in a non-invasive, non-disruptive manner.  CPP are beneficial over 
conventional drug delivery methods for numerous reasons, including improved drug 
bioavailability at the target site, reduction of unwanted side effects and the need for less frequent 
dosing (Malhotra & Prakash, 2011).  CPP such as TAT (transactivator of transcription) peptide, 
penetratin and polyarginine are among the most commonly used ligands which have the ability 
to transport cargos of much higher molecular weight.  CPP can also be referred to as protein 
transduction domains, referring to the section of the parent protein domain responsible for 
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cellular translocation (Snyder & Dowdy, 2004).  These sequences usually contain less than 30 
amino acid residues and positively charged amino acid segments of lysine and arginine residues, 
which are essential for electrostatic interactions with the negatively-charged proteoglycans of the 
cell (Ul Ain et al., 2016).  The exact mechanism of membrane transduction is not entirely 
understood, although it is thought CPP facilitate cellular uptake via energy-dependent 
absorption-mediated endocytosis (Zou et al., 2013).  
The cell penetrating effect of TAT has been evidenced in many studies, facilitating the delivery 
of antibiotics (Li et al., 2008b), cancer chemotherapy (Joshi et al., 2017; Wang et al., 2018) and 
imaging agents (Santra et al., 2004) across the BBB in vivo with significantly higher efficacy than 
unconjugated payloads.  Similarly, the CPP penetratin has also shown the ability to facilitate the 
brain accumulation of a conjugated cargo in vivo (Xia et al., 2012).  The use of these CPP thus 
far has proved a safe approach for drug delivery.  Davidson et al. (2004) used penetratin-1 to 
effectively deliver siRNA to primary cultures of hippocampal neurons without the disturbance 
caused by other classical transfection methods such as electroporation.  Polyarginine is perhaps 
the most superior CPP for enhancing cellular uptake, with sequences containing 9 arginine 
resides amongst the most efficient transporters (Mitchell et al., 2000; Wender et al., 2000).  One 
study showed how arginine-labelling of polymeric nanoparticles improved cellular uptake by 30% 
(Chiu et al., 2015) and when incorporated into a sequence with a specific receptor-targeting 
ligand, can be a very effective cellular targeting moiety (Zeller et al., 2015). 
The issue presented by the use of TAT and any of the aforementioned CPP as stand-alone 
ligands is the lack of tissue specificity, as they do not function via a particular receptor or carrier.  
TAT can penetrate many tissues in vivo (Schwarze et al., 1999), meaning there is limited 
constraint on where CPP-labelled payloads might accumulate.  This is potentially problematic 
when aiming to deliver expensive or toxic drugs.  It is now becoming more common to use CPP 
as part of a targeting ligand sequence or dual targeted system to aid specific cellular uptake 
(Kumar et al., 2008).  
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  1.4.2.  Endogenous transporters and receptors 
Taking advantage of endogenous transporters and receptors expressed by the BBB is an 
attractive approach in CNS drug delivery.  Utilising ligands which are recognised by endogenous 
receptors at the target site is an effective way of achieving drug delivery by non-invasive means.  
Polysorbate-80 is a non-ionic surfactant or emulsifier which has been used as a coating on 
various drug delivery vehicles to facilitate brain delivery of otherwise BBB-impermeable payloads 
(Reimold et al., 2008).  Kurakhmaeva et al. (2009) intravenously administered polysorbate 80-
coated poly(butyl-cyanoacrylate) nanoparticles loaded with nerve growth factor (NGF) to rats.  
This study showed how polysorbate 80 facilitated the enhanced delivery of NGF across the BBB 
through interactions with endogenous cell surface apolipoproteins.  A reduction in PD symptoms 
was observed in rats without the need for intracerebral administration, a significant development 
in achieving non-invasive and safe delivery of a NTF to the brain.  Polysorbate-80 has also been 
used to facilitate the in vivo brain delivery of drugs for Alzheimer’s disease (Wilson et al., 2008) 
and cancer (Gulyaer et al., 1999; Gelperina et al., 2002).  Rempe et al. (2011) reported the 
development of polysorbate-80 coated PBCA NP which could permeate a porcine in vitro BBB 
model and facilitate enhanced permeability of a FITC-BSA conjugate due to temporary barrier 
disruption after 4 hours of exposure.  Although this approach is effective in achieving enhanced 
accumulation of drug across the BBB, there are considerable associated risks which include 
long-term barrier dysfunction and passage of blood-borne neurotoxic proteins into the CNS.  
Lactoferrin is a globular glycoprotein member of the transferrin family which is important for 
cellular absorption of iron.  The lactoferrin receptor expressed on BBB endothelial cells has been 
used as a target to facilitate the active transport of therapeutic payloads across the BBB. Huang 
et al. (2010a) used lactoferrin as a targeting ligand to deliver a GDNF gene payload to a rat 
model of PD, which caused improved locomotor activity after repeated dosing.  Hu et al. (2009) 
took advantage of this endogenous receptor-mediated transport mechanism to increase the 
accumulation of polymeric nanoparticles housing a fluorescent coumarin-6 payload in mouse 
brain in vivo following intravenous administration.  In this study the lactoferrin ligand also 
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facilitated the in vitro internalisation of the fluorescent payload better in mouse brain endothelial 
cells than the unmodified nanoparticle treatment with low cytotoxicity (Hu et al., 2009).  The anti-
lactoferrin monoclonal antibody OX26 is another ligand which can be exploited to enable 
lactoferrin receptor-mediated transport of BBB-impenetrable peptides to the brain as shown by 
Penichet et al. (1999) and Aktas et al. (2005).  Antibodies against receptors overexpressed by 
solid tumours is an effective means of specific targeting to limit the cytotoxic side effects of 
chemotherapy.  For example, medulloblastoma is a type of primary brain tumour which 
overexpresses the HER2 receptor making it susceptible to anti-HER2 antibody-functionalised 
therapeutics (Bernardi et al., 2008).  This type of targeting could be useful for overcoming the 
BBB, should suitable receptors be identified. 
Transferrin is another iron-transporting serum glycoprotein, similar to lactoferrin, which has 
become a popular ligand for enabling targeted receptor-mediated transport of therapeutics at the 
cell surface of solid tumours (Li & Qian, 2002; Kang et al., 2009; Ulbrich et al., 2009).  
Overexpression of this receptor by tumours can be exploited for enhanced cytotoxicity and more 
effective use of expensive chemotherapeutics.  Yuan et al. (2009) conjugated the transferrin 
ligand to a nanoparticulate vehicle loaded with anti-cancer agent for the treatment of brain glioma 
in rats.  In this study, enhanced accumulation of drug in the tumour was facilitated by transferrin 
and extended the survival of rats compared to unconjugated treatment.  Yuan and colleagues 
showed the importance of the transferrin ligand as less than 2% of unconjugated nanoparticles 
accumulated in the brain due to uptake by the reticuloendothelial system (RES).  This shows that 
a targeting ligand may not only enable enhanced uptake at the target site, but also extend half-
life of the therapeutic payload.  
Another endogenous receptor expressed at the BBB is the low-density lipoprotein receptor 
(LDLR) which is also overexpressed by glioblastoma tumours (Nikanjam et al., 2007).  Zhang et 
al. (2013) developed a novel peptide named peptide 22 which showed affinity towards the LDLR 
to deliver paclitaxel-loaded nanoparticles to the brain of mice for the treatment of glioblastoma 
multiforme.  This peptide effectively reached tumour which infiltrated the brain tissue compared 
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to unconjugated drug vehicle, extending the survival time of glioma-bearing mice.  Targeting the 
overexpression of LDLR, lactoferrin or transferrin receptors has been effective for increasing 
drug accumulation in solid brain tumours however may not be as useful for other diseases where 
the target is not so obvious.  Whilst the BBB endogenously expresses these receptors, they are 
not unique to the BBB endothelium and are widely expressed throughout the peripheral tissues.  
In neurodegenerative conditions, this approach may not be sufficient to allow specific BBB 
crossing and the efficient distribution of a drug vehicle through neural tissue.   It would be more 
beneficial in these instances, to target a receptor more uniquely expressed by the BBB 
endothelium and neural cells to facilitate both specific identification of the target site and 
subsequent internalisation of a conjugated payload with minimal dosing. 
 
  1.4.3.  Toxin-derived peptides  
 
CNS-specific peptide-based targeting ligands have been explored in recent times for the 
delivery of therapeutic agents to the brain.  CNS-targeting peptides have had much success in 
animal studies, exploiting native receptors, transporters or enzymes to specifically deliver 
therapeutic cargo across the BBB.   Many of these peptides are derivatives from natural 
neurotoxic agents such as tetanus toxin, neurotropic virus glycoproteins and fragments of 
snake, scorpion and bee venoms (Soddu et al., 2015).  Taking advantage of the natural ability 
of these peptides to invade the CNS to achieve highly efficient drug transport across the BBB 
has one of the most promising brain-targeting strategies developed over the past decade.  
Despite this, the use of toxin or virus-derived ligands raises concerns of immune reactions and 
true specificity for neural cells only.   
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1.4.3.1.    Bacteria-derived neurotoxins 
Peptide derivatives of the tetanus toxin have been explored as potential CNS shuttles for the 
delivery of various cargo to the brain.  This toxin produced by Clostridium tetani is responsible 
for the potentially life-threatening tetanus infection of the CNS. Tet-1 peptide is one such 
derivative which has been used to deliver a nucleic acid-polymer conjugate specifically to neural 
cells in mice following intraventricular injection (Kwon et al, 2010).  After facile conjugation to 
polymeric nanoparticles, the 12-amino acid tet-1 peptide has also been used for in vitro uptake 
studies in neuronal cells (Mathew et al., 2012).  The retrograde transport properties of tet-1 might 
prove useful for targeting of motor neurons in particular (Bhatt et al., 2017), however at present 
more evidence of in vivo efficacy is required.  Tet-1 can specifically target neurons when 
administered directly, however it is not clear whether this peptide would be effective for BBB 
crossing following peripheral administration.  Tetanus toxin fragment C (TTC) is another peptide 
derivative of tetanus toxin which may be useful for CNS targeting.  It has in fact been used in 
combination with GDNF to target spinal cord motor neurons in mice (Larsen et al., 2006).  An 
extensive review by Toivonen et al. (2010) on the use of TTC highlights the potential benefits of 
this neuron-targeting entity for conjugated therapeutics, however there are still immunogenic 
concerns which need to be explored in greater detail. 
Cholera toxin produced by the vibrio cholerae bacterium contains a cell-penetrating fragment 
known as cholera toxin B fragment (CTB), which has potential applications as a promoter of 
cellular uptake.  CTB is part of the cholera toxin which is responsible for cell-invasion via cell 
surface ganglioside GM1 receptors rather than the disease-causing metabolic effects produced 
by the A fragment (Vajn et al., 2013).  CTB facilitated improved delivery of conjugated NGF to 
the brain in vivo utilising retrograde transport mechanisms following intranasal administration 
(Zhang et al., 2008).  The increased brain accumulation of NGF gave rise to a greater therapeutic 
response in Alzheimer’s disease model mice compared to treatment without CTB, including 
cholinergic neuron protection and improved memory ability.  GM1 receptors are present in the 
CNS, however as they are also present in the gastrointestinal epithelium, intranasal 
administration of CTB-NGF was the preferred route to minimise non-specific peripheral targeting.  
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The diphtheria toxin (DT) is another bacteria-derived source of targeting peptide which has been 
explored for its cell-penetrating potential via the diphtheria toxin receptor (DTR).  Although this 
receptor is not exclusively expressed by the CNS, DT derivatives such as CRM197 have shown 
efficacy in facilitating DTR-mediated endocytosis of conjugated siRNA-loaded polymeric 
nanoparticles to glioblastoma brain tumours in mice following systemic administration (Hobel et 
al., 2011).  
The use of peptide derivatives from bacterial toxins has shown promise in aiding BBB crossing 
and brain accumulation of conjugated therapeutics due to their cell penetrating properties. Many 
of these targeting moieties also have affinity for peripheral receptors, which introduces the risk 
of non-specific targeting of drug product.  Bacterial toxins may perhaps be useful for cellular 
uptake applications in combination with more specific neural cell-targeting ligands. 
 
1.4.3.2.    Animal-derived neurotoxins 
Common to all families of the snake species, toxins are non-enzymatic proteins found in snake 
venom with a common three-loop structure, which have various biological effects including 
neurotoxicity (Kini & Doley, 2010).  Snake neurotoxins are well-characterised for their ability to 
bind to various subtypes of the neuronal nicotinic acetylcholine receptor (nAChR) (Tsetlin & 
Hucho, 2004).    Candoxin is a 16-amino acid derivative of the Malayan krait snake toxin which 
has been used to promote the brain delivery of paclitaxel-loaded polymeric micelles via the α7 
nAChR subtype in mice (Zhan et al., 2011). This type of specific targeting permits maximal 
therapeutic effect from the drug, making treatment more efficient.   
Snake toxin derivatives are perhaps the most neural-specific source of targeting moieties utilised 
in recent drug targeting strategies towards the CNS.  Venom produced by the king cobra snake 
Ophiophagus hannah contains Toxin B, from which loop 2 residues have been identified to 
interact with the nAChR with high affinity.  A peptide derivative from Toxin B loop 2 (KC2S) 
effectively enabled intracranial delivery of an attached polymeric payload following intravenous 
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administration in mice in a study by Zhan et al. (2010).  In the same study, it was shown that 
KC2S preferentially targeted nAChR-expressing brain endothelial cells over non-neural HeLa 
cells (Zhan et al., 2010).   
Neurotoxins are not only produced by species of snake, but other animals also produce such 
proteins.  A neurotoxin produced by the scorpion species Leiurus quinquestriatus has been 
exploited for treatment of brain gliomas due to its ability to cross the BBB.  Scorpion-derived 
chlorotoxin binds cell membrane matrix metalloproteinase-2 (MMP-2) as part of a lipid-raft 
anchored complex (Soddu et al., 2015).  MMP-2 is overexpressed in many cancers and thus 
chlorotoxin has been utilised as a brain tumour-targeting ligand, enabling preferential drug 
accumulation in glioma cell types in vitro (Xiang et al., 2011) and therapeutic efficacy in vivo 
(Costa et al., 2013).  Similarly, a neurotoxic peptide from bee venom known as apamin has been 
used to create a non-toxic derivative (ApOO) capable of crossing an in vitro BBB model (Oller-
Salvia et al., 2013).  Despite having promise as shuttles for CNS drug delivery, few in vivo studies 
have been carried out to investigate the true potential for immune reactions following repeated 
exposure to neurotoxin-derived peptides. 
 
  1.4.4.  Virus-derived CNS targeting peptides 
 
Viral envelope glycoproteins have the ability to initiate cell penetration via interactions with 
various host surface receptors.  Glycoprotein derivatives from viruses such as Herpes simplex 1 
and vesicular stomatitis virus (VSV) have been used to enhance the cellular uptake of conjugated 
payload to various cell types in vitro, including BBB cells.  These virus-derived peptide ligands 
however do not confer any neural-specific targeting properties to the drug vehicle, using mainly 
non-specific uptake mechanisms or target receptors commonly expressed throughout numerous 
bodily tissues (Ammayappan et al., 2013; Guarnieri et al., 2013).  The highly efficient cellular 
internalisation displayed by viral glycoproteins is of utmost interest in drug delivery initiatives, 
particularly if a more target-specific in vivo mechanism of action can be sought.  Indeed, peptides 
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derived from the neurotropic rabies virus might hold the characteristics required of such a brain-
targeting ligand.  
 
1.4.4.1.    Rabies-virus glycoprotein 
Rabies virus is an infection of the CNS which has a high fatality rate amongst unvaccinated 
individuals.  Starting at the neuromuscular junction of the peripheral nervous system, the virus 
undergoes retrograde axonal transport to infect the CNS (Cherian et al., 2015).  Rabies virus 
infection causes various neurological symptoms manifesting as muscle spasms, respiratory 
problems, hallucinations or in some cases, paralysis (Jackson, 2013).  In later stages of the 
disease, the virus spreads to various other areas of the body such as the salivary glands.  The 
infected saliva of biting animals is the main source of rabies virus spread and hence the 
infective cycle is repeated (Michalicová et al., 2017).  Rabies is a rod-shaped virus from the 
Lyssavirus genus of the rhabdoviridae family, whose genome encodes five proteins 
(Rupprecht, 1996).  One of these proteins is the viral envelope glycoprotein, which is solely 
responsible for viral infection of the CNS.    
Retrograde axonal transport in the direction of the cell body from the axon terminus is a natural 
method of cellular recycling within neurons.  Rabies virus glycoprotein (RVG) is a 505-amino acid 
type-1 glycoprotein on the viral envelope which is responsible for BBB crossing and utilises the 
mechanism of retrograde axonal transport to traverse neurons of the CNS (Yan et al., 2002).  
Thus far, three key nerve cationic binding regions have been identified at positions 33–54, 189–
214 and 330–357 of the sequence (Fu et al., 2018).  Tuffereau et al. (1998) suggested that RVG 
interacts with a specific receptor on neural cells to allow such profound infectivity of the CNS.  
Nowadays, it is widely accepted that the identity of this receptor is most likely the neuronal 
nAChR, common to both the neuromuscular junction and neurons (Lafon, 2005; Vigerelli et al, 
2014; Gooding et al, 2015).   This is perhaps not surprising, as RVG shares homologous 
sequences with loop 2 of snake neurotoxins (Lentz, 1991).   
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Kumar et al. (2007) first exploited the CNS-specific action of RVG to successfully deliver siRNA 
to the brain in mice and subsequently observed positive therapeutic effects.  Kumar and 
colleagues fabricated a 29-amino acid derivative of RVG, termed RVG-29, which showed 
evidence of specific binding to neuronal cells in vitro and in vivo via the nAChR.  To enable RVG-
29 conjugation to siRNA, the peptide was fixed with a 9-arginine residue tail, which would also 
aid cell-penetrating ability.  Results from this early study on RVG-29 did not give rise to a 
detectable immune response in the form of antibodies or inflammatory markers, meaning drug 
delivery was specific, safe and non-invasive.  Over the past decade, further studies on RVG-29 
as a brain targeting ligand have been carried out with much success for a range of neurological 
disorders (Liu et al., 2009; Chen et al., 2011a; Son et al., 2011; Kuan et al., 2012; Cooper et al., 
2014; Lee et al., 2017). 
Liu et al. (2009) demonstrated how RVG-29 could be easily incorporated into a drug delivery 
vehicle of pegylated polyamidoamine dendrimers complexed with a gene payload.  RVG-29 
modification permitted improved transport efficiency across an in vitro BBB model in comparison 
to unlabelled dendrimers.  Furthermore, in vitro studies presented evidence of uptake in brain 
endothelial cells via clathrin or calveolae-mediated endocytosis mechanisms.  The neural-
specific properties of RVG-29 were further demonstrated by Chen et al. (2010) when 
itraconazole-loaded albumin nanoparticles were preferentially targeted to mouse brain 
endothelial cells over non-neural Hela cells in vitro.   Furthermore, RVG-29 facilitated greater 
brain distribution of itraconazole in vivo. 
Studies on gene delivery to the brain by Son et al. (2011), Kuan et al. (2012) and Cooper et al. 
(2014) have exploited the activity of RVG to overcome the obstacles presented by the in vivo 
BBB.  Kuan et al. (2012) used RVG-29 to deliver a therapeutic RNA payload to 6-OHDA PD 
model rats.  The RNA payload was only detected in neural cells which expressed neuronal 
nicotinic acetylcholine receptors.  Intravenous injection of the RVG-RNA conjugate lead to 
significant neuroprotection after 6-OHDA induced toxicity.  RVG-29 facilitated the positive effect 
of the viral RNA on mitochondrial complex 1 in DA neurons, creating a potential treatment for PD 
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caused by mitochondrial complex 1 dysfunction.  No immune response was reported following 
testing.  The authors reported that for future development, the encapsulation of the RNA would 
prolong half-life and protect against degradation.  Similarly, Cooper et al. (2014) achieved 
successful delivery of siRNA-loaded exosomes to the brain to reduce α-synuclein aggregation in 
a mouse model.  RVG-29 is a versatile brain targeting ligand which can be used within many 
types of transport vehicle or therapeutic system.  More recently, RVG-29 has been employed to 
maximise the in vivo distribution of silica-coated gold nanorods for photothermal therapy of brain 
tumours (Lee et al., 2017). 
RVG-29 is derived from residues 189-214 of the parent RVG sequence, however another 
derivative from the 330-357 position has also gained attention for its promising brain-targeting 
properties (Fu et al., 2018).  Rabies virus-derived peptide (RDP) has a total 39-amino acid 
sequence composed of the residues -KSVRTWNEIIPSKGCLRVGGRCHPHVNGGG- and fixed 
with an arginine (9) tail -RRRRRRRRR- at the peptide C terminal.  Fu et al. (2012) used RDP to 
deliver different therapeutic proteins to the CNS of mice as part of a fusion protein delivery 
system.  RDP facilitated the in vivo BBB crossing of the therapeutic proteins without affecting 
their biological activity.  It was later shown in studies by Fu et al. (2013a) and (2013b) how RDP 
preferentially targeted different therapeutic payloads to cells of neural origin only, both in vitro 
and in vivo.  These studies also showed the significant benefit of RDP as part of a fusion protein 
with the growth factor GDNF (Fu et al., 2013a) and the BDNF gene (Fu et al., 2013b) in reducing 
PD symptoms in mice. 
 
It has also been proposed that the mechanism of RDP cellular uptake in neural cells is via 
clathrin-coated pit endocytosis, however the mechanism of cell entry is not fully understood at 
present.  The relative ease of RDP conjugation to various therapeutics and delivery vehicles 
offers a wide range of applications for this peptide as a brain targeting ligand.  In addition to this, 
investigations in animal models so far have not detected any significant toxicity or immune 
response, indicating that RDP may be safely used in vivo.  In fact, RDP has already been used 
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for diagnostic purposes as Zhang & Fu (2015) functionalised RDP to gold nanoclusters for non-
invasive brain screening in mice.   
 
1.5.  Conclusion 
 
The difficulties presented in achieving effective drug delivery across the BBB are one of the 
biggest challenges faced in PD therapy.  It is clear that the most beneficial solution to PD would 
be the restoration of DA neurons in the SNpc, however to do this non-invasively requires the 
mobilisation of native neural stem cells in situ.  The potential advantages of NTF for PD are 
plentiful and with the correct means of brain delivery, could surely present a promising new 
treatment modality.   
Taking advantage of native BBB receptors is a hopeful means of achieving delivery and 
distribution of therapeutics to the brain.  Peptide ligands targeting a particular receptor have the 
ability to transport a conjugated drug or drug vehicle and subsequently facilitate cellular 
internalisation.  Peptides derived from neurotoxins have perhaps presented the most desirable 
properties of such a ligand, particularly of the snake species, which specifically target the nAChR.  
It is important however that the drug vehicle is non-toxic and so far, not enough data exists on 
the long-term in vivo safety of neurotoxin derivatives.   
Derivatives of RVG have emerged as lead candidates in the non-invasive, specific and safe 
targeting of neural cells.  Many studies have provided solid evidence of in vivo efficacy and thus 
the glycoprotein derived from the rabies virus is an exciting prospect in the development of a 
brain delivery vehicle.  It would be desirable to use a ligand such as RDP as a means of 
facilitating NTF delivery for the treatment of PD.  RDP has shown evidence of preferential uptake 
by neural cell types specifically and importantly can overcome the BBB in vivo following systemic 
administration.   
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Polymeric nanoparticles have versatile surface characteristics which allow ligand attachment, as 
illustrated in Figure 1.5.  Given the short half-life of NTF, encapsulation within a protective drug 
delivery vehicle surface-conjugated with RDP may be advantageous for increasing in vivo 
stability.  Thus far, RDP has been used predominantly as part of a therapeutic fusion protein 
which does not offer the protection required for payloads susceptible to degradation.  The benefit 
of growth-promoting factors on neural stem cells may be optimised to full potential following 
sufficient accumulation in the brain and protection from peripheral degradation. 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.  Diagrammatic representation of a targeted nanoparticle for specific drug delivery.  The 
encapsulated therapeutic payload is protected from degradation and targeted to a specific 
location with peripherally attached ligand. 
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1.6.  General aims 
 
The general aim of this research was to develop a neural cell-specific drug delivery system 
capable of crossing an in vitro BBB model.  Peptide-conjugated polymeric nanoparticles were 
formulated to encapsulate various model payloads, which were then tested in a range of cell-
based in vitro studies to observe the effects of RDP as a targeting ligand.  Following assessment 
of RDP serum stability, the sequence was optimised and assessed for targeting activity in a 
range of cell types.  Finally, a triple culture BBB model will be established and used to assess 
the efficacy of peptide-conjugated nanoparticulate preparations.  The aims are summarised as 
follows:  
(1) Explore various formulation parameters to synthesise a suitable polymer-based 
nanoparticulate drug vehicle with surface-conjugated RDP.   
(2) Test optimal RDP-conjugated nanoparticle formulation(s) on neural and non-neural cell 
types to assess neural-specificity of the drug delivery system. 
(3) Assess RDP stability characteristics and optimise the peptide sequence. 
(4) Develop an in vitro BBB model using three human cell types from the neurovascular unit 
and subsequently determine the ability of peptide-conjugated nanoparticles to traverse 
this model. 
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Chapter 2 
Development of a polymeric 
nanoparticulate drug delivery vehicle 
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2.1. Introduction  
 
2.1.1. Nanotechnology in drug delivery 
 
Nanoparticles (NP) have been at the forefront of new drug delivery strategies over the past 
couple of decades.  The use of NP is not exclusive to drug delivery alone, NP also have 
applications as diagnostic, theranostic and imaging agents in vivo (Lim et al., 2015; Wolfbeis, 
2015).  The small size and ability of NP to protect encapsulated sensitive therapeutics offers a 
unique advantage for controlled and targeted drug delivery (Wicki et al., 2015).  Nanoparticle-
based therapeutics have been researched extensively, particularly for use in targeted cancer 
chemotherapy, as reviewed by Sanna et al. (2014).  Many cytotoxic drugs have been 
encapsulated within nano-sized delivery vehicles for reduction of unwanted side effects resulting 
from non-specific targeting and enhanced tumour retention due to their ability to permeate leaky 
tumour vasculature (Peer et al., 2007).   
Encapsulation of drugs within NP can overcome pharmacokinetic issues associated with free 
drug formulations such as solubility and instability to blood enzymes (Blanco et al., 2015).  Many 
different types of NP have been used to encapsulate therapeutics for use as drug delivery 
systems across a range of disease states.  A plethora of research can be found in the literature 
for many different types of NP drug delivery vehicle, some of the most popular examples 
including metallic NP, stimuli-responsive NP, solid lipid NP and polymeric NP to name only a 
few.  Therefore, only the aforementioned nanomaterials and their role in NP-mediated drug 
delivery are highlighted below. 
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2.1.2. Metallic NP 
 
Metallic NP composed of materials such as iron oxide, gold and silver have gained recognition 
for their application as diagnostic and therapeutic agents (Mody et al., 2010).  Iron oxide NP have 
been used as a contrast agent in high resolution magnetic resonance imaging (MRI), targeted 
drug delivery and cell tracking.  Advantages of magnetic NP are mainly associated with the ability 
to produce a narrow particle size range and easily modify surfaces to improve cellular uptake 
characteristics. For example, Gupta & Curtis (2004) engineered PEG-coated iron oxide NP to 
improve cellular adhesion and uptake.   
Silver NP have been conjugated with targeting molecules for use as nanoprobes (Mody et al., 
2010) and also have shown efficacy as cytotoxic chemotherapeutic agents through anti-
proliferative effects on numerous cancer cells types (Nayak et al., 2016; Barua et al., 2017).  
Ruan et al. (2012) used fluorescent magnetic NP-labelled mesenchymal stem cells to locate, 
image and treat gastric cancer in vivo. Dual modality contrast through fluorescence imaging and 
MRI enabled specific application of an external magnetic field to induce hyperthermia therapy 
upon cancer cells. 
Silver NP are also antimicrobial in nature and thus have been incorporated into wound treatments 
and medical devices such as surgical instruments (Furno et al., 2004).  In fact, both silver and 
copper NP have been utilised for their antimicrobial action through mechanisms such as cell 
membrane disruption and oxidative stress (Applerot et al., 2012; Herman & Herman, 2014; Le 
Quay & Stellacci, 2015; Meghana et al., 2015).  Recently, Banik et al. (2018) detailed the 
preparation of bimetallic copper-silver NP which were successfully used to induce cytotoxicity in 
various cancer cell types through induction of apoptosis.  These bimetallic NP greatly affected 
cancer cell viability, with much less effect on normal cells.  Despite the apparent efficacy as an 
anti-cancer agent, these NP would be safer if they could be targeted more specifically to 
cancerous cells through surface modification with a targeting ligand.   
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Gold NP have mainly been reserved for biological imaging, particularly for cancer diagnosis (El-
Sayed et al., 2005; Tong et al., 2009).  They have however, been surface-conjugated with RDP 
for targeted brain imaging (Zhang & Fu, 2015) and gold nanorods have been utilised for targeted 
photothermal therapy due to their unique optical properties (Huang et al., 2010b).   Much interest 
has been drawn to metallic NP due to their versatility for use within drug delivery systems.  
Classical methods of synthesis however, require costly, hazardous starting materials and 
energy-intensive production processes which negatively impact the environment (Thakkar et al., 
2010; Edmundson et al., 2014; Mandava, 2017).  Biogenic synthesis can overcome these 
problems, which involves natural production of metal-based NP in organisms such as bacteria, 
yeast and fungi (Seabra & Duran, 2015).  Unfortunately, these methods are not reproducible and 
are difficult to scale up, as the exact method of NP synthesis is not clear.  
 
2.1.3. Stimuli-responsive NP 
 
NP can be synthesised to respond to one or more stimuli such as pH, temperature, magnetic 
fields, redox and enzymes (Chen et al., 2011b; Mura et al., 2013; Wang et al., 2016).  Response 
to stimuli from the external or intracellular environment can be used to trigger therapeutic effect 
or optimise payload release characteristics, offering an element of control to in vivo activity 
(Zhang et al., 2016).  These types of stimuli-responsive NP can also be coupled with a targeting 
ligand for enhanced specificity of drug release at the target site in vivo (Xiao et al., 2014). 
Zhang et al. (2018) recently fabricated pH- and redox- responsive NP for drug and gene delivery 
through use of a cationic polymer shell and a charge reversible pullulan coating.  Lee et al. (2018) 
also developed a NP vehicle which disintegrated in response to acidic microenvironment to 
release a chemotherapeutic payload for prevention of pulmonary colorectal carcinoma 
metastasis.  Thermo-responsive nanoparticulate systems have also been utilised for therapeutic 
response to external stimuli such as near infrared laser irradiation (Niidome et al., 2010; Nam et 
al., 2012).   
43 
 
These systems are relatively new developments in the field of nanoparticulate drug delivery and 
concerns have been raised over low drug loading capability and lack of biodegradability (Cheng 
et al., 2013).  Further research to address such issues is required for the clinical development of 
stimuli-responsive NP as drug delivery vehicles. 
 
2.1.4 Solid lipid NP  
 
Research into the use of solid lipid NP (SLN) has been on the rise since the mid-90s (Mukherjee 
et al., 2009).  Properties such as good biocompatibility and cost effective large-scale production, 
without the need to use organic solvents, are a few of the advantages of this type of NP vehicle 
(Muller et al., 2000).  SLN have been used to encapsulate a variety of drugs such as cytotoxic 
methotrexate (Ruckmani et al., 2006) and anti-hypertensive olmesartan medoxomil (Pandya et 
al., 2018), increasing the bioavailability of poorly water-soluble drugs (Hu et al., 2008).   
 
2.1.5. Polymeric NP 
 
Polymeric NP are a diverse group of nanocarriers in which a wealth of research has been 
invested for use in drug delivery strategies.  Properties such as high drug loading capacity, 
stability, facile surface modification and manipulation of characteristics such as release kinetics, 
size and charge are a few of the reasons which make polymers a favourable biomaterial (Patel 
et al., 2012).  Perhaps most importantly, evidence of in vivo safety in humans has contributed to 
the popularity of such materials (Kumari et al., 2010).  This combination of features coupled with 
simple methods of synthesis gives incentive for developing polymer-based nanomaterials. 
Polymers may be either natural or synthetic.  Naturally occurring polymers such as albumin, 
chitosan and sodium alginate are popular due to their biocompatibility and safety in humans (El-
Say & El-Sawy, 2017).  Despite this, synthetic polymers are still more popular at the present 
time, probably due to certain formulation hurdles in the use of the natural polymers.  For example, 
44 
 
some chitosan NP have a limited ability for controlled release due to high solubility at low pH and 
poor solubility at physiological pH, which often requires some form of chemical modification 
(Elgadir et al., 2015; Nur & Vasiljevic, 2017).  Additionally, alginate is useful due to its 
mucoadhesive properties, however problems with low encapsulation efficiency can be 
experienced unless used in conjunction with another polymer (Sarmento et al., 2007).  There are 
numerous synthetic polymers which have been made into NP such as polylactides, 
polyglycolides, poly(lactic-co-glycolic acid) (PLGA), polycyanoacrylate, polycaprolactone (PCL), 
poly(methacrylic acid) (PMAA) and poly(butyl-cyanoacrylate) (PBCA) to name only a few (El-Say 
& El-Sawy, 2017) . 
One of the most common applications of polymeric NP to date, has been for the targeting of solid 
tumours.  Many different polymers have been utilised for the encapsulation of cytotoxic drugs for 
chemotherapeutic purposes, sometimes with use of more than polymer in the same formulation.  
Rao et al. (2014) produced a thermally-responsive nanoparticulate system of two polymers, 
Pluronic® F127 and chitosan, to encapsulate curcumin for anti-cancer effects.  This polymer 
blend was used again but for a doxorubicin payload instead, which subsequently released 
payload in an accelerated manner in response to the acidic tumour microenvironment (Rao et 
al., 2015).   Most recently, Rychahou et al. (2018) formulated biocompatible poly(ethylene 
glycol)-ε-poly(caprolactone) (PEG-PCL) block co-polymer NP for the delivery of poorly soluble 
cytotoxic drug to lung metastasis.  Another biodegradable polymer, poly(beta-amino ester) 
(PBAE), has been used to fabricate NP capable of preferentially targeting hepatocellular 
carcinoma cells over healthy hepatocytes in vitro (Zambino et al., 2017).  Despite multiple reports 
of preferential endocytosis of PBAE-based NP in cancer cells, the underlying mechanism of this 
phenomenon is not yet entirely understood (Tzeng et al., 2013; Guerrero-Cázares et al., 2014).  
Polymeric NP have shown the ability to cross the BBB and enter the CNS to deliver a therapeutic 
payload.  Unlike targeting of solid tumours outside the CNS, NP often require surface 
modifications with targeting molecules or ligands which aid in cellular uptake mechanisms across 
the BBB.   Kreuter et al. (1995) first achieved CNS delivery of a polymeric NP formulation through 
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polysorbate-80-coated PBCA NP.  This NP preparation crossed the BBB in mice to deliver a 
therapeutic peptide which was bound to the PBCA polymer.  In more recent times, a number of 
different polymers have been used as drug delivery vehicles to the CNS.  Byeon et al. (2016) 
used cationic- and mannose-modified albumin NP to target brain tumours in mice through 
exploitation of membrane transporter molecules.  Enhanced accumulation of cytotoxic drugs was 
achieved in glioblastoma tumours by functionalisation of pluronic-based polymeric micelles with 
a small cyclic Arginine-Glycine-Aspartic acid peptide in animal studies by Miura et al. (2013) and 
Huang at al. (2016).    
Poly(lactic acid) (PLA) is another commonly used polymer for NP formulation.  Liu et al. (2008) 
detected accumulation of poloxamer 188-coated PLA NP in the brain of mice, amongst other 
organs, with particle sizes of up to 300 nm.  The cell penetrating peptide TAT enhanced the CNS 
bioavailability of the anti-HIV drug ritonavir when conjugated to PLA NP in a study by Rao et al. 
(2008).  These non-specific NP surface ligands aid cellular uptake of polymeric NP across the 
BBB, but also show substantial accumulation in other major organs such as the liver.  Although 
most commonly used polymers are non-toxic and biocompatible, it is desirable to avoid 
unnecessary biodistribution in other areas apart from the target organ.  Emulsifiers such as 
poloxamers and polysorbates can promote cell uptake via temporary membrane disruption, 
which may be harmful in high doses and prolonged exposure (Pardridge, 2005).  It is therefore 
preferable to attach a more specific targeting ligand to these polymeric nanocarriers, such as an 
RVG derivative, which utilises mechanisms such as receptor-mediated endocytosis.  For 
example, poly(ethylenimine) was the polymer of choice to conjugate to RVG in a study by Hwang 
et al. (2011) for non-toxic brain targeting of mRNA in mice. 
Micelles are drug carriers commonly formed from amphiphilic polymers, however they tend to be 
much smaller in size (<100 nm) than traditional polymeric NP.  Targeted micelles have been 
utilised in recent times to achieve drug delivery across the BBB predominantly for the treatment 
of solid tumours (Wang et al., 2012; Zhu et al., 2017).  The hydrophobic core formed by 
amphiphilic block co-polymers in aqueous solution can house hydrophobic drugs (Sezgin-
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Bayindir et al., 2016), however are not the best choice for highly water-soluble or protein 
payloads.  
 
2.1.5.1. Poly(lactic-co-glycolic acid) (PLGA) NP 
 
PLGA is one of the most commonly used biodegradable synthetic polymers for drug delivery and 
scaffolding in tissue engineering (Burg et al., 2000; Nair & Laurencin, 2007).  The popularity of 
PLGA over recent decades has been due to its favourable degradation properties, ability to 
encapsulate molecules of a large size range, solubility in many common solvents, sustained drug 
release characteristics and established clinical experience (Makadia & Siegel, 2011).  PLGA 
hydrolyses in vivo degrading into monomer units, lactic acid and glycolic acid, which are 
subsequently eliminated as carbon dioxide and water by normal metabolic processes (Catiker et 
al., 2000; Jana et al., 2014).  These by-products are toxicologically safe in humans and 
consequently PLGA has been approved by the Food and Drug Administration (FDA) for use in 
drug products (Jain, 2000).  FDA-approved preparations containing PLGA already on the market 
include Somatuline LA (Ipsen) for acromegaly and Trelstar Depot (Pfizer) for prostate cancer 
(Mundargi et al., 2008). 
PLGA NP formulation processes such as the double emulsion technique (w/o/w) have become 
a favourable choice for encapsulating highly water-soluble drugs and protein-based therapeutics 
(Makadia et al., 2008; Mundgardi et al., 2008).  Growth factors are examples of expensive protein 
payloads which can be encapsulated within PLGA NP with loading efficiency for targeted drug 
delivery, whilst offering protection against enzymatic degradation in vivo.  Untargeted PLGA NP 
can accumulate in organs such as the liver, spleen, lymph nodes and peritoneal macrophages 
due to their recognition by the reticuloendothelial system (RES) upon blood circulation (Anderson 
& Shive, 1997).  This issue can be overcome by the facile surface modification of polymeric NP 
with a targeting ligand, which can potentially enable site-specific accumulation.   
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Incorporation of another polymer alongside PLGA, such as polyethylene glycol (PEG), can 
reduce non-specific accumulation of NP due to anti-aggregative effects and shielding of the 
particle surface from RES recognition (Amoozgar & Yeo, 2012; Jokerst et al., 2012).  Attachment 
of a targeting ligand on the surface of PLGA NP can also reduce non-specific accumulation in 
organs (Cheng et al., 2007; Scott et al., 2007).  There are examples in recent times of PLGA NP 
functionalisation with targeting ligands to achieve drug delivery across the BBB, either through 
non-specific membrane interactions (Kulkarni & Feng, 2011) or receptor-mediated mechanisms 
(Geldenhuys et al., 2014).  Li et al. (2011) improved specificity of a PEG-PLGA NP system to the 
brain in mice through surface-conjugation with a 12-amino acid phage display peptide compared 
to unmodified NP, which accumulated at higher levels in the liver and spleen.  Similarly, Li et al. 
(2018) recently conjugated lactoferrin to the surface of PEG-PLGA NP to enhance accumulation 
in mouse brain, due to high expression of the lactoferrin receptor on BBB endothelial cells, for 
the treatment of gliomas.   
The use of a ligand-modified PLGA-based nanoparticulate vehicle is an attractive prospect for 
the non-invasive delivery of sensitive therapeutics to the brain.  Potentially beneficial treatments, 
such as growth factors for the treatment of PD or other neurodegenerative conditions, may be 
selectively targeted to the brain where therapeutic effect can be exerted.  Exploiting the 
neurotropism of a targeting ligand such as RDP in combination with a safe, versatile and 
biodegradable nanovehicle may produce such a drug delivery system.     
The aims of the work reported herein were therefore to: 
(1) Formulate and optimise PLGA NP preparations encapsulating various model payloads, 
including analysis of particle characteristics, stability and release data. 
(2) Facilitate the surface-conjugation of targeting ligand RDP to optimal NP preparations via 
amide bond formation.  Free carboxyl groups of PLGA can be activated to react with 
amine groups of the RDP sequence, promoting attachment of RDP to the NP. 
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2.2. Materials and Methods 
 
2.2.1. Materials 
 
Resomer® RG 502 H, Poly(D,L-lactide-co-glycolide) (PLGA) 50:50, acid terminated (MW 7,000-
17,000), dichloromethane (DCM), poly(vinyl) alcohol (PVA) 87-89% hydrolyzed- MW  85,000-
124,000, poly(ethylene glycol) methyl ether-block-poly(L-lactide-co-glycolide) (PEG-PLGA), 
bovine serum albumin, myoglobin, 3,3-dimethylglutaric acid (DMGA), MES hydrate, 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccinimide (NHS), were all purchased 
from Sigma-Aldrich (UK).  RDP was synthesised by GL Biochem (Shanghai) Ltd.  Doxorubicin 
hydrochloride was obtained from VWR International (Pennsylvania, USA).  4-12% Bis-Tris 
NuPAGE® gel, NuPAGE® MES SDS Running Buffer (20X), Coomassie Brilliant Blue R-250 dye 
and SeeBlue® Plus 2 pre-stained protein standard were all purchased form ThermoFisher 
Scientific (UK). 
 
2.2.2. Preparation of Nanoparticles (NP) 
 
2.2.2.1.    Preparation of blank NP by a single emulsion solvent-evaporation method 
Acid terminated (Resomer® 502 H) PLGA (100 mg) was dissolved in 4 mL of dichloromethane 
(DCM).  PVA was prepared as a 1.25% solution in double distilled water (ddH2O).  The 
PLGA/DCM organic phase was added dropwise to 50 mL of 1.25% w/v PVA solution and 
homogenised on full power for 6 minutes (Silverson LST homogeniser, Silverson, USA).  Solvent 
was evaporated from the resulting o/w emulsion by stirring overnight at room temperature.  The 
NP emulsion was then centrifuged at 18809 g for 30 minutes at 4 °C, before washing the pellet 
with ddH2O thrice for ten minutes each time. The final pellet was resuspended in 5 mL ddH2O 
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and freeze dried using a Labconco FreeZone 4.5 plus benchtop freeze dry system on automatic 
mode (-40°C, 0.12 mbar) for 48 hours. 
 
2.2.2.2.    Preparation of doxorubicin-loaded NP (Dox NP) by a double emulsion-solvent 
evaporation technique 
Doxorubicin hydrochloride was selected as a model hydrophilic drug for incorporation into PLGA 
NP due its cytotoxic effects, which is easy to quantify in cell-based assays.  A double emulsion-
solvent evaporation technique, as depicted in Figure 2.1, was initially used to fabricate drug-
loaded PLGA NP according to methods similar to McCarron et al. (2008) and Kalaria et al. (2009).   
Model drug, doxorubicin hydrochloride (2 mg) was dissolved in 1 mL of 2.5% w/v PVA solution 
in ddH2O.  This was added dropwise to a solution of 100 mg PLGA in 4 mL DCM and 
mechanically homogenised on full power for 2 minutes (on ice) to produce the primary w/o 
emulsion (VDI 12 S2 homogeniser, VWR International Ltd., USA).  This w/o emulsion was then 
added dropwise to 50 mL of 1.25% w/v PVA solution and homogenised (on ice) for a further 6 
minutes on full power to produce a w/o/w double NP emulsion.  After allowing solvent to 
evaporate overnight at room temperature, the NP formulation was centrifuged and freeze dried, 
as detailed in section 2.2.2.1.  Supernatant from centrifugation was retained to analyse 
doxorubicin entrapment efficiency (EE) using UV-Visible spectroscopy at 480 nm. 
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Figure 2.1.  Diagrammatic representation of a double emulsion technique used to prepare drug-loaded 
PLGA NP. 
 
 
 
2.2.2.3.  Method development of NP preparation 
To optimise the PLGA NP formulation parameters bovine serum albumin (BSA) was used as a 
model drug to mimic a hydrophilic protein payload (MW 66.5 kDa).  Using the same double 
emulsion method as previously detailed in section 2.2.2.2, the addition of PEG-PLGA co-polymer 
(5% and 10% w/w) to PLGA was analysed along with varying the internal and external aqueous 
phase percentage of PVA surfactant.  The effect of using different solvents in the organic phase 
on hydrophilic drug entrapment was subsequently investigated in comparison to DCM.  The 
solvents used in addition to DCM were ethyl acetate, DCM/acetone 1:1, DCM/acetone 4:1 and 
DCM/methanol 1:1.  Following these modifications, lead formulations were selected based on 
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best characteristics such size, PDI, zeta potential and drug entrapment.  Additional adjustments 
such as reducing internal/external aqueous phase volumes were also explored to further 
optimise NP characteristics.  BSA loading was maintained constant at 4% w/w (4 mg BSA per 
100 mg polymer).    
Finally, the effect of using a probe sonicator in small volumes rather than a mechanical 
homogeniser was investigated for effect on NP characteristics.  The primary w/o emulsion phase 
was sonicated on ice with a Fisher Scientific FB50 sonicator probe (Pittsburgh, PA, USA) for 60 
seconds at 80% amplitude (55 W).  The second emulsion (w/o/w) was formed after sonication 
for a further 2 minutes, on ice, under the same conditions.    
An optimised method of Dox NP formulation was subsequently developed as a result of 
investigations carried out in section 2.2.2.3.   
 
2.2.2.4.  Preparation of myoglobin-loaded NP (Myo NP) 
Myoglobin (16.7 kDa) was selected as a second model protein payload, due its similarity in 
molecular weight to basic fibroblast growth factor (18 kDa).  The optimal NP formulation 
conditions, as a result of investigations from section 2.2.2.3, were selected to fabricate 
myoglobin-loaded NP (Myo NP) at 4% w/w loading (4 mg drug per 100 mg polymer).  Various 
Myo NP were prepared by the double emulsion-solvent evaporation method and characterised 
according to methods in section 2.2.4. 
 
2.2.3.  Determination of drug entrapment efficiency (EE) 
 
Doxorubicin EE was calculated indirectly using supernatant from the formulation process.  A 
standard curve of doxorubicin concentration was prepared using UV-Visible absorbance 
spectrometry at 480 nm (Figure 2.2).  The amount of drug present in the supernatant was 
measured at 480 nm and calculated according to the equation from the standard calibration 
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curve.  This value was subtracted from the total amount of doxorubicin initially added during the 
formulation process.   
Percentage EE was subsequently calculated according to the following formula: 
 
Equation 2.1.    𝐸𝐸 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑− 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑
 𝑥 100% 
 
 
For proteins payloads, BSA and myoglobin, the EE was also calculated indirectly using a BCA 
(bicinchoninic acid) assay.  A standard calibration curve was obtained through dilutions of 
albumin standard (2 mg/mL) provided in the Pierce™ BCA Protein Assay Kit (ThermoFisher 
Scientific).  Using the microplate method, 25 µL of protein solution was added per well.  200 µL 
of working reagent was added to protein samples in each well and subsequently incubated at 
37°C for 30 minutes.  After 30 minutes, UV-Visible absorbance of samples at 562 nm was 
measured.  Protein causes the reduction of Cu2+ to Cu1+ under alkaline conditions.  The cuprous 
cation (Cu1+) is detected by bicinchoninic acid to induce a colour change of the sample from 
green to purple.   BCA assay was carried out on supernatant from the NP formulation process of 
either BSA or myoglobin payload.  Protein concentration was calculated according to the 
standard calibration curve (Figure 2.3) and EE was subsequently obtained according to Equation 
2.1 above, as for doxorubicin. 
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Figure 2.2.  Calibration curve of doxorubicin hydrochloride using UV-Visible spectroscopy at 480 nm, used 
to calculate doxorubicin entrapment efficiency in PLGA NP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.  BCA assay calibration curve of bovine serum albumin (BSA) using UV-Visible spectroscopy 
at 562 nm, used to calculate protein drug entrapment efficiency in PLGA NP.  
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2.2.4.  Dynamic Light Scattering (DLS) 
 
NP were characterised for size, zeta potential (ZP) and polydispersity index (PDI) by dynamic 
light scattering (DLS) analysis using a Malvern Zetasizer (Nano-series, Malvern Instruments, 
UK).  Prior to DLS analysis, 1 mg of NP were dispersed in 1 mL of ddH2O for measuring size and 
PDI.  For ZP measurements, NP were dispersed in 1.0 mM KCl, pH 7.5, to maintain a constant 
ionic strength.  NP suspensions were filtered using a using a 0.45 µm sterile filter prior to analysis 
to remove aggregated material.  Results were taken as an average of three measurements and 
reported as average ± standard deviation (SD). 
 
2.2.5.  Drug release studies 
 
Release of doxorubicin and myoglobin from leading NP formulations was measured at 37 °C in 
both 0.1 M PBS at pH 7.4 and 0.01 M dimethylglutaric acid (DMGA) buffer at pH 4.5, according 
to a method similar to Betancourt et al. (2007).  The acidic environment in DMGA buffer mimics 
the pH conditions of endocytic vesicles during cellular uptake, as late endosomes/lysosomes can 
have a pH of around 4.5 (Sorkin & von Zastrow, 2002).   
DMGA buffer (0.01 M) was prepared by addition of 3, 3-dimethylglutaric acid (6 mM), sodium 
hydroxide (3.9 mM) and sodium chloride (150 mM) to ddH2O.  Sodium hydroxide (2 M) was used 
to adjust the buffer to pH 4.5.  PBS was prepared by dissolving one PBS tablet per 100 mL of 
distilled water.  Dox NP or Myo NP (15 mg) were added to a centrifuge tube and dispersed in 10 
mL of either PBS or DMGA buffer before being incubated at 37 °C in an orbital shaker at 100 
RPM.  Drug release was measured at various time points over 7 days by centrifuging the 
respective NP samples at 18809 g for 12 minutes and then transferring 200 µL aliquots of 
supernatant to a 96-well plate.  200 µL of fresh buffer was replaced to maintain sink conditions. 
Doxorubicin UV-Visible absorbance was measured at 480 nm (FLUOstar Omega microwell plate 
reader, BMG Labtech, Germany).  The amount of drug in the supernatant was calculated using 
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a standard curve for doxorubicin.  Doxorubicin release was calculated as a percentage of 
maximum total doxorubicin in the NP, determined from the EE, with results expressed as 
percentage cumulative release.  The same process was used to calculate myoglobin release; 
however, a BCA assay was used to determine myoglobin concentration in the collected samples.  
 
2.2.6.  NP and payload stability studies 
 
2.2.6.1.  Scanning electron microscopy (SEM) imaging of NP morphology 
Blank PLGA NP preparations were prepared and re-suspended in ddH2O.  Samples were 
incubated at 37 °C for 0, 1, 4, 10, 30 and 60 days prior to freeze drying, to assess changes in 
polymeric NP characteristics at normal body temperature (36.5-37.5 °C).  Small quantities of NP 
were mounted onto an aluminium stub and sputter coated in a Polaron E5100 sputter coater 
equipped with a gold/palladium target, prior to imaging under high vacuum in secondary electron 
mode (F.E.I Quanta Environmental).  The use of ddH2O was preferred over phosphate buffered 
saline (PBS) or indeed cell culture media, due to the possibility of salt deposits or other residual 
material causing decreased SEM image quality.  
 
2.2.6.2.  Assessment of myoglobin payload stability using SDS-PAGE  
The stability of the NP payload on dry storage over 6 months was evaluated using sodium 
dodecyl sulphate- polyacrylamide gel electrophoresis (SDS-PAGE).  Freshly prepared 
myoglobin-loaded NP were lyophilised prior to storage at room temperature in a desiccator and 
protected from light.  At various time points, NP (1 mg) were added to 1 mL of ddH2O and 
vortexed to aid dispersion. 50 µL of NP sample was immediately added to 10 µL Laemmli 
treatment buffer (5x) and boiled for 10 minutes to denature NP and protein payload.  Denatured 
samples were frozen and stored until required. 
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Approximately 30 µL of myoglobin samples and 10 µL of SeeBlue® Plus2 protein markers 
(Invitrogen, UK) were loaded onto a 4-12% Bis-Tris NuPAGE® gel in MES SDS running buffer 
(1x).  Gel electrophoresis was carried out in a Novex XCell SureLock™ Mini-Cell electrophoresis 
system (Life Technologies, USA) over 45 minutes and subsequently stained for 2 hours with a 
gel stain containing Coomassie Brilliant Blue dye.  The gel was destained overnight under gentle 
agitation at room temperature.  Formulas of treatment buffer and staining reagents are given in 
Appendix 1. 
 
2.2.7. Conjugation of peptide to Dox NP 
 
RDP was surface-conjugated to Dox NP via NHS/carbodiimide-mediated amide bond formation 
between peptide and free PLGA carboxyl groups, as shown in Figure 2.4 (Scott et al., 2008; 
Mathew et al., 2012; Liu et al., 2017a).  Firstly, 10 mL of 25 mM MES buffer (pH 5-6) containing 
30 mg/mL EDC and 60 mg/mL NHS was prepared as one solution.  This was added to 10 mL of 
a 30 mg/mL suspension of Dox NP, also in MES buffer (25 mM), to produce a total volume of 20 
mL.  This suspension was stirred at room temperature for one hour to activate free carboxyl 
groups of the acid terminated PLGA using EDC/NHS chemistry.  The activated Dox NP 
suspension was centrifuged at 18809 g for 30 minutes at 10°C, before washing the pellet thrice 
with ddH2O to remove excess EDC/NHS.  The activated Dox NP were resuspended in a small 
volume of PBS and 1 mL of peptide solution containing 3 mg RDP was added (500 mcg RDP 
per 5 mg NP).  The Dox NP/peptide mixture was initially incubated overnight at 4 °C to allow 
peptide conjugation to activated carboxyl groups.  However, upon method development to 
improve conjugation efficiency, this step was subsequently altered.  Instead, Dox NP/peptide 
were agitated gently on an orbital shaker (75 RPM) at room temperature for 8 hours.  Finally, the 
Dox NP were recovered by centrifugation as before and resuspended in PBS to produce RDP-
labelled Dox NP (RDP Dox NP).  The supernatant was collected to assess peptide conjugation 
efficiency (CE) using a BCA assay and UV-Vis spectrometry at 562 nm. 
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Figure 2.4.  Schematic diagram of amide bond formation between PLGA NP and RDP via EDC/NHS 
chemistry.  Free carboxyl groups of PLGA are activated by formation of two reactive 
intermediates, which are then able to form the amide bond with free primary amine groups 
on RDP.   
 
 
 
2.2.8. Determination of RDP conjugation efficiency (CE) 
 
RDP CE to PLGA NP was determined indirectly by a BCA assay.  A standard curve was prepared 
from absorption of albumin standards at 562 nm as before, allowing the amount of unconjugated 
RDP in the supernatant from the peptide conjugation process to be determined.  Using this value, 
the amount of RDP conjugated to NP was calculated indirectly, based on the total amount added 
during formulation.   
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The peptide CE was calculated according to the following formula: 
 
Equation 2.2.   𝐶𝐸 =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑎𝑑𝑑𝑒𝑑−𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑎𝑑𝑑𝑒𝑑
 𝑥 100% 
 
 
2.2.9. Statistical Analysis 
All results reported were statistically analysed using either an unpaired two-tailed t-test or a 
one/two-way ANOVA with or without post-hoc tests.  A P-value of < 0.05 was considered 
statistically significant.   
 
                                                                                    
 
 
2.3.  Results & Discussion 
 
2.3.1. NP formulation using a double emulsion-solvent evaporation method 
 
NP were formulated according to a double emulsion-solvent evaporation method and 
characterised for size, zeta potential (ZP) and polydispersity index (PDI) using dynamic light 
scattering (DLS).  Table 2.1 shows the results of NP characterisation studies and entrapment 
efficiency of cytotoxic model drug doxorubicin.   Doxorubicin was selected as a model payload 
as its cytotoxic effects are easy to detect and is relatively inexpensive compared to other drugs.   
PDI, reflecting the homogeneity of particle size, was 0.26 ± 0.04 for blank PLGA NP indicating a 
relatively narrow size range (scale 0-1).  It was determined that blank PLGA NP had an average 
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particle diameter of 240.2 ± 14.7 nm and a zeta potential of -18.4 ± 1.82 mV.  PLGA NP are often 
sized between 200-300 nm, even after drug loading (Azizi et al., 2013).    
 
 
Table 2.1.  Characterisation properties of blank PLGA NP and doxorubicin-loaded PLGA NP formulated 
in a pilot study using the double emulsion-solvent evaporation method. 
 
 
 
 
 
 
NP size is important as it can affect cellular uptake ability and in vivo distribution (He et al., 2010).  
Polymeric NP of around 50 nm are most efficiently internalised by cell endocytosis (Jiang et al., 
2008).  In vivo however, small particles (<100 nm) can non-specifically accumulate in many areas 
of the body.  Alternatively, uptake in target cells is difficult to achieve when particles are too large 
(> 500 nm) for most endocytosis mechanisms (Iversen et al., 2011) and are eventually 
sequestered by the liver (Cheng et al., 2007).  It is difficult to predict how size of NP will affect 
their biodistribution in vivo, as this can vary with different body organs (Cheng et al., 2007).  
Conjugation of NP to a specific targeting ligand such as RDP, would help to control in vivo 
biodistribution despite particle size.  Nevertheless, NP size of around 240 nm as reported in 
Table 2.1, is ideal for drug targeting. 
Incorporation of a doxorubicin payload caused a negligible effect on average NP diameter (242.7 
± 18.6 nm) and PDI (0.23 ± 0.01) compared to the blank NP formulation as P values were 0.86 
and 0.28 respectively (two-tailed T-test, statistically significant if < 0.05).  The zeta potential of 
Formulation Size (nm) PDI a       ZP b (mV) Dox EE c (%) 
Blank NP 240.2 ± 14.7 0.26 ± 0.04 -18.4 ± 1.8 - 
Dox NP 242.7 ± 18.6 0.23 ± 0.01 -14.6 ± 1.3 35.5 
ͣ  Polydispersity index ± standard deviation (SD), n=3;  b Zeta potential (mV) ± SD, n=3; c  Percentage 
drug entrapment efficiency (EE).  Following drug EE of 35%, drug content = 7 µg per 1 mg NP. 
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the Dox NP however increased to -14.64 ± 1.32 mV, which was a statistically significant change 
compared to the blank NP (P value 0.04).  Doxorubicin encapsulation caused NP zeta potential 
to become less negative, possibly due to drug molecules at the NP surface as well as in the core 
of the NP, affecting surface charge.  Zeta potential is important for the stability of a NP emulsion, 
as charge at the NP surface means particles are less likely to aggregate through electrostatic 
repulsion (Honary & Zahir, 2013).  Additionally, this can aid cellular uptake through electrostatic 
interactions at cationic and anionic sites of the cell membrane (Frohlich, 2012).  It is desirable 
that NP zeta potential holds a value between +/- 10-30 mV (Clogston & Patri, 2011) as particles 
which are too positive can cause membrane damage and those which have a large negative 
charge risk being repelled from the largely anionic cell membrane.  Due to these reasons, it is 
preferable to formulate NP which are not of neutral zeta potential, unless modified with a targeting 
ligand.   
Doxorubicin entrapment efficiency (EE) was determined indirectly using UV-Visible spectroscopy 
and was calculated to be 35.5%, using the original formulation method described in section 
2.2.2.2.  This meant that 0.7 mg of doxorubicin was encapsulated in 100 mg of PLGA polymer 
from a theoretical maximum of 2 mg (2% w/w drug loading).  The difficulty in achieving a high 
entrapment of doxorubicin is possibly owing to the high water solubility of doxorubicin 
hydrochloride.  Indeed, highly hydrophilic drugs are generally difficult to encapsulate, due to rapid 
diffusion of drug into the external aqueous phase during formulation.  Different factors such as 
organic phase solvent, surfactant content and phase volumes may all affect how much drug is 
encapsulated and thus these parameters were investigated herein. 
 
2.3.2. NP formulation development studies 
 
2.3.2.1. BSA formulation studies 
The NP size, zeta potential and PDI shown in Table 2.1 are satisfactory characteristics of a drug-
targeting nanoparticulate delivery vehicle.  However, the poor EE of hydrophilic drug could be 
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improved for better therapeutic efficiency and reduction of expense due to drug wastage.  
Considering this, certain formulation parameters from the original method were modified to 
investigate the effect on drug encapsulation, whilst maintaining good size and zeta potential 
properties.  The ideal payload, such as basic fibroblast growth factor, is a protein and much larger 
than doxorubicin.  Growth factors however are expensive and therefore for optimisation of NP 
formulation, bovine serum albumin (BSA) was used as a model payload to identify lead 
formulations.  Table 2.2 shows the formulation parameters tested in the first stage of 
investigations.  BSA loading (4% w/w), phase volumes, surfactant type and homogenisation 
times were kept constant for Formulations 1-10 (Table 2.2).   
 
 
Table 2.2. Preliminary investigation of NP formulation parameters to optimise hydrophilic drug 
encapsulation.  Ten different NP formulation conditions are detailed, varying solvent, PEG-
PLGA content and PVA concentration of the aqueous phases.  All other conditions are as 
previously described for the original formulation.   
 
 
 
Formulation            Solvent      PEG-PLGA (%) W1 PVA (%) W2 PVA (%) 
1 DCM 0 2.5 1.25 
2 DCM 0 4 2 
3 DCM 5 2.5 1.25 
4 DCM 5 4 2 
5 DCM 10 2.5 1.25 
6 DCM 10 4 2 
7 Ethyl acetate 0 2.5 1.25 
8 DCM & Methanol 1:1 0 2.5 1.25 
9 DCM & acetone 1:1 0 2.5 1.25 
10 DCM & acetone 4:1 0 2.5 1.25 
Constant formulation conditions- 4% drug loading, internal aqueous phase (W1) 1 mL, external aqueous phase 
(W2) 50 mL, full power mechanical homogenisation 2 min (w/o) & 6 min (w/o/w). 
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Surfactants such as PVA in the external aqueous phase are necessary for the formation of NP 
emulsions.  PVA acts as a stabilising agent, reducing surface tension and thus preventing 
coalescence between newly-formed particles (Rao & Geckeler, 2011).  Surfactant inclusion in 
the inner aqueous phase (W1) has been reported to further decrease particle size and aids drug 
entrapment in PLGA NP prepared by double emulsion-solvent evaporation methods (Chen et 
al., 2008; Yan et al., 2010; Mobarak et al., 2013).  Chen et al. (2008) prepared peptide-loaded 
PLGA NP using similar formulation parameters to the methods described in this work.  Chen and 
colleagues reported poor entrapment of peptide when surfactant was not used in the inner 
aqueous phase and a larger particle size.  PVA was therefore also included in the original 
formulation in the W1 phase, at a concentration of 2.5% (w/v).  It was subsequently investigated 
whether increasing PVA concentration to 4% (Formulations 2, 4 & 6) would improve drug 
entrapment efficiency, results of which are shown in Table 2.3.    
 
 
Table 2.3.  Results of characterisation studies for the 10 formulations detailed in Table 2.2.  Dynamic light 
scattering analysis was used to obtain size, PDI and zeta potential measurements.  
Entrapment efficiency of protein model drug, BSA, was measured by BCA assay.  
 
 
Formulation Size (nm) PDI a ZP b (mV) BSA EE c (%) 
 
1 177.4 ± 6.8 0.29 ± 0.01 -15.6 ± 0.0 11.0 
2 203.5 ± 4.0 0.43 ± 0.02 -9.6 ± 0.7 0 
3 258.8 ± 18.4 0.53 ± 0.05 -12.0 ± 0.7 16.6 
4 256.5 ± 0.5 0.28 ± 0.02 -6.6 ± 0.5 0 
5 315.0 ± 39.2 0.35 ± 0.06 -2.5 ± 0.0 10.0 
6 324.7 ± 17.3 1.00 ± 0.00 -2.5 ± 0.0 0 
7 108.3 ± 55.5 0.61 ± 0.40 -8.6 ± 0.3 0 
8 131.3 ± 3.8 0.29 ± 0.03 -8.6 ± 0.1 0 
9 178.2 ± 9.6 0.28 ± 0.01 -24.4 ± 2.8 0 
10 137.1 ± 4.6 0.35 ± 0.03 -5.6 ± 0.3 0 
ͣ  Polydispersity index ± standard deviation (SD), n=3;  b Zeta potential (mV) ± SD, n=3; c drug entrapment 
efficiency (%).    Statistical analysis between groups was carried out using a one-way ANOVA with Tukey’s 
HSD post-hoc test. 
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No BSA entrapment was detected in Formulations 2, 4 and 6 containing 4% (w/v) PVA (W1).  
Despite low entrapment efficiency, some BSA was encapsulated when W1 contained 2.5% w/v 
PVA in Formulations 1, 3 and 5.  In this instance, higher W1 PVA content did not improve 
encapsulation of drug and therefore remained at 2.5% (w/v) to investigate the effect of using 
more water-miscible solvents in the organic phase (Formulations 7-10).  PEG-PLGA co-polymer 
was introduced as part of the polymer blend at either 5% or 10% (w/w) in combination with 
different PVA concentrations (Formulations 3-6).  It has been well established in the literature 
the potential advantages of including PEG in NP formulations, mainly due to its shielding effect 
from the reticuloendothelial system and ultimately prolongation of in vivo half-life (Choi et al., 
2011). 
From the NP formulations which did show some BSA encapsulation, the size ranged from 177.4 
± 6.8 nm (Formulation 1) to 315.0 ± 39.2 nm (Formulation 5).  The only difference in these three 
formulations was the PEG-PLGA content, which appeared to significantly increase average BSA-
loaded NP diameter when results were statistically analysed using a one-way ANOVA (P value 
0.0016) and Tukey’s HSD post-hoc test (all P values < 0.05).  Increasing PEG-PLGA content 
also significantly affected surface charges between Formulations 1, 3 & 5 (P value < 0.05).  The 
10% PEG-PLGA in Formulation 5 caused zeta potential to become less negative and closer to 
neutral (-2.5 mV) compared to 5% PEG-PLGA in Formulation 3 (-12.0 mV) and no PEG in 
Formulation 1 (-15.6 mV).     
The organic phase was altered to contain more water-miscible solvents such as ethyl acetate, 
methanol and acetone (Formulations 7-10).  The primary emulsion from section 2.3.1 was 
produced using the water immiscible solvent, DCM, which might encourage rapid partition of 
doxorubicin hydrochloride into the outer aqueous phase during formulation of the second 
emulsion.  Use of a different solvent, which is more water miscible, could perhaps improve the 
amount of doxorubicin entrapped in the inner organic phase as suggested by Cohen-Sela et al. 
(2009).  This was investigated as the most likely factor to affect drug entrapment and so to 
compare effect, PVA and polymer composition were kept the same as the original formulation.   
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Ethyl acetate has been used previously as the organic phase in the formulation of drug-loaded 
PLGA NP (Song et al., 2006; Mobarak et al., 2013), however did not improve BSA EE of 
Formulation 7 (Table 2.3).  Liu et al. (2010) introduced acetone to the organic phase alongside 
DCM in a ratio of 1:4, which improved entrapment efficiency of hydrophilic daunorubicin from 
26% to 81%.  This organic phase composition was tested in different ratios (Formulations 9 &10) 
and once again, no BSA was encapsulated.  Introduction of water miscibility to the organic phase 
was not successful for protein encapsulation in these studies, despite some desirable NP size, 
PDI and zeta potential measurements (Table 2.3).  Bilati et al. (2005a) similarly found DCM 
preferable over ethyl acetate for encapsulation of BSA in PLGA NP.  However, in a different 
study, Bilati et al. (2005b) also showed that choice of solvent is protein-dependent.  Bilati and 
colleagues achieved high entrapment of insulin using DCM as the organic phase, however 
tetanus toxoid and lysozyme were more efficiently entrapped in PLGA NP using ethyl acetate 
(Bilati et al., 2005b).  Drug encapsulation is most essential and therefore higher PVA content and 
water-miscible solvents were excluded at this stage from further studies.   
DCM is an organic solvent associated with environmental and health risks due to its mutagenic 
potential (Schlosser et al., 2015).    The International Committee for Harmonisation limit of 
residual DCM detection in pharmaceuticals is no more than 600 ppm (Hu & Liu, 2011).  Han et 
al. (2012) reported that residual DCM in NP prepared by solvent evaporation method can be 
reduced to around 300 ppm when NP are washed thrice after preparation and aqueous phase 
PVA concentration remains around 1% (w/v).  Given the NP prepared in this study were washed 
thrice as detailed in section 2.2.2.1, DCM was selected as the organic phase to be used for 
further in vitro studies without major concerns of toxicity.  The residual DCM was not analysed 
for the NP reported herein, however should be considered as a potential limitation of future use 
in vivo.   
Since no improvements to the original NP formulation process were identified through this pilot 
study, further parameters were explored as shown in Table 2.4.   
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Table 2.4.  Varying formulation parameters during the second phase of NP formulation development.  
Optimal conditions identified from results of Table 2.3. were chosen to remain constant whilst 
varying the volume of the internal (W1) and external (W2) aqueous phases.  The effect of 
removing PVA surfactant from the internal aqueous phase (W1) was also investigated. 
 
 
 
 
 
 
 
Due to observations of better BSA encapsulation with less PVA (Table 2.3.), the effect of 
removing PVA from the internal aqueous phase (W1) was explored during the second stage of 
NP formulation development (Table 2.4.).  Additionally, reduction in PVA content would be 
preferable for reducing the risks associated with residual DCM in the NP.  Furthermore, the effect 
of changing the aqueous phase volumes was also observed for Formulations 11-14 (Table 2.4.).  
Mao et al. (2007) found that reducing both the internal aqueous phase (W1) and external 
aqueous phase (W2) volumes during PLGA NP formulation had minimal effect on particle size, 
however improved hydrophilic drug entrapment efficiency.  Mao and colleagues hypothesised 
that reduced phase volumes would lead to a more profuse organic phase, which might reduce 
the rate of drug diffusion from W1 to W2 during solvent evaporation.  Drug loading, solvent and 
polymer composition (no PEG-PLGA) were kept constant for these studies, results of which are 
shown in Table 2.5.   
Characterisation of Formulation 11 in Table 2.5 shows the effect of removing PVA surfactant 
from the internal aqueous phase (W1), which improved BSA EE (36.9%) compared to the original 
formulation conditions used in Formulation 1 (11% EE).  A considerable improvement in BSA 
encapsulation was observed for Formulation 12 (67.5% EE), which was formulated with a 
Formulation W1 volume (mL) W2 volume (mL) W1 PVA (%) 
11 1.0 50 0 
12 1.0 20 0 
13 1.0 20 2.5 
14 0.5 20 0 
Constant formulation conditions- 4% drug loading, DCM solvent, 0% PEG-PLGA, 1.25% PVA in 
external aqueous phase (W2), full power mechanical homogenisation 2 min (w/o) & 6 min (w/o/w). 
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reduction in external aqueous phase (W2) volume to 20 mL (from 50 mL), with no W1 PVA.  
Feczko et al. (2011) reported a reduction in particle size when the volume of W2 phase was 
reduced, simply due to higher power density per unit volume during emulsification.  Formulations 
13 & 14 (Table 2.5) both have significantly smaller average particle sizes with 20 mL W2 phase 
volume compared to 50 mL with Formulation 11, as P values of < 0.05 were obtained following 
one-way ANOVA analysis with Tukey’s post-hoc test.  The reduced phase volume however did 
not decrease the particle size of Formulation 12, with the marginally larger measurement 
compared to Formulation 11 being of nil significance (Tukey’s post-hoc test P value- 0.6185).  
Once again, it is shown in Formulation 13 that inclusion of 2.5% (w/v) PVA in W1 is detrimental 
to BSA EE (34.5%), even with reduced W2 phase volume.  Based on these results, future NP 
formulation procedures would include a smaller volume of external aqueous phase (20 mL or 
less) and remove the inclusion of PVA in the internal aqueous phase when formulating the 
primary emulsion (w/o).   
 
 
Table 2.5.  Results of characterisation studies of the four formulations detailed in Table 2.4.  The effect of 
varying phase volumes and presence of PVA surfactant in the aqueous phase primary 
emulsion (W1) is reflected by dynamic light scattering analysis and determination of BSA 
entrapment efficiency. 
 
 
 
 
 
 
 
Formulation Size (nm) PDI a ZP b (mV) EE c (%) 
11 390.2 ± 5.8 0.33 ± 0.09 -18.5 36.9 
12 401.3 ± 4.7 0.24 ± 0.02 -15.9 67.5 
13 311.5 ± 6.1 0.39 ± 0.06 -10.1 34.5 
14 226.9 ± 19.6 0.36 ± 0.03 -8.7 73.7 
ͣ  Polydispersity index ± standard deviation (SD), n=3;  b Zeta potential (mV) ± SD, n=3; c drug entrapment 
efficiency (%).   Statistical analysis between groups was carried out using a one-way ANOVA with 
Tukey’s HSD post-hoc test. 
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Substantial improvement in BSA encapsulation was achieved by varying the external phase 
volume (W2), therefore the effect of also reducing the internal aqueous phase (W1) volume was 
investigated for Formulation 14.  Interestingly, compared with Formulation 12, reduction in W1 
volume from 1 mL to 0.5 mL maintained favourable BSA EE (73.7%) and decreased NP size 
from 401.3 nm to 226.9 nm.  The particle size of NP Formulation 14 is more favourable in this 
instance, as sizes of 400 nm may be too large for cellular internalisation. NP sized around 200 
nm are still large enough to avoid non-specific uptake and accumulation, hence in combination 
with a specific receptor-targeting ligand, would be ideal drug delivery vehicles.  
The zeta potential of Formulation 14 is higher at -8.7 mV compared to Formulation 12 at -15.9 
mV.  It is not clear why a smaller W1 volume might affect the zeta potential, however it could be 
due to location of drug within the polymer matrix during the formulation process.  The PDI was 
mostly unaffected by changes in the formulation procedure.  Following this second stage in NP 
formulation development, the lead formulation conditions identified from the results displayed in 
Table 2.5 are a reduction in the external aqueous phase volume and elimination of PVA from the 
internal aqueous phase.  Favourable NP characteristics were also identified after reducing 
internal aqueous phase volume to 0.5 mL, therefore both lead NP Formulations, 12 & 14, were 
selected for further investigation. 
Due to the reduction in phase volumes, it was decided that the use of a probe sonicator may be 
more appropriate in the formulation process than a mechanical homogeniser.  The use of high 
intensity sonication bursts can reduce particle size and agglomeration and thus is an essential 
step in the production of a homogenous, nanoparticulate emulsion (McCall & Sirianni, 2013).  
Formulations 12 & 14 were prepared using a probe sonicator to test whether sonication of the 
w/o/w emulsion would result in the successful formation of BSA-loaded NP with favourable 
characterisation properties (Table 2.6).   
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Table 2.6.  The characterisation properties of Formulations 12 & 14 (Table 2.4) using probe sonication to 
form uniform BSA-loaded NP emulsions.   
 
 
 
 
Results from Table 2.6 show that sonicating the NP formulation significantly reduces average 
particle size compared to the previous method (Table 2.5).  Sonication reduced particle size to 
330.1 nm from 401.3 nm for Formulation 12 (P value < 0.01), whilst Formulation 14 reduced from 
226.9 nm to 173.0 nm (P value < 0.05).  Furthermore, the zeta potential of Formulation 14 was 
much improved from -8.7 mV previously, to a more negative value of -15.2 mV.  Again, the PDI 
largely remained at a similar value to previous results, which is acceptable for these studies.  The 
BSA EE following sonication is above 70% for both Formulations 12 & 14, further supporting the 
use of these formulation parameters and showing a vast improvement from the formulation 
conditions used in Table 2.3.  
 
2.3.2.2. Myoglobin formulation studies 
Following the identification of various modifications to the formulation process that improved the 
encapsulation of a protein payload, the optimal formulation conditions were selected to fabricate 
myoglobin-loaded NP (Myo NP).  Myoglobin is a 16.7 kDa protein which is similar in molecular 
weight to basic fibroblast growth factor (18 kDa).  Myoglobin therefore more closely represents 
a model growth factor payload than BSA (66.5 kDa).   
Formulation Size (nm) PDI a ZP b (mV) EE c (%) 
12 330.1 ± 5.71 0.26 ± 0.05 -12.6 ± 0.78 70.7 
14 173.0 ± 11.27 0.31 ± 0.05 -15.2 ± 0.40 76.7 
ͣ  Polydispersity index ± standard deviation (SD), n=3;  b Zeta potential (mV) ± SD, n=3; c drug entrapment 
efficiency (%).  All formulation conditions are as detailed in Table 2.4 apart from use of a probe sonicator 
(55 W, 80% amplitude) for 1 min (w/o) and 2 min (w/o/w) and reduction of W2 volume to 15 mL.  Statistical 
analysis was carried out using a two-tailed Student’s T-test. 
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Myo NP were prepared according to the lead formulation conditions (Table 2.7) and 
characterised as for previous NP formulations, the results of which are shown in Table 2.8. 
Addition of PEG-PLGA and different internal aqueous phase volumes were investigated whilst 
the solvent (DCM), external aqueous phase (W2) volume (15 mL) and PVA content (1.25% w/v 
W2 only) remained constant for the sonicated NP preparations (Table 2.7).  W2 volume was 
further reduced from 20 mL to 15 mL during Myo NP formulation in accordance with manufacturer 
recommendations on use of the probe sonicator. 
 
 
 Table 2.7.  The lead formulation parameters identified from previous investigations (Tables 2.2-2.6) were 
used to formulate myoglobin-loaded PLGA NP.  Model drug, myoglobin (16.7 kDa), was 
loaded at 4% (w/w).  The effect of varying PEG-PLGA content and internal aqueous phase 
volume were investigated. 
 
 
 
 
 
 
 
 
Table 2.8 shows the successful preparation of Myo NP, with Formulation 15 achieving 79.2% EE 
and favourable size, when W1 phase volume was 0.5 mL and PEG was not included in the 
formulation.  Again, it is shown that a W1 phase volume of 1 mL results in a larger particle size, 
which was statistically significant (P value < 0.05) between the preparations containing 0% PEG-
Formulation PEG-PLGA (%) W1 volume a (mL) 
15 0 0.5 
16 0 1 
17 5 0.5 
18 5 1 
19 10 0.5 
20 10 1 
ͣ  Internal aqueous phase (W1) volume (mL).  Formulation conditions- DCM solvent, W2- 15 mL 
(1.25% PVA), 4% drug loading, sonication (55 W, 80% amplitude) for 1 min (w/o) and 2 min (w/o/w).   
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PLGA (Formulations 15 & 16) and 10% PEG-PLGA (Formulations 19 & 20).  Considering this, 
0.5 mL was selected as the W1 phase volume for future NP formulation in this work.  
The inclusion of PEG-PLGA in the polymer caused slightly less myoglobin to be incorporated 
into the NP, especially at 10% (w/w) (Formulations 19 & 20).  There was no significant effect of 
increasing PEG concentration on the NP size between Formulations 15, 17 & 19 (P values > 
0.05), however it did seem to cause a significant increase in PDI and reduction in zeta potential 
(P values < 0.05) between Formulations 15 (0% PEG-PLGA) & 19 (10% PEG-PLGA).  The 
inclusion of 5% and 10% (w/w) PEG-PLGA in the polymer blend may be beneficial and thus 
Formulations 15, 17 & 19 were selected for further studies. 
 
 
 
Table 2.8.  Characterisation properties of myoglobin-loaded PLGA NP preparations.  Entrapment 
efficiency of myoglobin (16.7 kDa) is consistent with previous protein payload, BSA (66.5 
kDa), despite being smaller in molecular weight. 
 
 
 
 
 
 
 
 
 
2.3.2.3. Doxorubicin formulation studies 
Using the new formulation parameters, doxorubicin-loaded NP (Dox NP) were prepared once 
again prior to surface-conjugation with RDP.   The new Dox NP formulations were characterised 
as previously detailed and results of these studies are shown in Table 2.9.    
Formulation Size (nm) PDI a ZP b (mV) EE c (%) 
15 254.6 ± 27.8 0.29 ± 0.08 -8.5 ± 0.5 79.2 
16 319.0 ± 28.1 0.33 ± 0.11 -7.5 ± 1.2 73.3 
17 227.7 ± 15.4 0.31 ± 0.02 -9.3 ± 0.9 70.2 
18 263.5 ± 12.4 0.31 ± 0.03 -7.7 ± 0.9 66.0 
19 242.9 ± 14.8 0.40 ± 0.04 -11.4 ± 0.4 51.0 
20 384.1 ± 21.8 0.42 ± 0.02 -10.3 ± 1.0 60.5 
a Polydispersity index ± standard deviation (SD), n=3; b Zeta potential (mV) ± SD, n=3; c drug 
entrapment efficiency.   Statistical analysis between groups was carried out using a one-way 
ANOVA with Tukey’s HSD post-hoc test. 
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Table 2.9.  Doxorubicin NP characteristics showing improved doxorubicin encapsulation and incorporation 
of PEG-PLGA co-polymer following formulation with a modified double emulsion-solvent 
evaporation method.   
 
 
 
The average particle size of all three preparations shown in Table 2.9 narrowly range between 
268.2 ± 4.8 nm (10% w/w PEG-PLGA) and 293.5 ± 18.8 nm (no PEG).  In contrast to the BSA-
loaded NP in Table 2.3, increasing PEG content in this instance slightly decreased Dox NP size 
however this was not significant following one-way ANOVA statistical analysis (P value 0.2).  It 
has been suggested that PEG reduces co-polymer chain length and hence causes NP size to 
decrease, as the hydrophobic core is smaller (Lin et al., 2003). 
The zeta potential measurements of Table 2.9 vary slightly amongst preparations (not 
significant), however remain adequately negative for stability and cell targeting.  The PDI is 
significantly higher for the Dox NP containing 10% PEG-PLGA when compared to the 0% and 
5% PEG-PLGA groups (P values < 0.01), suggesting a larger range of particle sizes.  Most 
importantly, the doxorubicin EE improved from the original formulation (Table 2.1) to over 50% 
in all three instances, regardless of PEG content.  Similar to the BSA payload, hydrophilic 
doxorubicin was better encapsulated following the changes in formulation parameters.  
 
 
 
PLGA-PEG (%) Size (nm) PDI a ZP b (mV) Dox EE 
c (%) 
0 293.5 ± 18.8 0.27 ± 0.02 -13.8 ± 1.2 55.0 
5 283.8 ± 17.7 0.21 ± 0.02 -16.6 ± 2.6 59.8 
10 268.2 ± 4.8 0.43 ± 0.06 -11.0 ± 2.8 56.5 
ͣ  Polydispersity index ± standard deviation (SD), n=3;  b Zeta potential (mV) ± SD, n=3; c drug entrapment 
efficiency (%).  Formulation parameters- doxorubicin loading at 2%, sonication (55 W, 80% amplitude) for 
1 min (w/o) and 2 min (w/o/w), DCM solvent, internal aqueous phase volume 0.5 mL (0% PVA), external 
aqueous phase volume 15 mL (1.25% PVA).   Statistical analysis between groups was carried out using a 
one-way ANOVA with Tukey’s HSD post-hoc test. 
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2.3.3. NP Stability studies 
 
2.3.3.1. Scanning electron microscopy (SEM)  
Blank PLGA NP were imaged by SEM to visualise NP morphology and the effects of incubating 
in ddH2O at 37°C over various periods of time.  All SEM images shown in Figure 2.5 were 
captured at x24 000 magnification.  Freeze dried sample with no prior incubation in Figure 2.5A 
shows that NP are spherical in shape, with the presence of many sub-micron particles in the 
unfiltered sample.  Despite some of the largest particles within the sample measuring 
approximately 1 µm in size, the majority are 200-300 nm, supporting the data obtained from 
previous DLS analysis in sections 2.3.1 and 2.3.2.  Figures 2.5 (B)-(F) show NP which have been 
incubated at 37 °C for 1, 4, 10, 30 and 60 days in ddH2O respectively.   
It is evident that incubation for 1 day caused the NP to swell and become slightly larger in 
diameter, with early signs of degradation due to minor surface pitting, as indicated in Figure 2.5B.  
There were some changes in shape and aggregation of material highlighted in Figure 2.5C, 
suggesting that after 4 days incubation at 37 °C, degradation processes were underway within 
the sample.  After 10 days of incubation, much larger and aggregated particles were present 
within the sample, with more signs of structure irregularity in Figure 2.5D.  By 30 days of 
incubation, in Figure 2.5E, most particles increased in size into the micrometre scale.  There was 
continued loss of the regular spherical morphology of individual particles, with agglomeration 
more apparent.  These larger particles were susceptible to breakdown under the beam of the 
microscope.  Finally, in Figure 2.5F after 60 days of incubation, there was complete loss of NP 
within the sample.  Evidence of remaining larger spherical structures are highlighted in Figure 
2.5F, as the remainder of the image shows only amorphous residual material.  
Obvious NP swelling caused by water absorption through the polymer matrix lead to a 
progressive increase in NP diameter from time 0 through 30 days (Figure 2.5A- 2.5F).  Figures 
2.5B and 2.5C are representative of how NP incubated for 1 and 4 days respectively, started to 
show signs of breakdown through emergence of surface pitting (2.5B) and loss of regular 
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spherical shape (2.5C).  This was minimal at the 1 and 4-day time points, suggesting that despite 
degradation processes being initiated early, they are perhaps slow.  Major differences are 
observed in Figures 2.5D and 2.5E at 10 and 30 days incubation respectively.  At these time 
points larger and aggregated particles are visible, with loss of regular morphology.  Despite the 
appearance of these irregular particles, there was little to no debris or breakdown material visible, 
unlike the sample imaged in Figure 2.5F.  It is apparent that a gradual degradation is occurring 
over time and that NP structure is relatively stable over the specified conditions for at least 4 
days, with complete loss of nano-sized particles at 60 days. 
PLGA is composed of repeating poly lactic acid and poly glycolic acid units.  Both poly glycolic 
acid and poly-L-lactic acid are crystalline solids (Makadia & Siegel., 2011), which may explain 
the presence of crystal-like deposits among the amorphous breakdown material in Figure 2.5F.  
A similar SEM image of degraded PLGA NP was reported by Hamoudeh et al. (2008).  Between 
30 and 60 days in water at 37 °C, the PLGA NP appear to have undergone complete degradation.  
This degradative process induced by hydrolysis of ester bonds in the polymer matrix, is further 
autocatalysed by the formation of acidic breakdown products, lactic and glycolic acid, which can 
be excreted in vivo (Catiker et al., 2000).   Catiker et al. (2000) found that this hydrolytic activity 
was quicker in the presence of bovine serum albumin, a major blood protein, than in PBS.  It 
could therefore be hypothesised that complete NP degradation would occur quicker than 30-60 
days in the presence of serum, rather than ddH2O used in this study.  This is advantageous, as 
the ideal drug delivery vehicle would not accumulate in the body over a long period of time.  
Nevertheless, these NP have shown the ability to swell, form aggregates and develop pits, 
following a similar pattern of degradation to those imaged by Panyam et al. (2003), Stevanovic 
et al. (2007) and Hussein et al. (2013).  This shows that the PLGA polymer is biodegradable, 
which is why it is already approved for use as a drug carrier by the Food and Drug Administration 
(FDA).   
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Figure 2.5.  SEM images of (A) lyophilised PLGA NP at room temperature and lyophilized PLGA NP after 
incubation at 37°C in ddH2O for 1 day (B), 4 days (C), 10 days (D), 30 days (E) and 60 days 
(F).  Evidence of pitting on the NP surface (B) and loss of spherical morphology (C) are 
highlighted.  Traces of spherical NP after 60 days incubation are highlighted in image (F).   All 
SEM images are at x24 000 magnification. 
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2.3.3.2.  Payload stability study using SDS-PAGE 
The stability of myoglobin-loaded NP (Myo NP) upon dry storage at room temperature was 
investigated to assess long-term payload stability.  Myo NP were stored over 6 months under the 
aforementioned conditions in section 2.2.6.2 and samples were taken at various time intervals.  
Myoglobin payload or potential myoglobin breakdown products were separated and detected 
using SDS-PAGE.  Figure 2.6 shows the bands detected for myoglobin near the 18 kDa marker.  
Lane 1 shows myoglobin at time zero, detected from freshly prepared freeze-dried NP.  All bands 
in Figure 2.6 are approximately of equal size and no myoglobin breakdown products were 
detected on the gel, even in lane 8 which represents 6 months of storage.  This suggests that 
the myoglobin payload was stable within the NP structure under such conditions, which is 
important when utilising expensive drugs and for therapeutic efficacy.  As shown with the SEM 
images in Figure 2.5, degradative processes begin when NP are exposed to an aqueous 
environment and higher temperature (37°C).   
Despite no evidence of myoglobin breakdown, it cannot be determined from these results 
whether model payload activity would be affected over the observed experimental period.  
Myoglobin has no measurable activity in vitro or in vivo, however the ideal growth factor payload 
could be tested for subsequent activity after storage under the same conditions.      
 
 
 
 
 
 
 
 
Figure 2.6.  Image of an SDS-PAGE gel showing myoglobin (16.7 kDa) payload stability on dry storage 
of myoglobin-loaded NP at room temperature over a 6-month period.  Lanes 1-8 indicate 
storage times of 0, 1, 2, 4, 6, 16, 20 and 24 weeks respectively.   A marker for approximately 
18 kDa is indicated.   
1 3 2 4 5 6 7 8 
18 kDa 
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2.3.4. Drug release studies 
 
The release profiles of lead NP formulations encapsulating either doxorubicin or myoglobin as 
model drugs are shown in Figures 2.7- 2.12.  Ligand-facilitated uptake of NP is largely considered 
to occur via energy-dependent endocytosis mechanisms (Danhier et al., 2012).  Indeed, receptor 
mediated endocytosis is the proposed mechanism of RDP cellular uptake (Fu et al., 2013a).   In 
order to resemble endocytic conditions, drug release was measured under two different pH 
environments, to assess how NP payload release would be affected.  This would also further 
assess the stability of the PLGA NP and suitability as part of a targeted drug delivery system.   
NP were exposed to two different buffers to reflect drug release under the harsher conditions of 
the endocytic process at 37°C and cumulative release was measured over 10 days. 10 mM PBS 
buffer at pH 7.4 provided conditions similar to the extracellular environment, whereas DMGA 
buffer at pH 4.5 would mimic the acidic environment of the late endosome or indeed the 
lysosome.  Figure 2.7 shows the release of myoglobin from NP in both PBS and DMGA buffer 
over 5 hours (Figure 2.7A) and 10 days (Figure 2.7B).  It can be seen that release in both pH 
environments is similar for the first four hours, at which point release in DMGA buffer accelerates 
until 78% of the payload is released after 10 days.  This is in contrast to the 35% of myoglobin 
released in PBS at pH 7.4.  Following the first 24 hours, myoglobin release was significantly 
higher for every time point in DMGA than PBS until day 10 (P values < 0.001).  It has previously 
been shown by Colzani et al. (2016) that 100% cumulative myoglobin release from PLGA NP 
can take up to 60 days in PBS.     
Myoglobin release in PBS is biphasic, with an initial burst phase in the first 5 hours followed by 
a slower sustained phase over the following days.  This is a typical characteristic of PLGA NP, 
as many reports of a biphasic release profile exist in the literature (Fonseca et al., 2002; Ma et 
al., 2010; Surolia et al., 2012; Zhu & Braatz, 2015), even when the polymer is pegylated (Park et 
al., 2009; Yalcin et al., 2018).  Contact between the release medium and soluble drug at the NP 
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surface can affect release rate in the burst phase, therefore location of drug within the NP matrix 
is one factor which may influence how much drug is initially released (Makadia & Siegel, 2011).   
A different release profile is observed in Figure 2.8 when NP contain 5% PEG-PLGA polymer 
composition.  Release in DMGA buffer at pH 4.5 follows a very similar pattern to PBS for the first 
4 days, after which drug release in DMGA accelerates to 100% payload release on day 10.   The 
difference between release in PBS and DMGA was not significant until days 7-10 of incubation 
(P values <0.01).  Following 10 days, myoglobin release from 5% PEG-PLGA NP in PBS is 39%, 
closely resembling results from the Myo NP without PEG in Figure 2.7.  The biphasic release 
pattern in PBS is also evident for 5% PEG-PLGA Myo NP in Figure 2.8B.      
In Figure 2.9, 10% PEG-PLGA Myo NP display a release profile in DMGA (pH 4.5) comparable 
to the 5% PEG-PLGA Myo NP in Figure 2.8, with 93% of myoglobin payload released by day 9 
at 37°C (Figure 2.9B).  In Figure 2.9A, myoglobin release in DMGA is slower in the first 5 hours 
than in PBS.  Interestingly, 47% cumulative release of myoglobin was measured after 10 days 
of incubation in PBS.  This is slightly more than was observed for Myo NP and 5% PEG-PLGA 
Myo NP in Figures 2.7 and 2.8 respectively, over the same time period.  Once again, release in 
DMGA buffer was significantly higher than PBS after 5 days (P values < 0.01). 
For NP loaded with model protein payload, myoglobin, release in DMGA of all preparations was 
much greater than in PBS over 10 days.  In all cases, around twice as much myoglobin was 
released in total after incubation in an acidic pH environment.  Release of myoglobin in PBS was 
representative of a biphasic release profile.  Release in DMGA however, could perhaps be more 
appropriately described as triphasic.  The initial burst release is followed by a slower phase until 
a final accelerated release phase occurs for all Myo NP preparations in DMGA buffer (pH 4.5).  
A triphasic release profile is more uncommon than biphasic, however it is an indication of 
heterogenous polymer erosion (Xu et al., 2017).  The polymer is probably undergoing faster 
degradation under acidic conditions (Fredenberg et al., 2011), which might explain the 
acceleration of myoglobin release in DMGA buffer. 
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PEG content in the polymer appeared to slow down pH-induced myoglobin release in DMGA to 
the same level as in PBS for the first 4 days of incubation.  The stabilising effects of PEG can 
reduce particle-particle interactions and also polymer surface reactions (Jokerst et al., 2011), 
which might explain why myoglobin release did not accelerate rapidly until day 5 in DMGA buffer.   
Figure 2.10 shows the release of doxorubicin from PLGA NP in PBS and DMGA buffer.  Notably, 
release in DMGA was much more rapid than in PBS, achieving 86% release after 1 day and 
100% release after 7 days of incubation at 37°C.  Following an initial burst phase where 20% of 
payload was released in the first 5 hours (Figure 2.10A), doxorubicin release in PBS was slowly 
continuous until 54% release was detected after 10 days (Figure 2.10B).  Compared with the 
larger myoglobin payload, doxorubicin release from PLGA NP was quicker in both pH 
environments, but particularly so at pH 4.5.  After 1 hour, doxorubicin release in DMGA was 
significantly higher than in PBS at every time point until day 10 (P value < 0.001).   
A similar release profile was observed for 5% PEG-PLGA Dox NP in Figure 2.11.  After 2 days 
of incubation, 98% of the doxorubicin payload was released in DMGA buffer (Figure 2.11B).  In 
PBS, an initial burst release of less than 20% was observed in the first 5 hours of incubation as 
shown in Figure 2.11A.  This was followed by a slow, controlled release of doxorubicin until 62% 
of the NP payload was cumulatively detected by day 10 (Figure 2.11B).  Once more, the 
difference in release between PBS and DMGA was significant after just one hour of incubation 
(P values < 0.001).  This was also the case for doxorubicin release from 10% PEG-PLGA Dox 
NP as shown in Figure 2.12.  The presence of 10% PEG-PLGA caused slightly less doxorubicin 
release (47%) after 10 days in PBS in Figure 2.12B than was observed in Figures 2.10B and 
2.11B.  Again, this is possibly due to the stabilising effect of PEG at the polymer surface or indeed 
due to hydrophilic interactions between PEG and doxorubicin.  Release of doxorubicin from NP 
in both pH environments followed biphasic patterns.  This would suggest that polymer erosion 
was not a factor in doxorubicin release from PLGA in DMGA, unlike observations made for 
myoglobin NP. 
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(A) 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
Figure 2.7.  Release profile of myoglobin-loaded PLGA NP at 37 °C in PBS (pH 7.4) and DMGA buffer 
(pH 4.5) over (A) 5 hours and (B) 10 days.  Error bars represent ± SD (n=3).  Statistical 
analysis was performed using a two-way ANOVA with Bonferroni post-hoc tests to compare 
individual time points between PBS and DMGA.  A P value < 0.05 was considered statistically 
significant. 
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Figure 2.8.  Release profile of myoglobin-loaded PLGA NP formulated with 5% PEG-PLGA co-polymer 
blend at 37 °C in PBS (pH 7.4) and DMGA buffer (pH 4.5) over (A) 5 hours and (B) 10 days.  
Error bars represent ± SD (n=3).  Statistical analysis was performed using a two-way ANOVA 
with Bonferroni post-hoc tests to compare individual time points between PBS and DMGA.  
A P value < 0.05 was considered statistically significant. 
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Figure 2.9.  Release profile of myoglobin-loaded PLGA NP formulated with 10% PEG-PLGA co-polymer 
blend at 37 °C in PBS (pH 7.4) and DMGA buffer (pH 4.5) over (A) 5 hours and (B) 10 days.  
Error bars represent ± SD (n=3).  Statistical analysis was performed using a two-way ANOVA 
with Bonferroni post-hoc tests to compare individual time points between PBS and DMGA.  A 
P value < 0.05 was considered statistically significant. 
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(B) 
 
Figure 2.10.  Release profile of doxorubicin-loaded PLGA NP at 37 °C in PBS (pH 7.4) and DMGA buffer 
(pH 4.5) over (A) 5 hours and (B) 10 days.  Error bars represent ± SD (n=3).  Statistical 
analysis was performed using a two-way ANOVA with Bonferroni post-hoc tests to compare 
individual time points between PBS and DMGA.  A P value < 0.05 was considered statistically 
significant. 
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Figure 2.11.  Release profile of doxorubicin-loaded PLGA NP formulated with 5% PEG-PLGA co-polymer 
blend at 37 °C in PBS (pH 7.4) and DMGA buffer (pH 4.5) over (A) 5 hours and (B) 10 days.  
Error bars represent ± SD (n=3).  Statistical analysis was performed using a two-way ANOVA 
with Bonferroni post-hoc tests to compare individual time points between PBS and DMGA.  
A P value < 0.05 was considered statistically significant. 
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Figure 2.12.   Release profile of doxorubicin-loaded PLGA NP formulated with 10% PEG-PLGA co-
polymer blend at 37 °C in PBS (pH 7.4) and DMGA buffer (pH 4.5) over (A) 5 hours and 
(B) 10 days.  Error bars represent ± SD (n=3).  Statistical analysis was performed using a 
two-way ANOVA with Bonferroni post-hoc tests to compare individual time points between 
PBS and DMGA.  A P value < 0.05 was considered statistically significant. 
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Betancourt et al. (2007) has reported similar findings on a much greater initial release of 
doxorubicin at pH 4.0 compared to pH 7.4.  In addition to pH-induced polymer erosion, it could 
be postulated that the rate of drug diffusion out of the NP polymer matrix is increased at pH 4.5 
due to fully ionised doxorubicin (Ayen et al., 2011), which has a pKa of 8.2 (Makkouk et al., 2015).  
Either of these possibilities or indeed a combination of factors are likely to cause more 
doxorubicin payload release at pH 4.5 compared to that observed at pH 7.4. 
It is most probable that the major mechanism of drug release in PBS (pH 7.4) over this 10-day 
period is by drug diffusion through water-filled pores in the PLGA polymer (Fredenberg et al., 
2011).  This is supported by the SEM data presented in Figure 2.5, which generally indicates 
swelling of the NP rather than erosion in distilled water up to 10 days, at 37 °C.   Furthermore, 
after 10 days the majority of NP are still intact, albeit as more irregular entities.  The PLGA used 
in these studies was composed of lactic and glycolic acid units in a 50:50 ratio, however the rate 
of polymer degradation and subsequent payload release can be manipulated by adjusting this 
ratio.  For example, increasing the lactic acid content of the polymer causes increased 
hydrophobicity due to methyl side chains and therefore less water is absorbed (Gentile et al., 
2014). 
Drug release data in PBS was analysed for both model drugs according to zero order, first order 
and Higuchi kinetics models, as shown in Table 2.10.  Zero order kinetics models are used to 
describe drug release which is constant and linearly increases with time (Siepmann & Siepmann, 
2012).  First order kinetics indicates that release of drug is dependent on its concentration and 
is often the model used to describe the in vivo metabolism of most drugs (Kasperek et al., 2014).  
More recently, the Higuchi model has been used to describe release of water-soluble drugs from 
a matrix system or other type of modified release dosage form into solution (Dash et al., 2010).   
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Table 2.10.  R-squared (R2) values of myoglobin and doxorubicin release from PLGA NP in PBS following 
analysis using zero order, first order and Higuchi kinetics models. 
 
 
 
 
 
 
Table 2.10 shows the R2 values obtained when release data of both myoglobin and doxorubicin 
in PBS was plotted according to the three kinetics models.  The highest R2 value and therefore 
the strongest correlation was obtained using the Higuchi model, the plot of which is shown in 
Figure 2.13 for both drugs.  This supports a diffusion-based mechanism of drug release from the 
polymer matrix in solution (Dash et al., 2010).  The R2 values obtained from modelling release 
data according to zero and first order kinetics (Appendix 2) were notably lower than for the 
Higuchi model.  This indicates that drug release is not always constant and changes in payload 
concentration are unlikely to have a major impact on the polymeric NP release profile. 
 
 
 
 
 
 
Kinetics Model R2 Value Myoglobin R2 Value Doxorubicin 
Zero order 0.857 0.862 
First order 0.652 0.754 
Higuchi 0.921 0.949 
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(A) 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
Figure 2.13.  Higuchi plot showing release kinetics of (A) myoglobin and (B) doxorubicin from PLGA NP 
at 37°C in PBS. 
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Findings from all release data indicate that drug leaching in PBS at pH 7.4 and 37 °C is relatively 
low, however in an acidic environment, this is accelerated.  Since these NP are not very leaky 
under normal physiological conditions, it could be hypothesised that the full NP payload will only 
be released inside the cell when the NP is exposed to the progressively acidified environment of 
the endocytic pathway (Abdul-Hammed et al., 2010).  This is a very desirable property for a 
polymeric drug carrier, to show sustained release characteristics and release the majority of its 
contents at the endosomal stage.  In all likelihood, it would limit the amount of drug released at 
unspecific locations and enhance drug accumulation at the target site in therapeutic 
concentrations. 
 
2.3.5. RDP conjugation studies  
 
RDP was attached to different PLGA NP preparations as a surface ligand via activated carboxyl 
groups using EDC/NHS chemistry.  RDP was conjugated to all leading Dox NP preparations with 
a view of potentially being used for in vitro cell-based assays in future work.  Since Myo NP have 
no therapeutic effect, only the Myo NP with no PEG were conjugated with RDP to assess the 
ability of protein-loaded NP to attach a targeting ligand.  Furthermore, to preserve use of 
expensive peptide, CE was assessed for one sample (n=1) of each NP preparation therefore 
statistical analysis was not possible for results on Table 2.11. 
RDP was conjugated to NP initially at 4 °C to prevent any denaturation of the peptide, however 
as shown in Table 2.11, conjugation efficiencies were low.  As a result of this, RDP conjugation 
was subsequently carried out at room temperature.  This greatly improved the amount of peptide 
which attached to NP.  All Dox NP, regardless of PEG content, showed conjugation efficiencies 
of over 50%.  RDP conjugated to Myo NP with an efficiency of 68%. This is positive for potential 
peptide attachment to NP loaded with bFGF or other growth factors in future work due to 
similarities with model drug, myoglobin.  Through these studies it has been shown that 
biodegradable polymeric NP can be loaded with high amounts of protein payload, which show 
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good stability and release properties.  Furthermore, these NP can be easily surface-coated with 
a good abundance of targeting ligand (at least 50 µg per 1 mg of NP).  This drug delivery system 
of RDP-conjugated NP could potentially be used to target a therapeutic growth factor payload 
across the BBB for the treatment of Parkinson’s disease.  Prior to in vivo testing however, the 
ability of this nanoparticulate system to selectively target neural cells in vitro must be assessed. 
 
 
 
Table 2.11.  RDP conjugation efficiency (CE) to various PLGA NP preparations under different reaction 
conditions following addition of RDP (10% w/w) to carboxyl-activated NP. 
 
 
 
 
 
 
 
In vitro cell assays studying the effect of RDP as a targeting ligand would involve comparing 
peptide-modified NP with an unlabelled version.  Drug release or leaching from the NP should 
be similar for both unlabelled and peptide-conjugated NP.  RDP was conjugated to Dox NP 
(RDP-Dox NP) and doxorubicin release was measured in PBS at 37°C.  The release profile of 
RDP-Dox NP was compared to that of unlabelled Dox NP in Figure 2.14, to observe the effect of 
RDP ligand on drug release.   
Doxorubicin release from RDP-Dox NP followed a similar pattern of biphasic release under 
physiological conditions as the unlabelled Dox NP.  After 10 days, both preparations released 
NP Formulation RDP CE (%) 4°C RDP CE (%) 20°C 
Blank NP 21.0 61.5 
Dox NP 12.9 54.0 
Dox NP (5% w/w PEG) 4.2 55.2 
Dox NP (10% w/w PEG) 1.8 54.6 
Myo NP 35.5 68.0 
CE= peptide conjugation efficiency (%); 100 µg RDP conjugated per 1 mg NP; n=1. 
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around 50% of payload showing no significant difference due to RDP (P value > 0.05).  Release 
from RDP-Dox NP was significantly slower for the first five days than Dox NP (P values < 0.05), 
possibly due to a steric hindrance effect of the peptide on the NP surface.  Alternatively, the 
peptide may be affecting early hydrolysis-induced degradative processes of the polymer matrix 
at the particle surface.   
 
 
 
 
Figure 2.14.  10-day release profile of doxorubicin from unlabelled NP (Dox NP) and RDP-conjugated NP 
(RDP-Dox NP) at 37°C in PBS.  Error bars represent ± SD (n=3).  Statistical analysis was 
performed using a two-way ANOVA with Bonferroni post-hoc tests to compare individual 
time points of Dox NP v RDP-Dox NP.  A P value < 0.05 was considered statistically 
significant. 
 
 
 
These results show that Dox NP can be successfully conjugated with RDP targeting ligand and 
maintain controlled release of payload under physiological conditions (pH 7.4, 37°C).  This 
means such NP will be suitable for in vitro testing on various cell types.  Amoozgar & Goldberg 
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(2017) reported that surface protein conjugation can help prevent particle aggregation and 
control doxorubicin release from polymeric NP.  In addition to the controlled release profile 
observed in the results of Figure 2.14, RDP may also confer stability to the NP suspension due 
an overall positive charge as a result of many arginine and lysine residues in the sequence.  
Similar to a good zeta potential value, this charge may prevent particle aggregation in 
suspension.  
It could be hypothesised that NP functionalisation with RDP will ultimately be the determining 
factor to the success of such a targeted drug delivery system for specific neural cell 
internalisation and its ability to traverse an in vitro BBB model.  Given the difficulties in drug 
delivery across the BBB, size and zeta potential are perhaps of less consequence (Voigt et al., 
2014), especially when a functionalised surface ligand can facilitate strong interactions with a 
target receptor. 
 
 
2.4.  Conclusion 
 
PLGA NP were successfully formulated using a double emulsion-solvent evaporation method 
and loaded with various model payloads.  Various NP formulation parameters were investigated, 
resulting in modification of the original protocol to formulate NP with improved drug encapsulation 
whilst maintaining desirable size and zeta potential characteristics.  Following the development 
of lead NP formulations, myoglobin and doxorubicin were incorporated as model payloads and 
release characteristics were analysed in different environments.  Drug-loaded NP preparations 
showed controlled, sustained release of payload under physiological conditions (pH 7.4, 37°C) 
with the ability to undergo pH-induced accelerated release in an acidic environment 
representative of the cellular endocytosis pathway.    
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NP were surface-conjugated with neural cell targeting ligand, RDP, with acceptable conjugation 
efficiencies regardless of payload or PEG-PLGA co-polymer content.  The versatility of these 
PLGA NP to load various drugs and attach surface ligands offers a wide scope of possibilities 
for future development, such as formulation of growth factor-loaded NP with surface-conjugated 
RDP.   
Table 2.12 shows the optimal formulation parameters identified through these studies to be used 
in further NP investigations.  Although it has been shown that PEG can be introduced into the 
polymer component and maintain favourable NP characteristics, PEG will be excluded from 
further in vitro cell-based work in these studies.  This is to avoid any potential influence of PEG 
on RDP activity in vitro.  However, this does not rule out the use of PEG in future studies beyond 
the scope of the work reported herein.  The specific neural targeting effect of RDP, as part of a 
polymeric nanoparticulate system, can consequently be assessed on various cell types in vitro 
as a result of these formulation studies.   
 
 
 
Table 2.12.  Optimised NP formulation parameters selected for further in vitro studies on the specific 
targeting ability of conjugated RDP 
 
 
 
 
 
 
 
Formulation Parameter Specifications 
Polymer 100 mg PLGA 
Solvent 4 mL DCM 
External aqueous phase (W1)   15 mL PVA (1.25%) 
Internal aqueous phase (W2)  0.5 mL ddH2O 
Emulsification method Probe sonication 
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Chapter 3 
In vitro testing of RDP and neural cell 
receptor identification 
 
 
 
 
 
 
 
 
 
 
This chapter reports work (with permission) from the following publications:  
Huey, R., Hawthorne, S. and McCarron, P. (2017) The potential use of rabies virus glycoprotein-derived 
peptides to facilitate drug delivery into the central nervous system: a mini review. Journal of drug 
targeting, 25 (5), 379-385.  The original article can be found in Appendix 3. 
Huey, R., O’Hagan, B., McCarron, P. and Hawthorne, S. (2017) Targeted drug delivery system to neural 
cells utilizes the nicotinic acetylcholine receptor. International journal of pharmaceutics, 525 (1), 12-20. 
The original article can be found in Appendix 4. 
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3.1. Introduction  
 
New approaches are arising for the successful delivery of therapeutics to the central nervous 
system (CNS). Although notoriously challenging, the delivery of drug or gene payloads 
specifically to neural cells may be facilitated by the use of a targeting ligand or peptide.  The 
emergence of peptides derived from rabies virus glycoprotein (RVG) as brain targeting ligands 
have shown promise as an effective way of non-invasively overcoming the blood brain barrier 
(BBB) for targeted therapy.  In recent times, derivatives of RVG, such as rabies virus-derived 
peptide (RDP) and RVG-29, have been successfully utilised as targeting ligands for drug delivery 
to the CNS.  RVG is the only surface glycoprotein on the rabies virus envelope, which is 
responsible for the distinct neurotropism of the rabies virus infection (Yan et al., 2002).   The use 
of RVG for specific targeting of neurotherapeutics is therefore a promising concept, which Son 
et al. (2011) described as a potential “magic bullet”. 
RDP has shown potential as a new targeting ligand for the specific and non-invasive delivery of 
therapeutics to the brain, due to its ability to cross the BBB.  RDP is a 39-amino acid peptide 
derivative of RVG residues 330-358, which has not only been successful in safely directing 
conjugated therapeutic payloads to the brain in mice (Fu et al. 2012; 2013a; 2013b), but also 
preferentially targets neural over non-neural cell types in vitro (Fu et al. 2013a).  In a study by 
Gramlich et al. (2016), RDP surpassed non-specific cell penetrating peptide, TAT, and neural-
specific peptides, tetanus toxin fragment C and Tet-1, in delivering a glucocerebrosidase enzyme 
payload to neurons for the treatment of Gaucher’s disease. 
RDP has also recently been conjugated to gold NP for various purposes.  Zhang & Fu (2015) 
observed the ability of RDP-conjugated gold nanoclusters to specifically accumulate in neural 
tissue in vivo to allow a non-invasive approach to brain screening.  Xiao et al. (2017) 
functionalised RDP to 6-mercaptopurine-loaded gold NP to positively promote growth of neurons, 
without signs of toxicity.  Other nanomaterials used in conjunction with RDP include curcumin-
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loaded nanoliposomes, which successfully targeted intracranial glioma in a mouse model after 
intravenous administration (Zhao et al., 2018).   
RDP-facilitated transport of a drug may improve brain bioavailability; firstly, due to a reduction in 
non-specific uptake in other body regions and secondly, by the ability to penetrate the specialised 
endothelial cells of the BBB.  Moreover, sensitive and expensive therapeutics may be protected 
from degrading enzymes, particularly if encapsulated in a nanoparticulate delivery vehicle.  This 
type of facilitated delivery is possible as the surface of carriers such as polymeric NP, can be 
easily modified (Delehanty et al., 2010).  Such NP can be composed of biodegradable, 
biocompatible polymers with an established safety profile, such as FDA-approved poly(lactic-co-
glycolic acid) (PLGA) or chitosan (Auffinger et al., 2013).  Thus far, RDP has not been 
functionalised to polymeric NP for delivery of therapeutic cargo to the CNS. 
In order to optimise the characteristics of RDP for future development as an effective drug 
delivery entity, it is important to know which receptor on neural cells is the target for interaction.  
To date, there has been conflicting evidence in the literature as to which receptor is utilised in 
these synthetic peptide-neural cell interactions and indeed by RVG itself.  There is strong 
evidence of original RVG and other peptide derivatives, such as RVG-29, binding to the nicotinic 
acetylcholine receptor (nAChR) in a number of studies (Lentz et al., 1991; Gastka et al., 1996; 
Kumar et al., 2007; Sajjanar et al., 2015; Lee et al., 2017).   
RVG facilitates entry of the virus specifically into neurons at the neuromuscular junction (NMJ) 
through interaction with neural cell receptor molecules.  It was first proposed by Lentz et al. 
(1982), that the acetylcholine receptor is a rabies virus receptor, based on the detection of the 
virus at or near acetylcholine sites in cultured chick myotubes.  In this study, rhodamine-labelled 
alpha bungarotoxin (α-BTX) was used to detect the acetylcholine receptors, as this snake venom 
neurotoxin competitively binds to acetylcholine binding sites.  Following a pre-incubation period, 
α-BTX was able to significantly reduce the number of chick myotubes that became infected by 
rabies virus.  The authors acknowledged that other molecules may be involved as infection could 
not be totally prevented by blocking the acetylcholine receptor.  Despite this, any additional 
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elements must be closely associated with acetylcholine binding sites.  The detection of dense 
clusters of acetylcholine receptors at the tips of junctional folds may serve to enhance uptake at 
the NMJ, allowing eventual transport into the CNS.   
Lentz et al. (1991) compared a segment of RVG with the structure of a loop 2 domain of the 
curaremimetic neurotoxin, King Cobra Toxin b, and their subsequent interaction with the nicotinic 
acetylcholine receptor (nAChR).  The loop 2 of snake venom neurotoxins share a few invariant 
amino acid residues.  Interestingly, these sequences share a related homology with those found 
in RVG.  Snake venom neurotoxin is able to bind at or near the acetylcholine binding site of 
nicotinic acetylcholine receptors (nAChRs) and consequently block ligand binding.  It was shown 
by Lentz and colleagues how manipulating homologous residues of a King Cobra Toxin b 
derivative and a 29-residue RVG derivative decreased nAChR binding affinity.  This work 
suggested that the homologous sequences between snake venom neurotoxins and RVG might 
be responsible for strong interactions with the nAChR.  Furthermore, a 10-amino acid sequence 
of RVG-29 unrelated to the neurotoxin structure was identified as important for maintaining a 
high binding affinity to the nAChR.   
Similar work has been carried out using King Cobra Toxin b by Zhan et al. (2010), where a short 
20 residue neurotoxin-peptide was produced to facilitate drug delivery to the brain, via nAChRs, 
on endothelial cells of the BBB.  By successfully enhancing the accumulation of coumarin-6-
loaded micelles in mouse brain, it was shown that this synthetic peptide bound with similar affinity 
to an RVG derivative.  This study inadvertently proved that an RVG derivative binds to the 
neuronal-type nAChR, due to its inhibitory effect on α-BTX, which binds to residues 173-204 of 
the alpha-1 subunit on NMJ nAChRs (Gastka et al., 1996).  The aforementioned studies prove 
that RVG has a very strong connection with the nAChR, due to the similarities with snake venom 
neurotoxin residues. 
Pilot work on the novel peptide, RDP, by Fu et al. (2013a) however suggested that the GABA (a) 
receptor subtype is most likely utilised for cellular uptake by clathrin-mediated endocytosis.  In 
fact, Liu et al. (2009) implicated the GABA (b) receptor subtype as being responsible for the 
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cellular uptake of RVG-29, conflicting with the wealth of previous reports of nAChR dependence.  
It is possible perhaps, that different derivatives of RVG may bind different neural receptors.  A 
lack of experimental data on RDP to date however means that the question of whether the 
nAChR or a GABA receptor subtype is responsible for cellular uptake cannot be answered with 
certainty.   
The aims of this study were to: 
(1) Prepare PLGA NP incorporating different model payloads to observe the effect of RDP 
surface-conjugation in neural and non-neural cell types.  The targeting effects of RDP 
can be assessed following observation of NP payload effect in various cell types to 
determine the specificity of this ligand towards cells of neural origin only.   
 
(2)  Determine which receptor RDP binds to by blocking the nAChR, GABA(a) and GABA(b) 
receptors with various inhibitors in a cytotoxicity assay.  Blocking the receptor responsible 
for RDP-facilitated effects should diminish the effect induced by the cytotoxic payload 
encapsulated within RDP-conjugated PLGA NP. 
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3.2. Materials and methods 
 
3.2.1. Materials 
 
Resomer® RG 502 H, Poly(D,L-lactide-co-glycolide)-PLGA, acid terminated (MW 7 000-17 000), 
dichloromethane (DCM), poly(vinyl) alcohol (PVA) 87-89% hydrolysed- MW  85 000-124 000, 
MES hydrate, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccinimide 
(NHS), doxorubicin hydrochloride, fluorescein isothiocyanate–dextran (FITC-Dextran), 
phosphate buffered saline (PBS), Collagen (type IV), 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide (MTT), hexamethonium, bicuculline, saclofen and mecamylamine were all 
purchased from Sigma-Aldrich (UK).  RDP was synthesized by GL Biochem (Shanghai) Ltd.  
Anti-AChRα7 rat monoclonal IgG1 antibody (200 µg/mL) was purchased from Santa Cruz 
Biotechnology, Inc. (USA).  Lysotracker® red DND-99 solution (1mM) and SlowFade® diamond 
antifade mountant were purchased from ThermoFisher Scientific.  
 
3.2.2. Tissue culture 
 
All tissue culture reagents and media were purchased from Gibco®/ Life Technologies.  SH-
SY5Y (human neuroblastoma), PC-12 (rat pheochromocytoma) and HeLa (human cervical 
cancer) cell lines were all cultured in RPMI 1640 medium.  MDA-MB-231 (human breast cancer) 
cells were cultured in DMEM medium.  Finally, normal and non-neural epithelial CHO (Chinese 
hamster ovary) cells were cultured in Ham’s/F12 nutrient mixture.  All tissue culture media was 
supplemented with 10% (v/v) foetal bovine serum and 1% (v/v) penicillin-streptomycin (5,000U 
mL-1/5,000 µg mL-1).  PC-12 cells were additionally supplemented with 10% (v/v) horse serum 
and cultured on flasks pre-coated with 2 mL of 0.5 mg/mL type IV collagen in 0.25% (v/v) acetic 
acid.  Cells were passaged using trypsin-EDTA 0.5%.   
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3.2.3. Preparation of Nanoparticles (NP) 
 
3.2.3.1. Preparation of blank PLGA NP (Blank NP) 
Acid terminated PLGA (100 mg) was dissolved in 4 mL of DCM.  PVA was made up as a 1.25% 
(w/v) solution in distilled water (ddH2O).  The PLGA/DCM organic phase was added dropwise to 
15 mL of 1.25% (w/v) PVA solution and sonicated using a Fisher Scientific FB50 sonicator probe 
(Pittsburgh, PA, USA) at 80% amplitude for two minutes.  The resulting o/w emulsion was left to 
stir overnight to evaporate any solvent.  The NP emulsion was then centrifuged at 18809 g for 
30 minutes at 4 °C in a Sigma 2-16K refrigerated centrifuge (SciQuip,UK), before washing the 
pellet with ddH2O for ten minutes.  A 2% (w/v) sucrose solution was used to wash the NP for a 
second time, before a final wash with ddH2O.  The final pellet was resuspended in 5 mL ddH2O 
and freeze dried using a Labconco FreeZone 4.5 plus benchtop freeze dry system on automatic 
mode (-40°C, 0.12 mbar) for 48 hours. 
 
3.2.3.2. Preparation of doxorubicin-loaded NP (Dox NP) 
An optimised double emulsion technique was used to encapsulate doxorubicin in PLGA NP, as 
previously described in chapter 2 (see Table 2.12.).  Doxorubicin hydrochloride (2 mg) dissolved 
in 0.5 mL of ddH2O was added dropwise to 4mL of acid terminated PLGA (100 mg) in DCM and 
sonicated (Fisher Scientific FB50 sonicator probe, Pittsburgh, PA, USA) for 60 seconds at 80% 
amplitude.  The primary w/o emulsion was then added dropwise to 15 mL of 1.25% (w/v) PVA in 
ddH2O and sonicated for a further 2 minutes.  The resultant w/o/w emulsion was left to magnetic 
stir overnight to evaporate any solvent.  The doxorubicin-loaded NP (Dox NP) were collected by 
centrifugation at 18809 g for 30 minutes at 4°C and washed thrice with ddH2O.  Dox NP were 
finally resuspended in ddH2O and freeze dried for 48 hours as previously detailed in section 
2.2.2.1.  Supernatant from centrifugation was retained to determine doxorubicin entrapment 
efficiency (EE) using UV-Visible spectroscopy at 480 nm on a FLUOstar Omega microwell plate 
reader (BMG Labtech, Germany). 
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FITC-dextran (FITC-dex) loaded PLGA nanoparticles (FITC NP) for confocal fluorescence 
imaging were also prepared this way, using 4 mg of FITC-dex per 100 mg of PLGA polymer.  
Entrapment of FITC-dex in PLGA NP was detected using fluorescence spectroscopy (excitation 
485 nm, emission 520 nm), again on a FLUOstar Omega microwell plate reader. 
 
3.2.4. Conjugation of RDP to NP  
RDP conjugation to NP was carried out according to the same method as detailed in 2.2.7.  
Briefly, free PLGA carboxyl groups on NP were activated by EDC/NHS chemistry and reacted 
overnight with RDP solution (1 mg/mL) to produce RDP-Blank NP, RDP-Dox NP and RDP-FITC 
NP.  Supernatant from the fabrication process was collected to assess peptide conjugation 
efficiency (CE) using a BCA assay and UV-Vis spectrometry (562 nm).  The peptide CE was 
calculated according to Equation 3.1.  
 
 
Equation 3.1.    𝐶𝐸 =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑒𝑑 𝑡𝑜 𝑁𝑃
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑎𝑑𝑑𝑒𝑑
 𝑥 100% 
 
 
3.2.5. Evaluation of NP  
 
3.2.5.1. Dynamic Light Scattering (DLS) 
Size, zeta potential (ZP) and polydispersity index (PDI) measurements were carried out using 
dynamic light scattering (DLS) analysis (Zetasizer, Nano-series, Malvern Instruments, UK).  Prior 
to DLS analysis, 1 mg of NP were dispersed in 1 mL of ddH2O for measuring size and PDI.  For 
ZP measurements, NP were dispersed in 1.0 mM KCl, pH 7.5, to maintain a constant ionic 
strength.  Results were taken as an average of six measurements (n=6). 
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3.2.5.2. Determination of drug entrapment efficiency (EE) 
Doxorubicin and FITC-dex EE were calculated indirectly using supernatant from the formulation 
process, as described previously in section 2.2.3.  Doxorubicin EE was again calculated from a 
standard UV-Vis absorption curve at 480 nm.   A standard calibration curve for FITC-dex was 
prepared using fluorescence spectroscopy (excitation 485 nm, emission 520 nm), as shown in 
Figure 3.1.    
 
 
 
 
 
 
 
 
 
 
Figure 3.1.  Standard calibration curve for FITC-dextran fluorescence intensity (excitation 485 nm, 
emission 520 nm) with increasing concentration (mcg/mL). 
 
 
 
3.2.5.3. Determination of RDP conjugation efficiency (CE) 
RDP CE to PLGA NP was determined by a BCA assay, as detailed in section 2.2.8.  
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3.2.5.4. FITC-dextran release from PLGA NP 
Doxorubicin release from PLGA NP was described previously in section 2.2.5.  To analyze FITC-
dex payload release from PLGA NP under sink conditions, 3 mg of FITC-dex NP were dispersed 
in 1 mL of PBS and incubated at 37°C for a period of 7 days.  Samples of supernatant were taken 
after varying amounts of time by centrifuging the NP suspension at 1680 g for 5 minutes and 
replacing each aliquot with fresh PBS.   Samples were tested for fluorescence (excitation 485 
nm, emission 520 nm) to detect FITC-dex release from the PLGA NP.  Percentage cumulative 
release was expressed as a percentage of maximum FITC-dex in the NP, determined from the 
EE.  Fluorescence values were recorded in triplicate and standard deviation calculated (n=3). 
 
3.2.6. In vitro evaluation 
 
3.2.6.1. Cytotoxicity study 
Cells were seeded into 96 well plates at a concentration of 1x105 cells/mL (200 µL per well) in 
the relevant culture media and incubated at 37°C and 5% CO2 for 24 hours (Heraeus HERAcell, 
Thermo Fisher Scientific, UK).  Dox NP and RDP-Dox NP were prepared as 200 µg/mL 
suspensions in serum-free media (SFM) and filter sterilised using a 450 nm filter.  Blank PLGA 
NP with conjugated RDP (RDP-blank NP) were also prepared this way, to test for toxicity of the 
drug vehicle.  NP treatment (200 µL) or an approximate equivalent concentration of free RDP 
was added to each well, with six replicates for each of the treatment groups.  Control groups 
were treated with 200 µL of SFM only. 
Initially, SH-SY5Y cells were incubated (37°C/5% CO2) with RDP, RDP-blank NP, Dox NP and 
RDP-Dox NP for 1, 2, 4 or 24 hours.  Following this, four different cell lines (HeLa, CHO, MDA-
MB-231 and SH-SY5Y cells) were treated with the Dox NP and RDP-Dox NP formulations only 
for 24 hours.  After the elapsed treatment time, all media was aspirated, replaced with 200 µL of 
complete media and incubated (37°C/5% CO2) until an MTT assay was carried out to assess cell 
viability.  MTT assay was carried out at 24 hours post addition of NP treatment.  MTT solution 
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(25 µL of 5 mg/mL in sterile PBS) was added on top of the media in each well and incubated at 
37°C/5% CO2 for 2 hours.  The wells were then aspirated, and purple formazan crystals dissolved 
by the addition of 70 µL of dimethyl sulfoxide (DMSO) per well.  Absorbance was read at 570 nm 
(FLUOstar Omega microwell plate reader, BMG Labtech, Germany).   
 
3.2.6.2. Confocal Microscopy  
Cellular uptake of FITC NP preparations was evaluated in SH-SY5Y, PC-12 and HeLa cell lines 
using a Leica SP5 confocal microscope (x 63 000 magnification).  Cells were seeded onto 13 
mm glass coverslips at a concentration of 1x105 cells/ mL (500 µL) and cultured in complete 
RPMI media at 37°C/5% CO2 overnight.   Cells were treated with 500 µg/mL (500 µL) of either 
FITC NP or RDP-FITC NP in SFM for 24 hours, whilst incubating at 37°C/5% CO2.  Controls were 
treated with SFM only.  All treatments were subsequently aspirated, and cells were gently 
washed thrice with PBS to remove residual NP.  Prior to imagining, all cells including controls 
were treated with 75 nM Lysotracker® red in SFM for 30 minutes to visualise lysosomes in cells 
and track potential co-localisation with NP along the cellular internalisation pathway.   FITC-dex 
fluorescence emission was collected between 510-610 nm (excitation wavelength 488 nm).  
Lysotracker® emission was collected separately between 585-685 nm (excitation wavelength 543 
nm).  
 
3.2.6.3. Receptor identification study 
SH-SY5Y cells were seeded onto 96 well plates, as previously described.  RDP-Dox NP were 
prepared as 400 µg/mL suspensions in SFM.  All inhibitor stock solutions were prepared in SFM 
to produce 200 µM bicuculline, 200 µM saclofen, 2 mM hexamethonium, 2 mM mecamylamine 
and a 1:50 dilution of anti-AChRα7 antibody.  
SH-SY5Y cells were initially pre-treated for 30 minutes with 100 µL of either bicuculline, saclofen 
or hexamethonium prior to treatment with 100 µL of RDP-Dox NP suspension (400 µg/mL).  Final 
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concentrations of inhibitors, once all treatments were added, were 100 µM for the GABA 
antagonists (bicuculline and saclofen), 1 mM for nAChR antagonists (hexamethonium and 
mecamylamine) and a 1:100 dilution of anti-AChRα7 antibody.    Cells were incubated as before 
for 24 hours at 37 °C/5% CO2.   Control wells were treated with SFM only.  After incubation, wells 
were aspirated, washed gently with PBS and 200 µL of fresh complete media added per well.  
MTT assay was subsequently carried out.  This provided results for the first receptor identification 
assay, which was followed up by a second assay to block the nAChR only.  The subsequent 
assay followed the same protocol, only mecamylamine and anti-AChRα7 antibody solutions were 
allowed to incubate with SH-SY5Y cells for 60 minutes prior to RDP-Dox NP exposure.  This was 
to ensure adequate time for the antibody to bind any homomeric α7 nAChRs.   
RDP was finally tested on PC-12 (rat pheochromocytoma) cells, a second cell line of neural 
origin.  The effect of RDP-Dox NP in comparison to Dox NP was investigated according to the 
method previously described for SH-SY5Y cells.  Additionally, the effect of blocking the nAChR 
with anti-AChRα7 antibody was explored in this cell type also.   
 
3.2.7. Statistical analysis 
 
All analysis carried out on cell viability values was determined using an unpaired two-tailed t-test, 
with P values < 0.05 indicating a statistically significant difference.   
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3.3.  Results & Discussion 
 
3.3.1. NP characterisation 
 
NP were formulated according to the double emulsion method and characterised for size, ZP 
and PDI, the results of which are presented in Table 3.1.  Using DLS analysis, it was determined 
that blank PLGA NP had an average particle diameter of 240.27 ± 14.72 nm, ZP of -18.4 ± 1.82 
mV and PDI of 0.26 ± 0.04.  Incorporation of a doxorubicin payload had no significant effect (P 
value > 0.05) on average NP diameter (242.73 ± 18.64 nm) however ZP increased slightly to -
14.64 ± 1.32 mV, as did the PDI (0.39 ± 0.05).   FITC NP had an average NP diameter of 286.50 
± 11.30 nm, which was a statistically relevant increase compared to the blank PLGA NP (P value 
0.0125).  FITC NP displayed a significant increase in ZP to -10.30 ± 1.00 mV in comparison to 
the blank PLGA NP (P value 0.0025), however the PDI (0.27 ± 0.08) remained constant (P value 
> 0.05).  Reimold et al. (2008) prepared polymeric NP loaded with 70 kDa FITC-dex, which 
displayed identical ZP and PDI characteristics to the NP reported in Table 3.1.   
Doxorubicin hydrochloride (579 Da) and FITC-dex (70 kDa) are both water soluble molecules, 
however they vary greatly in molecular weight.  The high molecular weight of FITC-dex perha ps 
is responsible for the slightly larger NP size, however the difference observed is not crucial for 
this work.   The larger molecule size also aids encapsulation into the PLGA NP, unlike low 
molecular weight doxorubicin which easily escapes into the outer aqueous phase during the 
double emulsion NP formulation process.  A favourable entrapment efficiency (EE) of 77% (Table 
3.1) was obtained for the PLGA-based FITC NP reported herein, which correlates closely with 
previous work at similar w/w (%) loading (Nimesh et al., 2006).  Interestingly, Chiu et al. (2015) 
found that increasing molecular weight of FITC-dex corresponds with higher EE in polymeric NP.   
All NP formulations were successfully conjugated to RDP with efficiencies of over 50%.  
Conjugation efficiency (CE) of RDP to FITC NP (73%) was considerably better in comparison to 
both doxorubicin-loaded (54%) and unloaded NP (55%).  The presence of FITC-dex molecules 
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encapsulated in the PLGA NP potentially aids surface binding of RDP, through somehow 
influencing NP surface characteristics or availability of free, activated carboxyl groups for RDP 
to react with.   
 
 
Table 3.1.  Characterisation parameters of blank PLGA NP, Dox NP and FITC NP prepared by a double 
emulsion method.                                                                                                         
 
 
 
 
3.3.2. In vitro release of FITC NP in PBS 
 
FITC-dex release from PLGA NP, shown in Figure 3.2, was measured in vitro for 7 days under 
physiological conditions (37°C, pH 7.4).   After 7 days of incubation, up to 42% of the payload 
was released from the NP, as detected by FITC fluorescence emission.  Nimesh et al. (2006) 
reported a similar release profile for a polymeric NP formulation loaded with FITC-dex, in which 
release of around 50% was observed after 7 days in PBS (pH 7.4).  In Figure 3.2, the rate of 
payload release retarded following an initial burst phase, in which 25% of the payload was 
released in the first 24 hours.  This showed that the FITC-dex payload was able to escape from 
NP Sample Size (nm) ZPa (mV) PDIb DCc (µg/mg) RDPd (µg/mg) 
 
Blank NP  
 
240.27 ± 14.72 
 
-18.40 ± 1.82 
 
0.26 ± 0.04 
 
- 
 
55.00 
 
Dox NP 
 
242.73 ± 18.64 
 
-14.60 ± 1.32 
 
0.39 ± 0.05 
 
12.80 
 
54.00 
 
FITC NP  
 
286.50 ± 11.30 
 
-10.30 ± 1.00 
 
0.27 ± 0.08 
 
30.80 
 
73.00 
ͣ Zeta potential (mV), b polydispersity index, c DC= drug content per 1 mg of NP based on entrapment efficiencies of 
64% (Dox) and 77% (FITC-dex); d RDP content per 1 mg of NP based on conjugation efficiencies of 55.0% (blank 
NP), 54% (Dox NP) and 73.0% (FITC NP).  Size, ZP and PDI as measured by DLS are expressed as average ± 
standard deviation (n=6).  A student’s unpaired T-test was used for statistical analysis; a two-tailed P-value was  
considered statistically significant if < 0.05. 
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the NP matrix in a controlled manner, which is favourable for both in vitro testing and in vivo drug 
delivery.   
It Is essential that the payload can release from the NP during in vitro testing, however very leaky 
NP are of no value as free drug will affect results associated with tissue culture work.  Like the 
Dox NP which were analysed in chapter 2, the FITC NP described here are also suitable for 
cellular uptake studies to observe the effect of RDP conjugation.   The small fraction of payload 
released within 24 hours is unlikely to affect cellular uptake studies, particularly as FITC-dextran 
is too large and hydrophilic to be passively taken up into cells at such low concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.  In vitro 7-day release of FITC-dextran from PLGA NP in PBS at 37°C, as measured by 
fluorescence spectroscopy.  Error bars ± standard deviation (n= 3). 
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3.3.3. In vitro evaluation 
 
3.3.3.1. Cytotoxicity study  
SH-SY5Y neuroblastoma cells were treated with RDP, RDP-Blank NP, Dox NP and RDP-Dox 
NP to assess cytotoxic effects over varying exposure times (Figure 3.3).  RDP alone or 
conjugated to blank PLGA NP (RDP-Blank NP) showed no significant cytotoxicity over the 
experimental period, as average cell viability remained at 95% or above (no significant 
difference) compared to control, even after 24 hours of NP exposure.  Additionally, it is clear that 
any significant cell death observed in Figure 3.3 was due to release of the cytotoxic NP payload, 
doxorubicin.  This result showed that RDP can be used as a non-toxic targeting ligand in vitro 
and was in accordance with the in vivo findings by Fu et al. (2012; 2013a; 2013b) on the lack of 
RDP adverse effects.  In fact, Fu et al. (2013a; 2013b) reported no toxic reactions to RDP over 
experimental periods of three weeks following repeated systemic administration in mice.   
Moreover, these results confirm that the PLGA NP drug vehicle is also not toxic. 
Dox NP imparted 13% cytotoxicity on SH-SY5Y cells following up to 2 hours of exposure time, 
leading to a significantly lower cell viability of 87.0% compared to control (P value <0.05).  After 
24 hours, there was a small increase in cytotoxicity causing cell viability to decrease to 82.7% 
after Dox NP treatment.  This toxicity could be expected due to an initial release of cell permeable 
doxorubicin from the NP, according to the release data previously detailed in chapter 2.  
Alternatively, it is possible that some non-specific NP uptake has occurred through absorptive 
processes, particularly after 24 hours. 
Results from Figure 3.3 show that incubation of SH-SY5Y neuroblastoma cells with RDP-Dox 
NP resulted in a significant decrease in cell viability to 67.0% compared to control after 24 hours.  
The cytotoxicity caused by RDP-Dox NP (33%) was almost double that of Dox NP (17.3%) at 24 
hours, also causing a statistically significant difference (P value <0.05).   In fact, RDP-Dox NP 
were significantly more cytotoxic than Dox NP at all treatment times observed.  This is perhaps 
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not surprising, as it was first reported by Fu et al. (2012) that RDP activity was detectable within 
15 minutes of administration in vivo.   
Due to the fact that RDP itself does not appear toxic, this enhancement of cytotoxicity must be 
due to an increased accumulation of doxorubicin inside the cell.  It can therefore be deduced 
from the results in Figure 3.3, that RDP conjugation is responsible for facilitating enhanced 
cellular NP uptake, in comparison to an unlabelled formulation.   
The pilot in vitro study on SH-SY5Y cell viability (Figure 3.3) showed minimal difference between 
different NP exposure times, particularly for RDP-Dox NP treatment, for which there might be 
various explanations.  RDP-facilitated NP uptake could be limited by an initial rapid saturation of 
receptor sites within the first hour.  This would cause a temporary delay in further RDP-cell 
interactions, preventing further NP uptake until the ligand-receptor complexes are internalised 
and degraded or recycled back to the cell surface again.  Receptor recycling can occur over time 
periods ranging from a few hours to several days, depending on the ligand-receptor interaction 
(Bruneau et al., 2005). 
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Figure 3.3.  Percentage cell viability of SH-SY5Y neuroblastoma cells following treatment with either 
serum free media (control), RDP, RDP-Blank NP, Dox NP or RDP-Dox NP over varying 
exposure times.  Error bars represent ± standard deviation (n= 6).    * Statistically significant 
difference compared to control; ** statistically significant difference compared to control and 
Dox NP group (P value < 0.05).  
 
 
 
It is possible that observations beyond 24 hours might show further RDP-Dox NP enhanced 
cytotoxicity, however this is neither ideal nor necessary for further in vitro studies.  The effect of 
RDP is observed within 24 hours which is sufficient for many cell-based assays, as times beyond 
this may result in non-specific cell death from over-confluency.  Considering this, it was decided 
that for further work, NP would be incubated with cells for 24 hours.  This would give cells 
sufficient time to undergo potential NP internalisation processes such as endocytosis, which 
might be occurring during treatment.  It is also true that the consistency and effectiveness of 
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gentle cell washing after a given period of time cannot be guaranteed, leading to inaccuracies in 
amount of NP exposed to cells prior to MTT assay.  Furthermore, the amount of time NP are in 
contact with cells cannot be selected during in vivo studies and for these reasons, 24 hours 
treatment time was determined to be most appropriate for in vitro studies.   
RDP has been previously shown to preferentially target neural cells, both in vitro and in vivo (Fu 
et al., 2012; 2013a; 2013b).  Results from Figure 3.4 show that RDP conjugation significantly 
enhanced the cytotoxicity of the Dox NP treatment in the SH-SY5Y neural cell type as opposed 
to three other non-neural cell types (CHO, MDA-MB-231 & HeLa).  In Figure 3.4, cell viabilities 
for the non-neural cell types- MDA-MB-231, CHO and HeLa, remained similar following treatment 
with either NP formulation.    The MDA-MB-231 and HeLa cell lines (non-neural) were not 
significantly affected by either NP treatment, although some toxicity was certainly observed 
compared to control.  MDA-MB-231 cell line retained a cell viability of 91.9% after Dox-NP 
treatment and 92.6% following RDP-Dox NP treatment.  For the HeLa cell group, cell viability 
reduced to 91.0% following Dox-NP exposure and to 87.1% after RDP-Dox NP treatment (not 
significant).  RDP, therefore, had no significant effect on the cytotoxicity of the Dox-NP 
formulation within these non-neural cell types.   
The normal, non-neural CHO cell line displayed cell viabilities of 83.4% and 86.7% following 
treatment with Dox-NP and RDP-Dox NP, respectively.  Both of these values marginally turned 
out to have a statistically significant P value (< 0.05) compared to control, but not to each other.  
This means that RDP labelling did not have an effect on the toxicity of Dox-NP within the CHO 
cell line.  This was not the case for the SH-SY5Y neuroblastoma cells, which had a significantly 
lower cell viability of 65.9%, when treated with the RDP-Dox NP compared to 78.3% when treated 
with the unlabelled Dox NP.  The difference between these two treatment groups was 
approximately 13% and shown to be significant (P <0.05), indicating alteration in cell viability due 
to RDP labelling.   
It is clear from these findings that RDP enhanced cellular uptake of an attached nanocarrier 
within the neural cells exclusively.  It has already been conclusively shown by Fu et al. (2012; 
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2013a) that RDP conjugates enter neural cells by energy-dependent means.  If free doxorubicin 
was only causing effects through NP leakage, results for Dox NP and RDP-Dox NP treatments 
would be similar for SH-SY5Y cells, as was seen with the CHO, MDA-MB-231 and HeLa cell 
lines.  To this end, it would appear that when attached to a polymeric NP, RDP retains the 
neurotropism of the parent glycoprotein, RVG. 
 
 
 
 
Figure 3.4.  Percentage cell viability of MDA-MB-231, CHO, HeLa and SH-SY5Y cells following treatment 
with either serum free media (control), Dox NP or RDP-Dox NP.  SH-SY5Y cells of neural 
origin, are the only cell line to show a statistically significant difference in cell viability between 
the Dox NP group and RDP-Dox NP group (P value= 0.028, <0.05).  Error bars ± standard 
deviation (n= 6).  * Statistically significant difference compared to Dox NP treatment. 
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3.3.3.2. Confocal microscopy 
Visualisation of FITC-NP uptake by confocal fluorescence microscopy (Figure 3.5) demonstrates 
the ability of RDP to preferentially target SH-SY5Y neuroblastoma (Figure 3.5A) and PC-12 
(pheochromocytoma) neural cells (Figure 3.5B), promoting visibly greater cellular uptake 
compared to the unlabelled FITC NP.  In contrast, fluorescence signal detected in Hela cells of 
Figure 3.5C was low.  No notable difference in HeLa cell uptake was visualised between all 
formulations, indicating that RDP is not effective as a targeting peptide in this non-neural cell 
line, supporting the findings from Figure 3.4.   
St. Pierre et al. (2011) detected association of original RVG with the endocytic pathway in a 
mouse neuroblastoma cell line, concluding that RVG is most likely internalised by a receptor-
mediated endocytosis mechanism.  The signal pattern detected by Lysotracker® red indicates 
that there may be co-localisation of lysosomes and internalised FITC-NP in SH-SY5Y and PC-
12 cells.  It was first suggested by Fu et al. (2013a), that the cellular uptake mechanism of RDP 
may involve energy-dependent internalisation pathways, such as clathrin-dependent 
endocytosis.  It was later shown by Zhang & Fu (2015), that RDP-gold NP conjugates were 
detected in SH-SY5Y cell endosomes and cytoplasm by transmission electron microscopy.  This 
uptake was greatly reduced in an ATP-depleted environment, implicating the dependence of 
RDP on energy-mediated uptake mechanisms, rather than passive.  Indeed, observations of 
potential co-localisation between RDP conjugates and lysosomes in Figure 3.5 support this idea.   
No evidence of free FITC-dex entering cells could be detected after 24 hours of incubation, 
meaning concerns of free drug leaching from NP to affect uptake studies could be disregarded, 
probably due to the size and hydrophilic nature of the FITC-dex molecule.  If free drug were 
interfering with results, greater fluorescence would be seen with the unlabelled NP preparation.  
However, this was not the case, with minimal fluorescence from FITC NP detected in all of the 
cell lines studied.   
SH-SY5Y cells are commonly employed for studying drug delivery to neural cells and are often 
used as a dopaminergic model for PD research (Forster et al., 2016; Xicoy et al., 2017).  PC-12 
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cells were introduced as an additional cell line of neural origin to provide further insight into the 
neural-specific targeting capability of RDP.  The uptake of RDP-conjugated cargo, as detected 
by various microscope imaging techniques, has been most commonly studied in SH-SY5Y cells.  
For example, Wu et al. (2016) detected RDP-p53 fusion protein by confocal imaging in SH-SY5Y 
cells, but not in HepG-2 hepatocellular carcinoma cells.  Although using a different RVG 
derivative, Son et al. (2011) showed that an RVG-29-targeted gene delivery vector was detected 
by confocal fluorescence imaging in Neuro-2a cells, but not in non-neural HeLa cells.  Findings 
from this confocal study, as presented in Figure 3.5B, are the first reported images of RDP action 
in PC-12 cells and thus providing further support for the neural cell-specific permeability of this 
peptide. 
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Figure 3.5.  Confocal images showing location of intracellular lysosomes (red) and the effect of RDP 
labelling on the cellular uptake of FITC-NP (green) in (A) SH-SY5Y (B) PC-12 and (C) HeLa 
cells.   
 
 
 
25 µm 
25 µm 
25 µm 
120 
 
3.3.4. Receptor identification study 
 
Receptor mediated endocytosis is the proposed mechanism of RDP cellular uptake (Fu et al., 
2013a) and indeed for most NP modified with targeting ligands (Danhier et al., 2012).   In order 
to determine which receptor is responsible for cellular interaction with RDP, SH-SY5Y 
neuroblastoma cells were used alongside various inhibitors of the main neural receptor types, 
namely the GABA receptor and the nicotinic acetylcholine receptor (nAChR).    
Results from Figures 3.4 & 3.5 provided evidence that RDP enhanced the cytotoxic effect of Dox 
NP on these cells specifically.  SH-SY5Y cells were therefore an appropriate selection for 
receptor identification.  Different antagonists of the nAChR, GABA(a) and GABA(b) receptors 
were utilised to test the effect on RDP-Dox NP treatment of SH-SY5Y cells.   Cells were pre-
treated with either bicuculline or saclofen (competitive antagonists of the GABA receptor A and 
B subtypes, respectively) or hexamethonium (competitive antagonist of the nAChR).  Results 
displayed in Figure 3.6 show that the hexamethonium pre-treated group was the only one to 
maintain a cell viability of 99.3%, compared to control.   The GABA inhibitors bicuculline and 
saclofen were unable to prevent a significant decrease in cell viability, as RDP-Dox NP treatment 
caused cell viability to decrease to 84.8% (P <0.05 compared to control) for both groups.  This 
suggested that RDP did not depend on either GABA receptor subtype for gaining cell entry, 
conflicting with the findings of Fu et al. (2013a).     
Treatment with hexamethonium, saclofen or bicuculline alone did not cause any cell death and 
so any decreases in cell viability was due to RDP-Dox NP treatment.  The SH-SY5Y cell viability 
of the RDP-Dox NP treated cells with no prior treatment with a receptor inhibitor was 80.5%.  
This level of cell death was similar to the bicuculline and saclofen pre-treated groups, where 
there was approximately 16% cell death.  In contrast, the hexamethonium pre-treated cells were 
significantly different to those with no prior inhibitor treatment (P < 0.05). 
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Figure 3.6.  Percentage cell viability of SH-SY5Y neuroblastoma cells following treatment with RDP-Dox 
NP for 24 hours to assess the effect of 30 minutes pre-treatment with different receptor 
inhibitors on RDP-facilitated NP uptake.  Hexamethonium (Hexa), the competitive nAChR 
antagonist, was the only inhibitor able to block the effect of NP treatment.  Error bars 
represent ± standard deviation (n= 6).   *Statistically significant difference compared with 
control; Two-tailed T-test P value <0.05.  
 
 
 
Figure 3.7 shows that pre-treatment of SH-SY5Y cells with either anti-AChRα7 antibody or the 
non-competitive nAChR antagonist, mecamylamine, prevented RDP-Dox NP-induced SH-SY5Y 
cell death as viability remained comparable to control.  None of the inhibitors used in the 
experiments of both Figures 3.6 & 3.7 are cell permeable, but rather bind to extracellular 
receptors.  The lack of effect caused by RDP-Dox NP over 24 hours in the presence of 
hexamethonium, mecamylamine and anti-AChRα7 antibody indicated a receptor-dependent 
mechanism of RDP cellular uptake. 
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Results from Figure 3.6 and Figure 3.7 revealed that the nAChR is necessary for RDP-Dox NP 
to have any significant effect on SH-SY5Y cell viability.  A competitive nAChR antagonist 
(hexamethonium), a non-competitive nAChR antagonist (mecamylamine) and a specific antibody 
of the nAChR all prevented RDP-facilitated effects on SH-SY5Y cells.  Conversely, blocking 
either GABA(a) or GABA(b) receptor subtypes had no effect in preventing a significant decrease 
in SH-SY5Y cell viability (Figure 3.6).  It can, therefore, be concluded from this work that the 
nAChR most definitely plays an important role in cellular interaction with RDP.  It is most likely 
that via this receptor, RDP facilitates the internalisation of a conjugated payload, leading to the 
specific effects observed in SH-SY5Y cells. 
These findings conflict with Fu et al. (2013a), who reported that GABA itself prevented cellular 
uptake of RDP.  It is possible that high concentrations of GABA causes desensitisation of the 
nAChR through negative feedback mechanisms which control acetylcholine-mediated GABA 
release (McClure-Begley et al., 2014).  If this were the case, it would falsely appear as though 
GABA is preventing RDP uptake via a GABA receptor rather than the desensitising effect on the 
nAChR.  In this instance, the nAChR may not be able to bind RDP and consequently undergo 
receptor-mediated endocytosis.  This, however, does not explain why Fu et al. (2013a) found 
that nicotine was unable to prevent RDP uptake, unless RDP was able to outcompete the 
nicotinic agonist in a concentration-dependent manner. 
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Figure 3.7.  Percentage cell viability of SH-SY5Y neuroblastoma cells following pre-treatment with different 
nAChR inhibitors and exposure to RDP-Dox NP.  Mecamylamine (Mec) and anti-AChRα7 
antibody (AB) both blocked the effect of RDP-Dox NP.  Error bars represent ± standard 
deviation (n= 6).  * Cell Viability = 86.1%; statistically significant difference compared to control 
(P value= 0.027, <0.05).  “NP” represents RDP-Dox NP treatment. 
 
 
 
Following the confocal study of Figure 3.5, it was shown that RDP is active in both SH-SY5Y and 
PC-12 cells.  To further verify that RDP function is dependent on interaction with the nAChR, the 
specific AChRα7 antibody was tested for its effect on RDP-Dox NP action in PC-12 cells.  Results 
from Figure 3.8 showed that similar to SH-SY5Y cells, PC-12 cells were susceptible to the effects 
of RDP-enhanced uptake of Dox NP.  Treatment with RDP-Dox NP was significantly more 
cytotoxic than the unlabelled Dox NP preparation, however this difference was negated by pre-
incubation of PC-12 cells with anti-AChRα7 antibody.  Blocking this receptor caused cell viability 
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to remain higher (91%) after RDP-Dox NP treatment, in comparison to cell viability when the 
receptor was uninhibited (79%).  These findings substantiate the conclusions drawn from Figures 
3.6 & 3.7, that the nAChR is majorly involved in neural cell association with RDP. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8.  PC-12 cell viability in response to treatment with different NP preparations.  The effect of 
blocking the α7-nAChR on RDP-facilitated NP uptake was investigated by blocking the 
receptor with a specific antibody.  Error bars ± standard deviation (n=6). * cell viability= 79%; 
statistically significant difference compared to Dox NP (P value <0.05).  “NP & α7-AB” 
represents RDP-Dox NP treatment in combination with anti-AChRα7 antibody. 
 
 
There are two principal subtypes of acetylcholine receptor in the human body, the metabotropic 
muscarinic acetylcholine receptor and the ionotropic nicotinic acetylcholine receptor (nAChR).  
Both of these groups are activated by the endogenous ligand, acetylcholine, at neuronal and 
non-neuronal sites.  The muscarinic subtype has been distinguished by its typical activation by 
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muscarine, the mushroom toxin from Amanita muscaria, whereas the nicotinic subclass is 
prominently activated by the exogenous ligand, nicotine.  nAChRs are a family of cationic 
channels and along with the muscarinic subtype, 5-Hydroxytryptamine (serotonin) receptors and 
γ-aminobutyric acid (GABA) A/C receptors, they form part of the Cys-loop gene superfamily 
commonly known as ligand-gated ion channels (Gotti & Clementi, 2004; Dunckley & Lukas, 
2006).  They nAChR subfamily has classically been further subdivided into neuronal-type and 
muscle-type. 
Neuronal-type nAChRs exist as homopentameric or heteropentameric subtypes.  This means 
they are typically composed of 5 subunits surrounding a central pore, as depicted in Figure 3.9.  
Thus far, the subunits which have been identified in mammalian neuronal-type nAChRs are nine 
α (α1-α9) and three β (β2-β4) subunits. (Hadaddian et al. 2008; Quik & Wanacott, 2011).  The 
homopentameric arrangement (Figure 3.9A), also known as α-Bungarotoxin sensitive, is 
composed of five identical α7 subunits and therefore five identical agonist binding sites.  In the 
human central and peripheral nervous systems, α7 homomeric receptors are one of the most 
commonly found, particularly in neurons of hippocampal origin.  It is possible that α8 and α9 
subunits also compose these homomeric receptors, but so far, the α8 subunit has not been 
identified in humans and the α9 subunit has presently not been isolated in neurons (Gotti & 
Clementi, 2004).   
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Figure 3.9.  A representation of the neuronal-type nicotinic acetylcholine receptor subunit composition for 
the common (A) α7 homopentameric and (B) α4β2* heteropentameric subtypes.  The ligand 
binding sites (yellow) are situated between alpha subunits (homopentameric) or alpha and 
beta subunits (heteropentameric). 
 
 
 
The heteropentameric arrangement (Figure 3.9B) is generally in the stoichiometry arrangement 
of 2α3β*; where * signifies the possibility of a different additional α subunit in the complex 
(Paterson & Nordberg, 2000).  These receptors will have two agonist binding sites, between α 
and β units, both of which must be occupied for activation of the receptor.  These are also known 
as α-Bungarotoxin insensitive but show a higher affinity in agonist binding compared to their 
homomeric counterparts.  Although the α2, α3, α4, α6, β2 and β4 subunits play a role in binding 
and may be co-expressed by a particular neuron, only a few combinations may actually be 
formed.  This led to the conclusion that α5 and β3 subunits merely play a supportive role rather 
than being involved in agonist binding (Gotti & Clementi, 2006). 
The major nAChR subtypes in the mammalian central nervous system are α4β2* and α7*, 
comprising approximately 90%.  The structure of both these receptor subtypes and their 
respective binding sites are shown in Figure 3.9.   In the CNS, nAChRs are widely expressed, 
as they form a major part of the cholinergic transmission pathways in the brain and peripheral 
ganglia (Table 3.2).  Their role in pre-synaptic neurotransmitter release and post-synaptic 
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transmission means that central innervation gives rise to many different functions.  These include 
cognition, reward, pain processing, arousal and motor activity (Gotti & Clementi, 2006).  These 
functions of the nAChR depend on brain location and indeed subunit composition.  Table 3.2 
details nAChR subunits found throughout different areas of the nervous system.   
At the interface between the central nervous system and the blood circulation, there has been 
detection of nAChR subunits on brain endothelial cells of the BBB.  These cells specifically 
express the α3, α5, α7, β2 and β3 subunits, as reported by Abbruscato et al. (2002) in an 
immunoreactivity assay.  If RDP can enter neural cells and cross the BBB in vivo via nAChR-
dependent means, it must be able to bind to one or more nAChR subtypes expressed on brain 
endothelial cells.  
 
 
Table 3.2.  Evidence of neuronal-type nAChR subunit detection and composition in different areas 
throughout the brain and at the NMJ. 
 
 
It has been established that RVG can bind to residues 173-204 of the α1 subunit of muscle-type 
nAChRs present at the NMJ, hence leading to rabies virus infection (Lentz et al. 1990; Gastka 
et al. 1996).  In early studies by Lentz et al. (1990), it was concluded that the rabies virus shares 
Organ/system Location Neuronal-type nicotinic acetylcholine 
receptor subunits 
Brain Unspecified α3, α4, α5, α6, α7, β2, β3 & β4 (Maus et al., 
1998) 
 Hippocampus Mainly α7 (Court et al., 2000) 
Cerebellum α3, α4, α7 & β2 (Court et al., 2000) 
Striatum α3, α4, α7 & β2 (Court et al., 2000)  
Substantia Nigra α3, α4, α7 & β2 (Court et al., 2000) 
Cortex α3, α4*, α7 & β2(Court et al., 2000) 
Microglia α7 (De Simone et al., 2005) 
Blood Brain 
Barrier 
Brain Endothelial Cells α3, α5, α7, β2 & β3 (Abbruscato et al., 2002) 
Muscle Muscle Fibre (rat) α7 (Fischer et al., 1999) 
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a binding site with α-BTX (a competitive inhibitor of acetylcholine) at the α1 subunit.  Lentz and 
colleagues also found that that the virus was able to bind to the α3 subunit, confirming that the 
rabies virus does in fact bind to neuronal-type nAChRs as well as muscle-type. Evidence of 
neuronal-type nAChR subunits such as α7 have been detected in muscle (Fischer et al. 1999), 
meaning that additional subunits at the NMJ are very likely to play a role in RVG binding and 
explain the ability of the rabies virus to traverse the CNS so readily.   
Other molecules have been thought to be associated with rabies virus infectivity of the CNS.  The 
involvement of neural cell adhesion molecule (NCAM) in cell attachment and uptake of the rabies 
virus is somewhat ambiguous and subsequently passed over in comparison to the nAChR.  Also 
known as CD56, it is a glycoprotein from the immunoglobulin (Ig) superfamily with functions in 
cell adhesion and signalling (Paratcha et al., 2003).  NCAM plays a role in nervous system 
development by influencing cell migration, adhesion, neurite outgrowth and synaptic plasticity 
(Hubschmann et al., 2005).  There has also been evidence to suggest that NCAM is required to 
maintain normal synaptic function at the NMJ, particularly following injury (Chipman et al, 2010).   
Thoulouze et al. (1998) attempted to determine the role of NCAM in rabies virus infection, using 
NCAM-positive and NCAM-negative cells.  It emerged that NCAM-negative cells transfected with 
the NCAM gene, showed enhanced susceptibility to the rabies virus infection and that blocking 
NCAM with a specific antibody and a heparin ligand reduced susceptibility.  The authors believed 
this evidence would indicate that NCAM is a receptor for the rabies virus, certainly at the very 
least, it would suggest that NCAM plays a role in infection.  Thoulouze et al. (1998) considered 
that the nicotinic receptor and NCAM may both be closely involved or even synergistic in nature.  
The independence of NCAM from the acetylcholine receptor is questionable, as the in vivo work 
from this same study showed that the brains of NCAM deficient mice were still infected by rabies 
virus and equally so in the hippocampus, albeit far less efficiently than in the NCAM-positive wild-
type mice.   Furthermore, NCAM deficiency does not prevent rabies-induced death in mice but 
only delays it.  The fact that NCAM is not essential for infectivity means that although it seems 
to play an important role, it cannot be classified as a main receptor.  Given the expression of 
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NCAM throughout the central and peripheral nervous system in astrocytes, neurons and non-
myelinating Schwann cells, it is quite possible that NCAM forms part of a receptor complex which 
is responsible for the neurotropism of RVG at the NMJ (Lafon, 2005).  
Hislop et al. (2014) described how RVG associated with three types of receptor in vitro.  These 
were the aforementioned nAChR, NCAM and the low-affinity nerve-growth factor/neurotrophin 
(P75NTR) receptor.  P75NTR is from the tumour necrosis factor (TNF) family of receptors and 
although it is responsible for neurotrophin signalling pathways, it has also been implicated in 
neurodegenerative processes.  It was proposed by Tuffereau et al. (1998) that P75NTR could be 
a receptor for the rabies virus, after detecting association with RVG in infected cell lines in vitro.  
Almost a decade later, following doubts over association in vivo, Tuffereau et al. (2007) revisited 
this work and concluded that P75NTR was not essential for rabies virus infection.  It was also 
detailed that P75NTR expression alone was not sufficient enough to infect cells in vivo and other 
factors were almost certainly implicated. 
It should be noted that the interaction of RVG with P75NTR as accounted by Hislop et al. (2014), 
was in a mouse hybrid cell line of neuroblastoma and spinal cord cells.  This model was not 
representative of the in vivo NMJ and there appears to be no in vivo evidence of P75NTR presence 
at the NMJ (Lafon, 2005).  Whether or not NCAM and P75NTR play a key role in vivo or merely 
an accessory role in the neurotropism of RVG remains unclear, as conclusions drawn from in 
vitro results have deviated from in vivo behaviour. 
Prior to this work, the major receptor responsible for RDP cellular uptake had not been elucidated 
for certain.  It has been well established however, that an energy-dependent endocytosis 
mechanism is responsible, a theoretical representation of which is shown in Figure 3.10.   
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Figure 3.10.  Hypothetical route of uptake of rabies virus-derived peptide (RDP) via clathrin-dependent 
receptor-mediated endocytosis. 
 
 
 
Given the results from Figures 3.6-3.8, it is clear that the nAChR is responsible to a considerable 
extent for the effects of RDP as a targeting ligand in two different neural cell types, SH-SY5Y 
and PC-12.  Like BBB endothelial cells, SH-SY5Y and PC-12 cells are known to express α3 and 
α7 nAChR subunits (Madhok et al., 1995; Drisdel et al., 2004; Dunckley & Lukas, 2006).  This 
commonality between cell types certainly supports the conclusions drawn from this work, that 
like the original virus glycoprotein, RDP most likely interacts with at least one or more nAChR 
subtypes to facilitate internalisation of an attached payload.  The mutual expression of the α7-
nAChR subtype particularly amongst potential CNS entry points at the BBB and NMJ, presents 
a viable avenue for future receptor-ligand studies. 
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3.4. Conclusion 
 
In order for RDP to be advanced as a therapeutic CNS targeting ligand, it is necessary to know 
which neural surface receptor the peptide targets.  This study aimed to determine which receptor 
RDP binds to on neural cells following conjugation to a doxorubicin-loaded NP vehicle.  In 
agreement with work by others on RDP-conjugates, it was shown that RDP-Dox NP and RDP-
FITC NP selectively enhanced uptake of payload in two neural cell lines, SH-SY5Y and PC-12, 
compared to unlabelled preparations.  This preferential targeting ability was not observed in 
various non-neural cell types.  This study also showed neither RDP alone nor the PLGA vehicle 
are toxic in vitro.    
Various receptor inhibitors were used in attempt to block RDP activity in SH-SY5Y cells, which 
resulted in the nAChR being identified as necessary for RDP-facilitated uptake of Dox NP.  This 
was confirmed when RDP-enhanced cytotoxicity in PC-12 cells diminished upon blocking the 
homomeric α7 nAChR.  In identifying the nAChR as necessary for RDP uptake, progression can 
be made in the development of this ligand for use in targeted drug delivery systems. 
Early success and the attractive properties of this novel peptide for targeting neural cells can be 
attributed to inheritance of the strong neurotropism displayed by the parent glycoprotein, RVG.  
Mazarakis et al. (2001) proposed that viral envelope glycoproteins such as RVG, may be utilised 
for treating neurodegenerative disorders such as Parkinson’s, Alzheimer’s and Motor-Neuron 
diseases.  Taking advantage of the neurotrophic properties of RDP in vivo and the ubiquitous 
nature of the nAChR in the CNS may provide the basis for new brain targeting mechanisms, 
such as the work already mentioned by Fu et al. (2012 & 2013) and Zhang & Fu (2015) on RDP-
conjugates.  The use of RDP within polymeric drug carrier formulations may provide a safe and 
valuable approach to neural cell-targeting, protecting sensitive therapeutics from enzymatic 
degradation whilst enabling BBB passage.   
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Further investigation of RDP properties may highlight the need to optimise this large, hydrophilic 
peptide for future in vivo success.  RDP is relatively sizeable for a targeting ligand, presenting 
opportunity for enzymatic degradation by serum proteases following in vivo administration.  
Despite the early in vivo success of RDP, it remains to be seen how resistant RDP itself is to 
serum degradation and if this can be modified through sequence development.  It is certainly 
most desirable to achieve optimum stability whilst retaining targeting efficacy, to make advances 
in the pursuit for a viable brain-targeting ligand for neurodegenerative treatment. 
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Chapter 4 
Development of an optimised RDP 
sequence- evaluation of stability 
and in vitro efficacy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter reports work (with permission) from the following in press publication:  
Huey, R., Rathbone, D., McCarron, P and Hawthorne, S. (In Press). Design, Stability and Efficacy of a 
New Targeting Peptide for Nanoparticulate Drug Delivery to SH-SY5Y Neuroblastoma Cells.  Journal of 
drug targeting.  The original article can be found in Appendix 3. 
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4.1. Introduction 
 
Specific targeting of therapeutics is a growing area of research for a number of different disease 
states.  The benefits of this over conventional drug delivery are numerous, including better 
bioavailability of the drug at the target organ, reduction of unwanted side effects and smaller 
dosages required for therapeutic effect.  Cell penetrating peptides (CPPs) can greatly enhance 
the intracellular uptake of conjugated cargo across biological membranes in a non-invasive, non-
disruptive manner.  However, due to lack of tissue specificity, CPPs such as TAT (transactivating 
transcriptional activator) peptide, penetratin and polyarginine are not as efficient when aiming to 
deliver expensive or toxic drugs (Malhotra & Prakash, 2011).  A certain area of the body where 
it is particularly difficult to achieve efficient drug accumulation, due to the natural biological 
barrier, is the brain.  Active targeting of therapeutics to the central nervous system (CNS) is 
becoming essential, as many developed drugs for neurological disorders are unable to passively 
cross the blood brain barrier (BBB).  The difficulties in achieving drug delivery across the BBB 
due to its unique structure of brain endothelial cells, tight junctions and glial cells has been 
extensively reviewed in the literature (Teixido & Giralt, 2008; Alyautdin et al., 2014; Banks, 2016; 
Saraiva et al., 2016). 
CNS-specific peptide targeting ligands have been explored in the past decade to deliver 
therapeutic agents to the brain in animal studies with success (Kumar et al., 2007; Kwon et al., 
2010; Zhang et al., 2013; Gao et al., 2014; Soddu et al., 2015;).  Many promising CNS-targeting 
peptides take advantage of native receptors, transporters or enzymes to deliver therapeutic 
cargo across the BBB.  Derivatives from natural neurotoxic agents have been utilised due to their 
highly efficient transport abilities across the CNS.  These include tetanus toxin fragment C 
(Toivonen et al., 2010), neurotropic virus glycoproteins and fragments of snake, scorpion and 
bee venoms (Soddu et al., 2015).  Thus far, promising results with these ligands are still 
surrounded with concerns of immune reactions and true specificity for neural cells only.  Kumar 
et al. (2007) first showed that a derivative of RVG, RVG-29, utilised nicotinic acetylcholine 
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receptor (nAChR) transport to safely and non-invasively deliver siRNA to the CNS.   Following 
this success, derivatives of RVG have since been utilised to take advantage of this property for 
drug delivery to the CNS to treat a range of brain disorders (Liu et al., 2009; Chen et al., 2011; 
Son et al., 2011).   
Rabies virus-derived peptide (RDP) has shown early success as a neural cell-targeting ligand 
both in vitro and in vivo (Fu et al., 2012, 2013a, 2013b; Wu et al., 2016).  It was shown previously 
(Chapter 3) that RDP is dependent upon interaction with the nAChR and activity was 
considerably inhibited by blocking the homomeric α7 subtype of this receptor, commonly found 
throughout the CNS.  An obstacle in the development of many peptide targeting ligands is the 
issue of serum instability due to proteolysis, hence breakdown of the peptide upon systemic 
administration.   
Rapid degradation and clearance of therapeutic peptides is common, necessitating 
administration via intravenous, intramuscular or subcutaneous routes due to poor oral 
bioavailability (Uhlig et al., 2014).  Despite proven efficacy in vivo, substantial proteolysis post-
administration can limit the progression of peptide-linked therapeutics as serious drug 
candidates.  For many peptide-based drug delivery systems, prolonging blood plasma residence 
time is often a pre-requisite of clinical development (Werle & Bernkop-Schnurch, 2006).  
Degraded peptide often results in loss of receptor binding ability, meaning the need for higher 
drug concentrations and more frequent dosing. Consequently, patient safety is jeopardised due 
to higher risk of side effects and associated costs accelerate.  
The human body comprises at least 569 proteolytic enzymes (López-Otín & Matrisian, 2007), a 
multitude of which exist in the blood plasma.  Other enzymes, such as the cytochrome P450 
family, also contribute to in vivo drug metabolism.  Exopeptidases and endopeptidases favour 
degradation of large and flexible amino acid sequences (Rader et al., 2018).  BBB 
cerebrovascular endothelial cells are also enriched with numerous peptidases such as dipeptidyl 
aminopeptidase, endopeptidase and angiotensin-converting enzyme to name but a few, which 
carry out metabolism of blood-borne proteins (Witt et al., 2001).  Basic amino acid residues such 
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as lysine and arginine are especially prone to enzymatic cleavage, particularly by serine 
proteases, which are chiefly involved in blood coagulation (Boettger et al., 2017).  RDP 
(KSVRTWNEIIPSKGCLRVGGRCHPHVNGGGRRRRRRRRR) is enriched with potential 
cleavage sites and considering its relatively large 39-amino acid sequence, may be susceptible 
to high enzymatic degradation and stability issues in future studies.   
Enzymatic degradation is one pitfall in the development of peptide targeting ligands.  Other 
factors which affect bioavailability are the ability to cross biological barriers, receptor affinity and 
susceptibility to efflux mechanisms, particularly at the BBB.  Serum degradation is perhaps the 
simplest factor to assess through in vitro studies.  Indeed, for RDP, the need to improve receptor 
affinity or membrane permeability is not necessary at this stage in its development, due to the in 
vivo efficacy already reported.  Fu et al. (2012) found that RDP can cross the BBB in mice within 
fifteen minutes of intravenous injection, however the approximate in vivo half-life of RDP-fusion 
protein is only one hour.   Additionally, Fu and colleagues reported an RDP-DNA complex was 
stable in mouse serum for up to 8 hours in vitro (Fu et al., 2013b).  The stability of RDP ligand 
alone in human serum however, has not yet been reported in detail.   
In vitro testing of peptide stability in blood can be analysed using plasma or serum.  Blood 
plasma, composed of serum and clotting factors, is prevented from coagulating in vitro by 
addition of an anticoagulant, such as heparin or EDTA (Thavasu et al., 1992).  These 
anticoagulants inactivate enzymes, mainly serine proteases, which are involved in the 
coagulation cascade (Tanaka et al., 2009).  However, this inhibition also reduces non-specific 
proteolysis of peptides.  Proteolytic activity is greater in serum than plasma, as enzyme inhibition 
is not required due to absence of clotting factors (Falciani et al., 2007).  As a result, analysis of 
peptide stability in serum is more likely to resemble in vivo conditions, due to a higher level of 
active proteases. 
The somatostatin analogue, octreotide, is a well-known drug used for symptomatic relief in 
patients with gastroentero-pancreatic tumours.  It was optimised from the original somatostatin 
sequence for clinical use by enhancing stability in blood plasma, through reduction of sequence 
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size and substitutions with D-amino acids (Harris, 1994).  Changing the biodegradation of a 
therapeutic peptide may be achieved by methods such as N-methylation, polymer conjugation, 
pegylation and conformational/structural modifications for example, head-to-tail cyclisation and 
D-amino acid substitutions (Fominaya et al., 2015; Fosgeran & Hoffmann, 2015; Räder et al., 
2015).  Potential disadvantages exist for each method, commonly concerning non-specific 
peptide activity, plasma protein binding, lower receptor affinity and high production costs (Witt et 
al., 2001).  It is therefore necessary to select a feasible approach for improving stability, whilst 
balancing therapeutic efficacy.   
 
The aims of the work herein were to: 
(1) Analyse the stability of RDP in human serum.  
(2) Design a new peptide sequence based upon RDP interactions with the nAChR.  Following 
the assessment of RDP stability in human serum, attempts to improve proteolytic 
resistance will stem from the identification of important RDP residues involved in 
interactions at the receptor site.   
(3) Evaluate the in vitro targeting activity of the newly-derived RDP sequence in neural and 
non-neural cell types.  Stability studies and cell-based assays previously carried out for 
RDP in Chapter 3 will be repeated for a new targeting ligand to assess resistance to 
degradation and neural-specific targeting capability. 
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4.2. Materials and Methods  
 
4.2.1. Materials 
 
Trichloroacetic acid (TCA), human serum from male AB plasma (USA origin) and α-cyano-4-
hydroxycinnamic acid (CHCA) matrix were all purchased from Sigma-Aldrich (UK).  RDP, DAS 
and scrambled DAS (sc-DAS) peptides were synthesised by GL Biochem (Shanghai) Ltd.  All 
other materials used and cell culture conditions are as listed in section 3.2.1.   
 
4.2.2. Molecular modelling studies 
 
Potential interactions between RDP and the α7 homomeric nAChR were explored, using α-
subunit residues 173-204 as a starting point in this study.  Original rabies virus glycoprotein is 
reported to bind to these residues of the α1 nAChR subunit found at the neuromuscular junction 
(NMJ), hence facilitating the entry of the rabies virus into the nervous system (Lentz, 1990; 
Gastka et al., 1996). The residues of RDP which are responsible for interaction with the α7 
homomeric nAChR were identified by Dr Dan Rathbone (Aston University, Birmingham, UK) 
through in silico molecular modelling studies.  
Briefly, protein-ligand docking was carried out after obtaining the coordinates of the neuronal 
nAChR α7 subunit and acetylcholine-binding protein from the Protein Databank entry 3SQ6, 
chain A (Li et al., 2011).  This was imported into CACHe Worksystem Pro (version 7.5.0.85; 
Fujitsu Ltd).  The 30-mer of RDP, KSVRTWNEIIPSKGCLRVGGRCHPHVNGGG, was divided 
into all possible contiguous ten amino acid fragments (residues 1-10; 2-11; 3-12 etc.) and each 
docked four times, using CACHe Worksystem Pro, into the prepared protein structure from 3SQ6 
where the potential active site was defined as residues 173–204.  Molecular dynamics 
simulations of the docked protein-ligand complexes were prepared using version 14 of the 
AMBER Tools package (Case et al., 2005; Goetz et al., 2012; Le Grand et al., 2013; Salomon-
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Ferrer et al., 2013).   5 residues of interest from RDP (GCLRV) were identified from this work and 
subsequently were incorporated into the design of a new peptide.   
 
4.2.3. Design of novel targeting peptide  
 
A widely used flexible linking sequence -GGGGS- was subsequently added to the -GCLRV- 
sequence as a spacer in the design of a new peptide (Chen et al., 2013), to allow freedom of 
movement once conjugated to PLGA NP.  A similar linking sequence was used by Fan et al. 
(2016) to limit steric hinderance of a newly developed tumour-targeting peptide, GE11, upon 
conjugation to phospholipid micelles.  Two glycine residues followed by an arginine tail consisting 
of 6 alternating L- and D- arginine residues –GGRrRrRr- were also added to the sequence for 
enhanced stability and resistance to metabolic processes (Wender et al., 2008).  The new D-
arginine-containing 18-amino acid sequence, termed DAS, was NH2-GGGGSGCLRVGGRrRrRr-
COOH. 
 
4.2.4. Serum stability of RDP and DAS peptides 
 
Peptide stability testing in human serum was carried out according to a previously detailed 
method (Nguyen et al., 2010).  Briefly, human serum was diluted to 25% (v/v) with phosphate 
buffered saline (PBS) and subsequently centrifuged at 18809 g for 10 minutes to remove lipids, 
before incubating at 37°C.  RDP and newly derived peptide, DAS, were prepared so that final 
serum peptide concentration was 10 µM prior to incubation at 37°C.  A 200 µL aliquot was 
removed from each serum-peptide mixture at various time points and reacted with 40 µL of 15% 
(v/v) TCA for 15 minutes at 4°C to remove larger serum proteins.  The collected samples were 
centrifuged at 18809 g to remove precipitated serum proteins for 10 minutes and supernatant 
collected for storage at -20°C.  Samples were analysed by MALDI-TOF mass spectrometry 
(PerSeptive Biosystems Voyager-DE Biospectrometer, Herefordshire UK).  A 10 µL aliquot of 
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serum sample was mixed with 10 µL of CHCA matrix (10 mg/mL fully dissolved), 1.5 µL of which 
was used for analysis.  The mass/charge ratio (m/z) was plotted against relative abundance.  
Peptide stability was also assessed in double distilled water over 24 hours.  At various time 
points, samples were taken and subsequently analysed by MALDI-TOF mass spectrometry. 
 
4.2.5. Preparation of nanoparticles and conjugation of peptide to NP 
 
Doxorubicin-loaded PLGA nanoparticles (Dox NP) and FITC-Dextran-loaded PLGA 
nanoparticles (FITC NP) were prepared by a double emulsion technique and characterised 
according to methods previously described (sections 3.2.3-3.2.5).  DAS or a scrambled version 
of DAS peptide (scDAS) were conjugated to nanoparticles (NP) according to the method 
previously described for RDP.  The amount of DAS or scDAS added per 5 mg of carboxyl-
activated PLGA NP was 250 mcg. 
 
4.2.6. In vitro cellular uptake study 
 
Cellular uptake of FITC-NP preparations were evaluated in SH-SY5Y, PC-12 and HeLa cell lines 
using a Leica SP5 confocal microscope (x 63 000 magnification) as detailed in section 3.2.6.2.  
In summary, cells were cultured on 13 mm glass coverslips overnight in complete media, which 
was aspirated prior to treatment.  Cells were treated with 1 mg/mL (500 µL) of either FITC NP or 
DAS-FITC NP in serum-free media (SFM) for 24 hours whilst incubating at 37°C/5% CO2.   Prior 
to imaging, all cells were treated with 75 nM Lysotracker® red in SFM for 30 minutes as before, 
to visualise lysosomes within cells.  FITC fluorescence emission was collected between 510- 550 
nm (excitation wavelength 490 nm).  Lysotracker® emission was collected separately between 
590-650 nm (excitation wavelength 580 nm).  
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4.2.7. In vitro cytotoxicity study in neural and non-neural cells types 
 
An initial study was carried out to determine the effect of DAS-Dox NP over various 
concentrations.  SH-SY5Y cells were plated out at a concentration of 1x105 cells/mL in complete 
RPMI medium and incubated at 37°C/5% CO2 for 16 hours.  All existing media was aspirated 
before addition of DAS-Dox NP or Dox NP to cells at various concentrations ranging from 0.5- 
3.0 mg/mL in SFM.  Control groups were treated with SFM only.  Cell viability was assessed after 
incubating for 24 hours (37°C/5% CO2), using an MTT assay.  To calculate cell viability, 25 µL of 
MTT (5 mg/ml) in sterile PBS was added to each well on top of media and incubated at 37°C/5% 
CO2 for 2 hours.  After this, all media was aspirated and cells solubilised with 70 µL of DMSO 
per well.  UV-Vis absorbance was read at 570 nm and cell viability calculated.   
The cytotoxic effect of a scrambled version of DAS (NH2-RVGGCSGGGGGLRrRrRr-COOH) 
conjugated to Dox NP (scDAS-Dox NP) was also assessed in SH-SY5Y cells, according to the 
method described above.  Briefly, cells were treated with 160 µL of NP suspension (1.5 mg/mL) 
in SFM and incubated for 24 hours (37°C/5% CO2).  The cytotoxicity of free DAS was also 
evaluated by treating SH-SY5Y cells with a concentration of free peptide equivalent to maximum 
NP content, as determined by conjugation efficiency.  To further assess targeting specificity to 
neural cells, NP treatment was also added to neural PC-12 cells and non-neural cell lines CHO, 
HeLa and MDA-MB-231 according to the same protocol.   
It was demonstrated previously that RDP function could be blocked with nAChR inhibitors 
(Chapter 3, section 3.3.4).  To determine whether nAChR antagonists would affect the activity of 
DAS, SH-SY5Y cells were preincubated for 30 minutes with 100 µL of either 2 mM 
hexamethonium (competitive) or 2 mM mecamylamine (non-competitive) in SFM, prior to 
addition of 100 µL Dox NP or DAS-Dox NP (3 mg/mL), using the method described above.  SH-
SY5Y and PC-12 cell types were also preincubated for 60 minutes with 100 µL of anti-AChRα7 
antibody (1:50 dilution) before addition of NP treatment (final concentration 1.5 mg/mL) for 24 
hours as before. 
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4.2.8. Statistical Analysis 
All results reported were statistically analysed using an unpaired two-tailed t-test. A P-value of < 
0.05 was considered statistically significant.   
 
 
 
4.3. Results & Discussion  
 
4.3.1. Interaction between RDP segment GCLRV and α7-nAChR identified through molecular 
modelling  
 
RDP is a 39-residue peptide, with an overall positive charge due to arginine and lysine residues 
in the sequence.  The large size of RDP potentially increases the likelihood of proteolysis and so 
a smaller derivative, retaining any part of the sequence essential for binding to the nAChR, would 
be an ideal starting point for remodelling.  It was previously reported in section 3.3 (Chapter 3) 
that RDP requires the nAChR for function, a receptor first reported by Lentz et al. (1982) as being 
responsible for rabies virus infection.   
A model of the receptor was built using the X-ray crystal structure coordinates from the Protein 
Databank, entry 3SQ6, chain A (Li et al, 2011).  For the purposes of the docking experiments the 
active site was defined as residues 173 – 204. The 30-mer 
KSVRTWNEIIPSKGCLRVGGRCHPHVNGGG was divided into all possible contiguous ten 
amino acid fragments (residues 1-10; 2-11; 3-12 etc.) and docked into the receptor.  A 10-mer 
fragment comprising residues 9-18 (IIPSKGCLRV) was identified to contain potentially active 
residues through formation of a relatively stable conformation on the receptor.  Consequently, 
this 10-mer fragment -IIPSKGCLRV- was cut down to a version containing residues 14-18 
(GCLRV), where hydrogen bonding and hydrophobic interactions were observed with the 
receptor surface via the leucine and valine residues in the fragment.  A representation of the 
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receptor-GCLRV molecular dynamic simulation is shown in Figure 4.1.  A new peptide (DAS), 
incorporating the GCLRV fragment from RDP was designed accordingly, consisting of 18 amino 
acids (GGGGSGCLRVGGRrRrRr) as described in section 4.2.3.   
A common feature of many successful CPPs is the presence of guanidium-rich groups, such as 
arginine.  CPPs however, are non-specific and prone to degradation by peptidases (Kristensen 
et al., 2016).  The original RDP sequence ending with octa-arginine (R8) is an important 
component to aid rapid cell penetration and promote high water solubility.  The most frequently 
used polyarginines in targeting peptides are octa-arginine (R8) and nona-arginine (R9), however 
it has been shown that as little as six arginine residues confer highly effective cell penetrating 
properties to a conjugated cargo whilst prolonging circulation time (Liu et al., 2017b; Wender et 
al., 2008).  Purkayastha et al. (2013) found that having 6 consecutive L-Arginine (Arg) residues 
in a peptide sequence leads to better cell penetrating properties.  The number of arginine 
residues in the new RDP-derived sequence were subsequently reduced to six, which would 
reduce the overall positive charge of the peptide.  In doing this, the whole peptide would be less 
vulnerable to negatively charged plasma proteins, an effect which Liu et al. (2017) reported as 
similar to pegylation. 
It has been reported that D-amino acids improve serum stability and cellular uptake 
characteristics of a peptide (Molhoek et al., 2011).  The mix and positioning of L- and D- amino 
acids in the sequence can affect the cell uptake rate as well as modulating the peptide half-life 
(Purkayastha et al., 2013).  For example, if a sequence was composed of all D-amino acids, not 
only would this be more expensive, but it would be too stable (> 7 days) and perhaps accumulate 
extensively over time in vivo.   Due to this, alternating L- and D- Arg residues were incorporated 
into the design of DAS. 
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Figure 4.1. Molecular dynamics simulation of fragment IIPSKGCLRV (stick form) with the nicotinic 
acetylcholine receptor (ribbon form). Residues IIPS are not in contact with the receptor 
surface and thus were not included in the design of the new RDP derivative.   
 
 
 
 
 
4.3.2. Characterisation of NP preparations 
 
 PLGA NP were successfully loaded with either cytotoxic doxorubicin or FITC-dex and 
characterised as previously detailed in section 3.3.1 of Chapter 3.  NP characteristics such size, 
zeta potential and PDI are summarised in Table 4.1.  DAS ligand was successfully attached to 
Dox NP and FITC NP by EDC/NHS chemistry, in an identical method as described for RDP.  
Conjugation efficiency of DAS to FITC NP was particularly high at 88.0%, in comparison to Dox 
NP (58.0%), meaning the FITC NP had almost twice as much surface-conjugated DAS (µg/mg).  
This is consistent with findings for RDP conjugation to FITC NP (section 3.3.1), where NP surface 
characteristics might affect the EDC/NHS-enabled attachment of peptide to PLGA carboxyl 
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groups.  Such a peptide-decorated nanoparticulate drug vehicle is developed with a view of 
encapsulating payloads such as growth factors, for treatment of neurodegenerative processes.  
These larger, protein-based payloads are more likely to resemble model drugs such as 
myoglobin and FITC-dex, rather than small molecules such as doxorubicin.  Given the favourable 
conjugation of peptide to NP encapsulating the model payloads previously described, it is 
probable that a similar amount of peptide would be successfully added to growth factor-loaded 
NP, whether it is RDP or DAS.  For the purpose of this work, the difference in amount of surface-
conjugated peptide between different NP preparations is not a concern, so long as there is 
evidence of substantial conjugation.  Future studies however, may provide insight into how this 
may affect NP targeting.     
 
 
 
 
Table 4.1. Characterisation parameters of drug-loaded PLGA nanoparticles conjugated to 
newly-derived DAS ligand. 
 
 
 
 
 
 
 
NP Sample Size (nm) ZPa (mV) PDIb DCc (µg/mg) DASd (µg/mg) 
 
Dox NP 
 
242.73 ± 18.64 
 
-14.60 ± 1.32 
 
0.39 ± 0.05 
 
12.80 
 
23.20 
 
FITC NP  
 
286.50 ± 11.30 
 
-10.30 ± 1.00 
 
0.27 ± 0.08 
 
30.80 
 
43.90 
ͣ Zeta potential (mV), b polydispersity index, c DC= drug content per 1 mg of NP based on entrapment efficiencies of 
64% (Dox) and 77% (FITC-dex); d DAS content per 1 mg of NP based on conjugation efficiencies of 58.0% (Dox 
NP) and 88.0% (FITC NP).  Size, ZP and PDI as measured by DLS are expressed as average ± standard 
deviation (n=6). 
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4.3.3. Stability of RDP & newly-derived peptide, DAS, in distilled water and human serum at 
37°C 
 
RDP was incubated both in water (Figure 4.2) and 25% human serum (Figure 4.3) at 37°C and 
then analysed by MALDI-TOF mass spectrometry to determine stability.  RDP was firstly 
analysed in water to determine how prone RDP might be to hydrolysis, without the presence of 
enzymes.  It can be seen from Figure 4.2, that RDP does not break down and is stable over 24 
hours at 37°C, as mass-spectrometry traces are identical from time zero (Figure 4.2B) up to 24 
hours (Figure 4.2F).  Figure 4.2A shows the background signal detected due to the CHCA matrix 
in which the sample was prepared.    
The same time points were used, with the addition of a sample at 2 hours when RDP was 
incubated in serum.  RDP in serum (T=0) (Figure 4.3C) gave rise to a peak (4.6 kDa) consistent 
with its molecular weight.  The background trace due to serum is shown in Figure 4.3B.  Upon 
incubation in serum for 1 hour, the signal for intact RDP at 4.6 kDa was no longer detectable 
(Figure 4.2D).  New peaks detected between 2.7-3.2 kDa in Figure 4.2D, most likely represent 
RDP breakdown fragments.  These signals gradually lessened following 4 and 8 hours of 
incubation in Figures 4.3 (F)-(G).  A minimal trace of RDP-related fragments remained in Figure 
4.2H, suggesting RDP and its degradation products had continued to degrade over 24 hours. 
The recent success of RDP as a neural cell-specific targeting ligand both in vitro and in vivo has 
been a promising step towards facilitating delivery of therapeutics to neural cells.  It has not been 
explored as of yet whether this sequence may be optimised further, taking human serum stability 
into account.  Previously, Fu et al. (2013b) reported on the 8-hour stability of an RDP-plasmid 
complex in mouse serum, however this study has shown that RDP breaks down when incubated 
with human serum (37°C) within an hour (Figure 4.3).  The aforementioned work by Fu and 
colleagues described how the secondary conformational structure of RDP changed upon plasmid 
DNA binding, possibly making it more stable than it otherwise would be alone.  This means 
potential use of RDP with other types of therapeutic conjugates may not be so successful, hence 
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it would be preferable to optimise the peptide sequence to make it less prone to enzymatic 
degradation in serum.  
Palm et al. (2007) indicated that membrane bound proteases are also responsible for 
extracellular degradation of targeting peptides.  This is dependent on cell type and density, 
however it augments the need to minimise the risk of peptide degradation prior to cellular uptake, 
as intact targeting peptide on the NP is essential for delivery of therapeutic cargo.  If serum half-
life is longer, then potential dosing would be lower and less frequent, which is preferable when 
conjugating to expensive or toxic therapeutics. It is desirable however, that targeting peptides 
are eventually degraded intracellularly for cargo release and reduction of toxicity risk.   
Consequently, the newly-designed peptide (DAS) was investigated to establish the effect of D-
amino acid substitutions and sequence shortening on serum stability.   
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(A) CHCA matrix (500-8000 Da) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) RDP- T=0 
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(C) RDP- T=1h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D) RDP- T=4h 
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(E) RDP- T=8h 
 
 
 
 
 
 
 
 
 
 
 
 
(F) RDP- T=24h 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. MALDI-TOF mass spectrometry analysis of (A) CHCA matrix and (B)-(F) RDP following 
incubation at 37°C in double distilled water for varying lengths of time.  Peak for intact RDP 
is indicated in (B). 
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(A) CHCA matrix (500-8000 Da) 
 
 
 
 
 
 
 
 
 
 
 
 
(B) Serum 
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(C) RDP- T=0 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D) RDP- T=1h 
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(E) RDP- T=2h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(F) RDP- T=4h 
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(G) RDP- T=8h 
 
 
 
 
 
 
 
 
 
 
 
 
(H) RDP- T=24h 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.  MALDI-TOF mass spectrometry analysis of RDP stability in 25% human serum at 37°C for 
various periods of time.  (A) CHCA matrix and (B) Human serum with no peptide.  (C)-(H) 
Mass spectrometry profile detected for RDP (MW approx. 4.6 kDa) in serum up to 24 hours 
of incubation.  Peaks for intact peptide are indicated on the intensity/mass traces.  
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In water, a strong peak was detected for DAS at the expected molecular weight of 1.9 kDa at all 
time points observed.  This meant that like RDP, DAS was completely stable for 24 hours under 
these conditions as no evidence of breakdown could be detected (Figure 4.4).  The serum 
stability of DAS was subsequently assessed at the same time points as for RDP previously.  Fully 
intact DAS in serum (time zero) expectedly gave rise to a peak at around 1.9 kDa indicated in 
Figure 4.5B, prior to incubation at 37°C.  After 1 and 2 hours of incubation, peaks approximately 
50% the size of the original (Figure 4.5B) are detected in Figures 4.5 (C) and (D).  After 4 hours 
in serum, a peak approximately one third the size of the original at time zero was detected, 
signalling a small amount of intact DAS remained at this time (Figure 4.5E).  The DAS signal was 
again detected at 8 hours, despite now being approximately 10-20% of that detected in Figure 
4.5B.  Finally, DAS was no longer detected at 24 hours, indicating total degradation of the 18-
mer sequence (Figure 4.5G). 
Over the time course observed, the new peptide, DAS, was more resistant to degradation by 
serum proteases than RDP.  Mass spectrometry analysis detected intact DAS peptide up to 8 
hours after incubation in human serum at 37°C, suggesting improvement in stability 
characteristics compared to RDP, which degraded within 1 hour.  D-amino acids like the D-
arginine residues incorporated into DAS, have been used to improve the proteolytic resistance 
of peptides successfully within the area of drug delivery due to their ability to avoid quick 
metabolism (Wender et al., 2008; Purkayastha et al., 2013; Meng et al., 2017).   
There have been many successful findings on the use of D- amino acid substitutions to promote 
serum stability of targeting peptides, with no significant toxicity concerns in vitro and in vivo.  Di 
Grazia et al. (2015) reported improved human serum stability and activity when frog skin-derived 
antimicrobial peptide, esculentin-1a(1-21)-NH2,  was substituted with two D-amino acids at 
potential cleavage sites.  Wang et al. (2013) also successfully developed a targeting ligand, YSA, 
to target prostate cancer in vivo by taking advantage of EphA2 receptor (tyrosine kinase family) 
overexpression.  Wang and colleagues wanted to improve the efficacy and other 
pharmacological properties of YSA when conjugated to a therapeutic payload.  Two non-natural 
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amino acids were substituted in place of methionine and N-terminus tyrosine to produce newly 
optimised peptide, dYNH.  This new derivative was more stable in mouse serum after 24 hours 
whilst retaining selectivity for targeting EphA2 receptor-positive cells by receptor mediated 
uptake of payload into lysosomal pathways.   
The development of a peptide such as DAS, offers a more stable neural cell-targeting ligand than 
RDP, a property most essential for efficient drug delivery in vivo.   A 10-amino acid peptide for 
targeting of breast cancer cells showed instability against serum proteases in work by Soudy et 
al. (2011), limiting bioavailability in vivo.  Two L- to D- amino acid substitutions in the sequence 
of a new analogue improved resistance to protease-induced degradation in human serum, much 
like observations made for DAS from Figure 4.5.  Furthermore, the improvement in peptide 
stability displayed higher uptake into breast cancer cell lines compared to the parent peptide.  
Ngambenjawong et al. (2016) identified a lead analogue of macrophage targeting peptide, 
M2pep, through cyclisation of the sequence.  This new version of the peptide was more stable 
to serum degradation and displayed better in vivo accumulation at tumour sites.  Cyclisation of 
RDP is another avenue which could be explored in prospective studies, in addition to D-amino 
acid substitutions.     
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(A) DAS- T=0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) DAS- T=1h 
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(C) DAS- T=4h 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D) DAS- T=8h 
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(E) DAS- T= 24h 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  (A)-(E) MALDI-TOF mass spectrometry analysis of DAS following incubation at 37°C in double 
distilled water for varying lengths of time.  The peak for intact peptide is indicated in (A). 
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(B) DAS- T=0 
 
  
 
 
 
 
 
 
 
 
 
 
 
(C) DAS- T=1h 
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(D) DAS- T=2h 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E) DAS- T=4h 
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(F) DAS- T=8h 
 
 
 
 
 
 
 
 
 
 
 
 
(G) DAS- T=24h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.  MALDI-TOF mass spectrometry analysis of DAS stability in 25% human serum at 37°C for 
various periods of time.  (A) Human serum with no peptide.  (B)-(G) Mass spectrometry profile 
detected for DAS (MW approx. 1.9 kDa) in human serum up to 24 hours of incubation.  DAS 
signal in indicated by encircled peaks. 
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4.3.4. Confocal imaging of DAS-facilitated NP uptake in vitro 
 
Visualisation of DAS-FITC NP cellular uptake by confocal fluorescence microscopy (Figure 4.6) 
was carried out as for RDP-FITC NP previously reported in section 3.3 (Chapter 3).  It was 
demonstrated in Figure 4.6 that DAS preferentially promotes cellular uptake of NP in SH-SY5Y 
(Figure 4.6A) and PC-12 (Figure 4.6B) neural cells when compared to the untargeted FITC NP.  
In contrast, detected fluorescence signal was low in Hela cells (Figure 4.6C) and no notable 
difference in cellular uptake was observed between all formulations, indicating that like RDP, 
DAS is not effective as a targeting peptide in this non-neural cell line.  Lysotracker® red was used 
to visualise cell lysosomes and compare to any emission pattern of FITC within the cell.  
Similarities in signal detected from Lysotracker® emission and that of FITC would indicate that 
there may be co-localisation of lysosomes and internalised FITC NP.  Indeed, there was evidence 
of co-localisation in SH-SY5Y cells and also in PC-12 cells between lysosomes and internalised 
FITC.   
In Chapter 3, it was shown how RDP can enhance the uptake of a conjugated payload to induce 
cytotoxic effects in neural cells and this was supported by confocal fluorescence imaging.  
Results from Figure 4.6 suggest that DAS has retained the neural-specific targeting ability of 
RDP, as NP uptake was visibly greater in neural cells than the non-neural cell type.  It has been 
suggested by Fu et al. (2013a), that the cellular uptake mechanism of RDP may involve energy-
dependent internalisation pathways such as clathrin-dependent endocytosis.  Indeed, 
observations of co-localisation between RDP (Figure 3.5, Chapter 3) and DAS conjugates with 
lysosomes in this work (Figure 4.6) support this idea. 
Clathrin-dependent endocytosis accounts for the majority of receptor-mediated internalisation of 
NP, however intracellular trafficking routes are generally not well characterised for 
nanoparticulate transport (Yameen et al., 2014).  Non-targeted NP can be internalised by 
pinocytosis mechanisms such as clathrin- and caveolae-mediated endocytosis.  The mechanism 
of non-specific NP uptake is dependent on attributes such as size, zeta potential and shape, in 
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addition to cell type (Beddoes et al., 2015).  Most endocytosed NP will eventually end up in late 
endosomes or lysosomes where pH-induced degradation results in intracellular payload release 
(Iverson et al., 2011).   
Caveolae-mediated endocytosis is generally for small NP (<100 nm) and can sometimes be 
unpredictable, as internalised NP can evade lysosomal trafficking via this route (Yameen et al., 
2014).  The use of larger NP (200-300 nm), as in this study, limits non-specific uptake and 
attachment of a targeting ligand facilitates cellular uptake towards more predicable pathways.  It 
is essential for therapeutic affect that internalised NP are trafficked towards degradative 
pathways, to ensure payload release.  Non-specific uptake via endocytic mechanisms is most 
likely responsible for the low level of FITC NP and DAS-FITC NP uptake observed in HeLa cells, 
which do not express a neuronal-type nAChR (Figure 4.6C). 
Early endosomes are known as the sorting stations in which intracellular cargo is processed 
through either recycling or degradative pathways (Hu et al., 2015). Late endosomes eventually 
fuse with lysosomes which contain degradative enzymes at low pH 4.5.  Endogenous 
acetylcholine receptors undergo cell surface internalisation and lysosomal degradation for 
regulation of synaptic plasticity in excitable cells.  This response in the natural turnover of cell 
surface receptors is also replicated upon binding with agonists such as nicotine (St John & 
Gordon, 2001).  Kumari et al. (2008) found that binding of alpha-bungarotoxin at the nAChR 
caused ligand-receptor complex internalisation along an energy-dependent endocytic pathway 
into late endosomes.  The ligand-receptor complex was found to be co-localised with late 
endosomal markers such as LAMP-1 (lysosomal-associated membrane protein 1).  It is possible 
that both RDP and DAS binding at the nAChR in neural cell types induces a similar response, 
which results in NP localised in areas highlighted by Lysotracker®.   
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Figure 4.6. Confocal images of intracellular fluorescence emission from Lysotracker® (red) and FITC 
(green) in (A) SH-SY5Y, (B) PC-12 and (C) HeLa cells to assess the in vitro effect of targeting 
ligand, DAS.  Lysotracker® accumulates in acidic lysosomes, vesicles containing hydrolytic 
enzymes which are involved in the late-stage endocytosis uptake pathway within cells.  FITC 
fluorescence emission is due to uptake of FITC-dextran payload within polymeric NP.      
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4.3.5. In vitro cytotoxicity 
 
Figure 4.7 shows the cytotoxic effect of DAS conjugation to Dox NP in SH-SY5Y human 
neuroblastoma cells over 24 hours using a range of concentrations.  DAS significantly enhanced 
cytotoxicity of the nanoparticulate payload in comparison to the unlabelled Dox NP at 
concentrations between 1.0- 2.0 mg/mL.  The IC50 of DAS-Dox NP was 0.9 mg/mL in comparison 
to 1.35 mg/mL for Dox NP.  This supports the findings from confocal microscopy images in Figure 
4.6 and indeed suggests that DAS has retained the preferential targeting ability of RDP to neural 
cell types.  Concentrations above 2.0 mg/mL nullified the targeting effect of DAS in this study.  
This is possibly because extracellular doxorubicin leaching from both NP preparations at such 
concentrations over 24 hours imparted cytotoxicity beyond NP-induced effects.  Based on these 
observations, it was decided to use NP at 1.5 mg/mL for further cell-based in vitro assays.  
 
 
Figure 4.7.  Cell viability of SH-SY5Y cells following exposure to varying concentrations of doxorubicin-
loaded NP either unlabelled (Dox NP) or conjugated to peptide ligand, DAS (DAS-Dox NP).  
*Statistically significant difference compared to Dox NP (P value <0.05, n=6). 
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DAS peptide alone did not cause any detectable toxicity to cells over the time course observed 
in Figure 4.8, giving early indication that this ligand may also be safely used as part of a drug 
delivery system.  Treatment with DAS-Dox NP caused a significant enhancement in SH-SY5Y 
cytotoxicity, as cell viability decreased to 60.0% (± 7.0% SD) compared with 75.0% (± 5.0% SD) 
when treated with untargeted Dox NP.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8.  SH-SY5Y neuroblastoma cell viability determined by MTT assay following treatment with 
either serum-free medium (control), DAS ligand or different cytotoxic NP formulations for 24 
hours. Statistically significant difference to; *control, ** Dox NP (P value <0.05, n=6).  
ScDAS= scrambled version of DAS peptide. 
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To test the significance of the -GCLRV- fragment for neural cell interaction of DAS, a scrambled 
version of the peptide (scDAS) was conjugated to Dox NP and exposed to SH-SY5Y cells as for 
DAS-Dox NP.  Results from Figure 4.8 show that scDAS was ineffective at promoting enhanced 
cellular uptake of cytotoxic NP compared to the untargeted formulation.  Cell viability following 
scDAS-Dox NP treatment decreased to 79.4% (± 8.0% SD), which was similar to Dox NP and 
almost 20% higher than DAS-Dox NP.  This result confirms that the -GCLRV- sequence, as 
identified through molecular modelling of RDP, is essential for the inherent neurotropism of DAS. 
The effects of DAS-Dox NP on the non-neural cell lines HeLa, MDA-MB-231 and CHO are 
presented in Figure 4.9.  Cell viabilities for the non-neural, normal CHO cells and the cancer cell 
lines, HeLa and MDA-MB-231, showed no significant difference between Dox NP and DAS-Dox 
NP treatments. In the neural SH-SY5Y cell line however, DAS promoted susceptibility of the cells 
to the cytotoxic effects of Dox NP, causing a statistically significant decrease in cell viability to 
62.0% (± 9.8% SD) for DAS-Dox NP compared to 75.0% (± 7.1% SD) for the untargeted Dox 
NP.  Both NP treatments caused a certain amount of cytotoxicity to non-neural CHO, HeLa and 
MDA-MB-231 cells possibly be due to some extracellular doxorubicin leaching from NP over the 
24-hour experimental period.  It is clear however, that when the NP are targeted with DAS, there 
is a significant change within the neural cell type only. 
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Figure 4.9.  Effect of peptide targeting ligand, DAS, on doxorubicin-loaded NP toxicity towards non-neural 
cell lines HeLa, CHO and MDA-MB-231 compared to SH-SY5Y neural cells.  Control groups 
were treated with serum-free media only.  Error bars represent mean ± standard deviation 
(n=6).  * Statistically significant difference compared to Dox NP (P value <0.05). 
 
 
 
Given DAS was modelled upon RDP interactions with the nAChR, it was investigated whether 
blocking this receptor would affect targeting activity of the peptide.  Figure 4.10 shows the effect 
of preincubating SH-SY5Y cells with the nAChR antagonists hexamethonium, mecamylamine 
and anti-AChRα7 antibody.  In hexamethonium-treated cells, viable cell count remained at 82.0% 
(± 9.7% SD) of control when exposed to DAS-Dox NP compared to 72.0% (± 5.5% SD) with 
untargeted Dox-NP.  This is in distinct contrast to the cell viability of 63.4% (± 6.7% SD) obtained 
upon DAS-Dox NP exposure when there was no prior inhibition of the nAChR and this receptor 
was available for interaction.  Mecamylamine-treated cells produced an almost identical result, 
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with DAS-Dox NP causing cell viability to drop to just 85.0% (± 4.0% SD) compared to 62.0% (± 
7.0% SD) with no prior inhibitory treatment.  
Pretreatment with all of the antagonists inhibited SH-SY5Y cell susceptibility to the amplified 
cytotoxic effects of DAS conjugated Dox NP.  In fact, DAS-Dox NP treatment in the presence of 
nAChR inhibitors is less toxic than the unlabelled preparation.  This is possibly due to a steric 
hinderance effect caused by peptide on the NP surface, making the peptide-conjugated NP too 
bulky for non-specific membrane absorption and subsequent internalisation.  The unlabelled NP 
formulation however, may have particles small enough to undergo cellular uptake by non-specific 
endocytic routes over a 24-hour period. 
 
 
 
Figure 4.10.  Effect of nAChR antagonists hexamethonium (Hex), mecamylamine (Mec) and anti-AChRα7 
antibody (α7-AB) on DAS ligand activity following NP treatment on SH-SY5Y neural cells.  
Control groups were treated with SFM only.  Error bars represent mean ± standard deviation 
(n=6) * Statistically significant difference compared to Dox NP (two-tailed T-test P value 
<0.05). 
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An anti-AChRα7 antibody was once again employed to block the α7-nAChR to observe the 
effects on DAS-Dox NP cytotoxicity.  Results show that DAS did not promote more cytotoxicity 
than unlabelled Dox NP when this receptor subtype was blocked and thus the targeting effect of 
DAS was cancelled out in SH-SY5Y cells.   Gan et al. (2018) also used a competing antibody, 
cetuximab, to evidence the targeting ability of a newly identified peptide towards the epidermal 
growth factor receptor.  Ultimately, these results suggest that DAS is facilitating uptake of 
cytotoxic NP through mechanisms involving the nAChR, namely the α7-nAChR subtype, in these 
particular neuroblastoma cells.   At this early stage in the development of new peptide ligand, 
DAS, it can be postulated that the additional 13 amino acids added to the -GCLRV- sequence 
had no adverse effect on the neurotrophic properties of the ligand or affected its ability to interact 
with the nAChR.    
DAS was again tested on PC-12 (rat adrenal pheochromocytoma) cells, also of neural origin, to 
support the hypothesis that the new peptide preferentially targets neural cells (Figure 4.11).  After 
24 hours of DAS-Dox NP treatment, cell viability decreased to 71.6% (± 8.4% SD).  This was 
statistically significant (P value < 0.05) compared to the cells which were treated with untargeted 
Dox NP, where cell viability was 94.0% (± 3.0% SD).  Interestingly, DAS appeared slightly more 
effective in promoting NP uptake in PC-12 (Figure 4.11) than SH-SY5Y cells (Figures 4.7 & 4.8).  
Indeed, this could be due to the known varying expression of nAChR subtypes between neural 
cells (Court et al., 2000; Abbruscato et al., 2002; Gotti et al., 2006) and affinity of targeting peptide 
to them.   
It was established form Figure 4.10 that DAS is dependent upon the α7-nAChR for activity in SH-
SY5Y cells.  It was therefore investigated whether this anti-AChRα7 antibody would also block 
DAS activity in PC-12 cells (Figure 4.11).  Surprisingly, DAS-Dox NP still exhibited significantly 
more cytotoxic activity (77% cell viability) than unlabelled Dox NP.  Although anti-AChRα7 
antibody marginally inhibited the effect of DAS-Dox NP, it is possible that DAS does not solely 
function via the α7-nAChR in these cells.  The 28.4% cytotoxicity observed in PC-12 cells 
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following DAS-Dox NP treatment may be due to DAS interactions with other nAChR subtypes 
preferentially expressed by PC-12 cells.  This would require further investigation into receptor 
binding of the DAS ligand in future studies.  Alternatively, PC-12 cells may express a higher 
number of α7-nAChR than SH-SY5Y cells and thus a higher concentration of antibody would be 
required to completely block receptor interactions with DAS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11.  PC-12 cell viability following different cytotoxic NP treatments.  The effect of DAS targeting 
peptide conjugation to NP is compared to untargeted Dox NP and also pre-incubation with 
anti-AChRα7 antibody (α7-AB).  * Statistically significant difference compared to Dox NP (P 
value <0.05, n=6). cNP= conjugated NP (DAS-Dox NP). 
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It was first hypothesised by Kumar et al. (2007) that RVG derivative, RVG-29, might utilise the 
α7-nAChR to traverse the BBB and facilitate delivery of siRNA to the brain in vivo due to 
widespread expression of this receptor throughout the nervous system.  In this study, it has been 
shown that RDP and DAS target two different neural cell types, SH-SY5Y and PC-12.  
Additionally, Hwang et al. (2011) used nAChR-positive neuro-2a cells to show the neural-specific 
targeting properties of an RVG derivative in comparison to non-neural HeLa cells.  Many nAChR 
ligands have different specificities towards various nAChR subtypes (Resende et al., 2009) and 
to this end, it is possible that DAS may show higher targeting affinity to nAChR subunits 
expressed on PC-12 cells, than on SH-SY5Y.   Indeed, as with many nAChR ligands, it is 
possible that DAS might bind to more than one nAChR subtype, rather than the α7 subunit 
exclusively. 
 
4.4. Conclusion 
 
In silico modelling for interactions between RDP and the α7-nAChR uncovered a 5-amino acid 
section of the RDP sequence, ‘GCLRV’, as a potential target sequence.  This 5-mer was 
therefore incorporated into a newly developed sequence, termed DAS.  A flexible linking 
sequence allowed successful conjugation of DAS to a polymeric PLGA nanoparticulate drug 
delivery vehicle.  Increased resistance to degradation by serum proteases was achieved by 
addition of alternating artificial D-Arginine residues at the end of the sequence.  The final 18-mer 
peptide ligand showed enhanced resistance to degradation in serum over 8 hours than RDP, 
which degraded within an hour.  
In vitro testing of DAS revealed that the new ligand retained the neural cell targeting selectivity 
of the parent molecule, RDP.  DAS specifically enhanced uptake of two different drug-loaded NP 
preparations in SH-SY5Y and PC-12 neural cells, but not in non-neural cell types.  Furthermore, 
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it was demonstrated that DAS ligand alone was non-toxic to cells over the experimental period 
observed. 
It was previously shown that RDP relies upon nAChR interactions for uptake into neural cells.  
Since DAS was modelled upon interactions of RDP with the nAChR, it was investigated whether 
inhibiting this receptor with different antagonists would affect DAS activity in SH-SY5Y cells.  
Results showed that DAS does require nAChR function, more specifically of the α7-nAChR 
subtype, for uptake activity in SH-SY5Y cells.  This confirmed that DAS exhibits in vitro activity 
at the receptor upon which it was originally modelled.  It was subsequently explored whether this 
would also be the case for DAS targeting in PC-12 cells.  Studies revealed that DAS may in fact 
utilise more than one nAChR subtype in PC-12 cells, as inhibition of the α7-nAChR only 
fractionally affected cytotoxicity of DAS-Dox NP.  This is supported by the fact that DAS appeared 
more effective as a targeting ligand in PC-12 cells than SH-SY5Y cells.  Indeed, if a targeting 
ligand can bind more than one subtype of major neural receptor, it is likely to be beneficial in vivo 
and increase affinity for specific drug delivery to the brain. 
The promising results from the pilot work reported herein warrants further exploration into DAS 
as a neural cell-specific targeting ligand.  DAS was shown to be as effective as RDP in two neural 
cell lines and hence the ability of DAS to traverse an in vitro model of the BBB should be 
investigated.  The use of an in vitro BBB model as a pre-requisite to in vivo work is beneficial to 
allow observations of how efficiently DAS can target a conjugated payload across multiple cell 
layers in the presence of tight junction proteins, which characteristically make drug transport 
across brain endothelial cells challenging.    
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Chapter 5 
Modelling of an in vitro blood brain 
barrier model for the evaluation 
of RDP derivative, DAS, as 
targeting ligand. 
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5.1.  Introduction 
 
In vitro BBB models are useful for the assessment of targeted drug transport studies as a 
precursor to in vivo work.  This is due to lower costs, the ability to directly quantify compounds 
and gain information on their mechanism of action.  It is also beneficial to detect potential 
cytotoxicity at an early stage in development before commencing animal studies (Bicker et al., 
2014).  Different types of in vitro cell-based BBB models have been developed over recent years 
ranging from monoculture models to those including multiple cell types from the neurovascular 
unit (NVU).  Diverse sources of endothelial cells have been sought to create in vitro BBB models 
such as primary brain tissue, immortalised brain microvascular endothelial cells and stem cells 
(Toth et al., 2011).  Each source offers different advantages and drawbacks, however the TEER 
value and expression of BBB markers such as tight junction (TJ) proteins ultimately determine 
whether a model is robust enough for drug transport studies (Wilhelm et al., 2011). 
To assess the integrity of a BBB model, the trans-endothelial electrical resistance (TEER) across 
the endothelial monolayer is measured (Reichel et al., 2003).  The higher the TEER, the more 
restrictive the barrier to endothelial trans- and para-cellular transport.  The distinguishing 
characteristics of the BBB, which make CNS drug delivery so difficult, are typified by an in vivo 
TEER in excess of 1000 Ωcm2.   For in vitro BBB systems however, it is generally accepted that 
a minimum TEER of 150 Ωcm2 is sufficient for drug transport studies (Deli et al., 2005).   
Fluctuations in TEER can reflect disruption to the endothelial monolayer, as a decrease in barrier 
integrity leads to increased permeability.  In the development of in vitro BBB models, TEER 
measurement is important as it not only reflects the integrity of the barrier but can also indicate 
how experimental materials might affect endothelial monolayer integrity over time.  This is useful 
as an early predictor of in vivo toxicity for new brain-targeted drug formulations.  Traditionally, 
TEER is measured by AC systems such as the commercially available EVOM2 voltmeter and 
expressed as the product of the resistance measured (Ω) and the area (cm2) of the endothelial 
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membrane surface (Watson et al., 2013).  TEER values can also be calculated by impedance 
spectroscopy, which can consider the contribution from TJ proteins to the total resistance 
between and through cells (Srinivasan et al., 2015).  Additionally, impedance spectroscopy 
allows continuous monitoring during cell growth without causing damage (Benson et al., 2013).   
Cell-based in vitro BBB models can be derived from the same species (isogenic) or be composed 
of cell layers from different species (transgenic).  Cells of porcine, bovine, rat, mouse and human 
origin have all been utilised to make such models (Mukhtar & Pomerantz, 2000).   Immortalised 
endothelial cells of human (Duvar et al., 2000; Poller et al., 2008; Daniels et al., 2013), rat 
(Regina et al., 1999; Roux & Couraud, 2005) and mouse origin (Omidi et al., 2003; Watanabe et 
al., 2013) have all been used to construct in vitro BBB models.  Despite this, TEER values are 
usually lower than desired for drug transport studies in comparison to primary cell lines. This is 
due to loss of BBB phenotype through decreased expression of TJ proteins, transporters and 
enzymes.  Immortalised cell lines therefore, may only be useful for mechanistic studies where a 
tight barrier is not necessary (Reichel et al., 2003), for example when analysing NP endo-
lysosomal trafficking (Ye et al., 2013).  Primary cells generally exhibit better TEER values, 
however the main drawback of their use is the difficulty in obtaining them and loss of BBB 
phenotype with high passage number.  Regardless, primary cells of human origin remain the 
ideal for gaining invaluable information on pathophysiology and other physiological mechanisms 
in the brain (Reichel, 2006).  Most recently, stem cells have been used with much success to 
produce human in vitro BBB models which exhibit desirable TEER values and markers of BBB 
characteristics (Cecchelli et al., 2014; Appelt-Menzel et al., 2017; Canfield et al., 2017).  The use 
of stem cells however, is difficult due to controversial ethical issues and higher cost to culture.  
Cells used for constructing BBB models are usually seeded onto a microporous membrane which 
separates two compartments of culture medium, the apical (blood) side and the basolateral 
(brain) side.  Tissue culture wells with inserts containing the membrane allow cells to be seeded 
on either side, permitting bidirectional exchange of soluble components.  If a third cell type is 
introduced, it can be seeded in the bottom of the well creating a co-culture system.  Many brain 
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endothelial monolayer models have been created for looking at various aspects of drug transport, 
including peptide targeting studies (Dan et al., 2013; Zhao et al., 2016).  It has been shown 
however, that introducing other cells of the NVU to produce either double or triple co-culture 
models are superior to monocultures (Nakagawa et al., 2007, 2009; Veszelka et al., 2018) and 
thus more accurately represent a selectively permeable barrier.    
Co-culture models of the BBB can comprise any of the cells of the NVU, such as astrocytes, 
pericytes, neurons and macrophages.  Astrocytes are most commonly used in co-culture with 
endothelial cells in BBB models due to a wealth of evidence that they improve TEER values and 
enhance endothelial expression of the BBB phenotype (Abbott et al., 2006; Li et al., 2010; 
Shayan et al., 2011).  Triple cultures including astrocytes and pericytes have more recently been 
utilised in drug transport studies due to further improvements in BBB characteristics (Nakagawa 
et al., 2007,2009; Wisniewska-Kruk et al., 2012; Thomsen et al., 2015; Dos Santos Rodrigues et 
al., 2018).  The optimal arrangement of cells within these models however, has been reported 
with varying results.  Nakagawa et al. (2009) found that pericytes were better seeded on the 
underside of the microporous membrane, in direct contact with the endothelial cells seeded on 
top.  Conversely, Wisniewska-Kruk et al. (2012) found that optimal barrier tightness resulted 
when astrocytes were seeded directly below the endothelial cells.  Nevertheless, a functional in 
vitro BBB model can be useful to assess targeting efficacy and safety of neuro-pharmaceuticals 
prior to in vivo testing. 
Various features of nanoparticulate drug delivery including toxicity (Xu et al., 2015), transport 
pathways (Ragnaill et al., 2011) and size-dependence (Hanada et al., 2014) have been studied 
using such models.   The efficacy of peptides as brain targeting ligands for different therapeutics 
has also been studied, for example Song et al. (2017) described how lactoferrin-conjugated NP 
could cross the endothelial layer of a triple culture BBB model in vitro.  Similarly, Zhao et al. 
(2016) demonstrated how TAT-labelled magnetic NP could penetrate BBB endothelial cells to 
target basolateral glioma cells.  Size-dependent studies by Hanada et al. (2014) showed that NP 
with sizes around 400 nm were barely able to pass through a co-culture in vitro BBB model by 
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non-targeted means.  These recent advances are encouraging in the field of drug delivery, as 
the utility of nanoparticulate systems in delivering therapeutics across a selectively-permeable 
barrier can be assessed at an earlier stage of development.   
New RDP derivative, DAS, has shown the ability to specifically target neural cells, however it is 
not yet known if DAS can facilitate the uptake and subsequent passage of an attached payload 
across the BBB.  In vivo results previously reported in the literature suggests that RDP can target 
the brain.  Before in vivo work is carried out on a suitable animal model, it would be appropriate 
to assess the targeting ability and safety of DAS ligand on an in vitro BBB model when conjugated 
to a NP payload.  This would provide valuable information on how well DAS, as a neural-specific 
targeting ligand, can traverse a tight endothelial layer in comparison to RDP.  Additionally, the 
effect of DAS and RDP on barrier integrity in vitro could be monitored, as well as potential 
mechanism of action. 
 
The aims of the work reported herein were therefore to:  
(1) Develop an in vitro BBB model using primary human cell lines, investigating the optimal 
arrangement of cells based on TEER measurements and expression of TJ proteins.  To construct 
BBB models, major neurovascular unit cellular components such as brain microvascular 
endothelial cells, astrocytes and pericytes are cultured on multi-layer microwell inserts under 
specific protocols. 
(2) Use the leading BBB model to study the effect of RDP and DAS as targeting ligands when 
conjugated to polymeric NP with different drug payloads.  The appropriate BBB model should 
express sufficient barrier characteristics so that passive permeability to polymeric NP is 
restricted, thus allowing the effect of targeting ligand to be observed.  
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5.2.  Materials and Methods 
 
5.2.1.  Materials  
 
The following materials were purchased from Sigma-Aldrich (UK) unless otherwise stated.  Goat 
anti-mouse alkaline phosphatase secondary polyclonal antibody, goat anti-rabbit alkaline 
phosphatase secondary polyclonal antibody, fibronectin from bovine plasma, hydrocortisone 
0.05 mM aqueous solution, heparin sodium salt from porcine intestinal mucosa, human basic 
fibroblast growth factor (bFGF), BCIP®/NBT solution, Corning Transwell® 0.4 µm pore 
polycarbonate membrane cell culture inserts, 1% eosin solution, 0.1% haematoxylin solution 
(Mayer’s), fluorescein isothiocyanate–dextran (FITC-dex) average MW 70 000 and indocyanine 
green (ICG). 
Primary human brain microvascular endothelial cells (HBMVEC), human pericytes and human 
astrocytes were all purchased from iXcells Biotechnologies (USA).  Poly-L-lysine solution was 
purchased from Millipore (UK).  Anti-claudin-5 and anti-actin antibodies were purchased from 
Santa Cruz biotechnology (USA).  Anti-TJP1 (tight junction protein 1) (ZO-1) antibody was 
purchased from Abbexa, (UK).  Invitrogen NuPAGE 4-12% bis-tris gels, nitrocellulose/filter paper 
sandwich (0.45 µm pore size) 8.5 cm x 13.5 cm, DMEM culture medium, DMEM/F12 and insulin-
transferrin-selenium (ITS) 100x solution were all purchased from ThermoFisher Scientific (UK).   
 
5.2.2.  NP formulation 
 
High molecular weight (70 kDa) FITC-dex PLGA NP were synthesised according to the method 
described previously in section 3.2.3.2 of Chapter 3.  Indocyanine green (ICG) NP were similarly 
prepared by this method.  2 mg of ICG (MW 774.96) was dissolved in 0.5 mL of double distilled 
water (ddH2O) and loaded with 100 mg of PLGA polymer.   Following centrifugation of the 
183 
 
resulting ICG NP, supernatant was collected to quantify entrapment efficiency using UV-Vis 
spectrometry at 800 nm.   
 
5.2.3.  NP Characterisation 
 
NP were characterised for size, zeta potential and polydispersity index by DLS as described in 
section 2.2.4 (Chapter 2).  To calculate drug entrapment efficiency, supernatant following 
centrifugation of NP was collected and analysed using fluorescence spectrometry for FITC-
dextran (see section 3.2.5.2 of Chapter 3) and UV-Vis spectrometry for ICG.  A calibration graph 
for ICG absorption at 800 nm was generated to produce an equation for approximate ICG content 
expressed as µg/mL (Figure 5.1).    To measure release, 5 mg of ICG NP were dispersed in 1 
mL of ddH2O and incubated at 37 °C for 7 days.  ICG is poorly soluble in PBS, therefore this was 
not used as the release medium.  At various time points, the ICG NP suspension was centrifuged 
at 1680 g for 5 minutes and a sample of release medium was removed.  ICG content was 
measured using UV-Vis absorbance at 800 nm (n=3) and aliquots were replaced with fresh 
ddH2O.   
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Figure 5.1.  Calibration curve of indocyanine green (ICG) absorption at 800 nm in double distilled water. 
 
5.2.4.  Peptide Conjugation  
 
The protocol for attachment of both RDP and DAS to drug-loaded NP by EDC/NHS chemistry 
and subsequent assessment of conjugation efficiency by BCA assay are detailed in previous 
chapters (2-4).  250 µg of DAS or 750 µg of RDP were reacted per 5 mg of ICG NP. 
 
5.2.5.  BBB model construction 
 
Tissue culture vessels for all three BBB cell types were pre-coated overnight with 2.5 mL of poly-
L-lysine solution (0.01%) and washed thrice with sterile PBS before air drying under sterile 
conditions.   HBMVEC were cultured in DMEM/F12 medium supplemented with 1% PS, 10% 
FBS, 2.5 mL insulin-transferrin-sodium selenite (ITS) solution, 1.5 ng/mL basic fibroblast growth 
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factor (bFGF) and heparin sodium (100 IU/mL).  Both astrocytes and pericytes were cultured in 
DMEM supplemented with 1% PS and 10% FBS. 
BBB models were constructed according to methods described by Nakagawa et al. (2007, 2009) 
and Wisniewska-Kruk et al. (2012).   Corning Transwell polycarbonate membrane 0.33 cm2 
tissue culture inserts (0.4 µm pore size) were pre-coated overnight on both sides with 50 µL of 
0.1% poly-L-lysine solution prior to seeding of cells.  Firstly, on the underside of the inserts, 20 
000 pericytes or astrocytes in a volume of 40 µL were seeded and incubated for 2 hours 
(37°C/5% CO2).   After this, the inserts were placed in a well containing 600 µL of complete 
DMEM medium and incubated at 37°C/5% CO2  for 24 hours. Subsequently, 600 µL of astrocytes 
or pericytes (1x105 cells/mL) were then seeded in separate wells of the plate, also pre-coated 
with 0.1% poly-L-lysine (300 µL).  Following a further 24 hours of incubation (37°C/5% CO2), 
HBMVEC were seeded onto the upper side of the Transwell insert at a density of 1.5x105 
cells/cm2 in 100 µL of complete DMEM/F12 and the insert placed in the well containing 
pericytes/astrocytes.  The assembled Transwell plate was incubated overnight (37°C/5% CO2), 
at which point all media was aspirated and replaced with complete DMEM/F12 as previously 
described, with the addition of 500 nM hydrocortisone solution.  Medium was changed every two 
days and transendothelial electrical resistance (TEER) was measured daily from day 2 of 
culturing onwards to determine the optimum combination of cell layers in the BBB model.   
TEER was measured by impedance spectroscopy using a Flocel TEER Measurement Unit 
(Flocel Inc. Ohio, USA) with STX-2 chopstick electrodes (World Precision Instruments, Florida, 
USA).  TEER values were expressed as Ωcm2.  A blank surface-coated well was used as a 
control and subtracted from all TEER values obtained prior to reporting. 
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Figure 5.2.  Diagrammatic representation of a triple culture in vitro BBB model, including human brain 
microvascular endothelial cells (HBMVEC), pericytes and astrocytes. 
 
 
 
To ensure adherence of cells to the polycarbonate membrane of the Transwell insert, 
membranes with either cultured pericytes, astrocytes or HBMVEC were stained to visualise 
under a light microscope.  Inserts were soaked in 100% ethanol for 5 minutes, stained with 1% 
eosin solution for 1 minute, washed and then stained again with 0.1% haematoxylin solution for 
5 minutes.  Membranes were then washed, cut from the insert and mounted onto a glass slide 
to be visualised at x 20 000 magnification.    
 
5.2.6.  Western blot detection of Claudin-5 and ZO-1 levels in HBMVEC  
 
After 5 days of culture in Transwell vessels, HBMVEC were harvested from the polycarbonate 
inserts with lysis buffer and adjusted to an approximate equal concentration of protein for each 
sample using a BCA assay, to ensure fair sample concentrations of cells.  Any samples found to 
have an abnormally higher protein content were diluted with lysis buffer.   
HBMVEC 
Pericyte 
Astrocyte 
 Apical chamber 
Basolateral chamber 
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Briefly, cells were scraped into 50 µL of cold lysis buffer and left on ice for 20 minutes.  Samples 
were then centrifuged at 150g for 5 minutes, after which supernatant was removed and frozen 
until ready for analysis.   
Western blotting was used to detect levels of Claudin-5 (MW 23 kDa) and ZO-1 (MW 195 kDa), 
important tight junction proteins which indicate the formation of tight junctions within the 
endothelial cell layer of the BBB.   Cell lysates were prepared for SDS-PAGE by boiling 30 µL 
with 6 µL of 5x Laemmli sample treatment buffer for ten minutes.  Cell proteins were separated 
by gel electrophoresis using a 4-12% NuPage bis-tris gel and MES running buffer prior to western 
blotting.  The western blot was first blocked with a 5% BSA solution in tris-buffered saline (TBS) 
for one hour and then washed thrice with TBS for 5 minutes.  Anti-claudin-5 mouse monoclonal 
antibody (200 µg/mL) or anti-ZO-1 rabbit polyclonal IgG antibody (200 µg/mL) were diluted 1:400 
in TBS before incubating with the nitrocellulose for 90 minutes at room temperature with gentle 
shaking.  The nitrocellulose was then washed as before, prior to incubation with either a goat 
anti-mouse (for Claudin-5) or goat anti-rabbit (for ZO-1) alkaline phosphatase secondary 
antibody (1:30 000 dilution) for a further 90 minutes at room temperature.  After washing for a 
final time, the western blot was developed by addition of alkaline phosphatase substrate 
BCIP®/NBT solution until protein bands were visible.   
To provide a further control for cell concentration in each sample, western blots were stripped 
for 10 minutes with stripping buffer and subsequently re-probed for actin (MW 42kDa), a common 
and abundant cell protein.  Anti-actin mouse monoclonal IgG antibody (200 µg/mL) was diluted 
1:400 in TBS and the process was repeated as for Claudin-5 and ZO-1 detection.  Each band 
was quantified by densitometry on a G:Box chemi XRQ imaging system (Syngene, Cambridge, 
UK) using Genetools and Genesys software.     
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5.2.7.  Effect of targeting peptides RDP and DAS on NP uptake across a BBB model 
 
The optimum BBB model selected for uptake studies was determined by the work carried out in 
section 5.2.5.  The Transwell culture vessels were prepared as a triple culture of astrocytes, 
pericytes and HBMVEC according to the protocol previously described, however the poly-L-
lysine coating on the upper surface of the inserts was changed to 0.1 mg/mL fibronectin, in 
attempt to maintain better barrier integrity in NP treatment assays.  The BBB model was cultured 
until day 4 after assembly (37°C/5% CO2), at which point the TEER was measured in each well.  
Only wells with TEER measurements of at least 150 Ωcm2 were selected to commence NP 
uptake studies on day 4.  
 
5.2.7.1.  Analysis of FITC NP uptake in BBB model 
 
FITC-loaded NP (FITC NP), RDP-conjugated FITC NP (RDP-FITC NP) and DAS-conjugated 
FITC NP (DAS-FITC NP) were diluted from stock suspensions of 10 mg/mL in PBS to 0.5 mg/mL 
in serum-free DMEM/F12.  Existing culture medium was removed from the apical (upper) 
compartment of the BBB model and replaced with 100 µL of NP treatment.  Cells were incubated 
at 37°C/5% CO2 and samples of 300 µL were taken at 2 hours and 24 hours post treatment from 
the basolateral (bottom) compartment and replaced with fresh BBB medium.   TEER was 
measured before each sample was taken to monitor barrier integrity in response to the treatment.  
Following 24 hours, all inserts and media were removed from the plate.  The astrocytes remaining 
in the bottom wells were subsequently washed twice with sterile PBS and then lysed.  Ice cold 
lysis buffer (300 µL) was added to cells for 20 minutes before mixing and centrifuging at 150g for 
5 minutes.  The supernatant from lysed astrocytes was transferred to a Corning Costar microtiter 
plate and assessed for FITC fluorescence emission on an Omega FLUOstar plate reader 
(excitation 485 nm, emission 520 nm).   
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5.2.7.2.  Analysis of ICG NP uptake in BBB model 
 
ICG-loaded NP (ICG NP), RDP-conjugated ICG NP (RDP-ICG NP) and DAS-conjugated ICG 
NP (DAS-ICG NP) were diluted from stock suspensions of 10 mg/mL in PBS to 1 mg/mL in 
serum-free DMEM/F12.  To observe the effect of RDP and DAS on NP movement across the 
BBB model, RDP-ICG NP and DAS-ICG NP would also be incubated with the respective free 
peptide to provide competition for receptor binding.  An approximate equivalent concentration of 
free RDP (50 mcg/mL) or DAS (44 mcg/mL) were added to the BBB model and incubated at 
37°C/5% CO2 for 20 minutes prior addition of NP treatment. 
TEER was monitored and samples of BBB media were taken as described in section 5.2.7.1 
(Chapter 4) at 2 hours and 24 hours post treatment.  Following 24 hours of incubation (37°C/5% 
CO2), all media was aspirated to allow gentle washing of individual inserts and wells with PBS.  
Following washing, astrocytes in the bottom of the well and pericytes on the underside of the 
inserts were imaged for ICG fluorescence (excitation 780 nm, emission 820 nm) in situ using a 
VivoVision IVIS Lumina imaging system (Xenogen, California, USA) with Living Image 3.2 
software.  The BBB media samples collected were also analysed after addition to a 96 well plate.  
Regions of interest on fluorescence images were quantified in photons/second/cm2/steradian 
(p/sec/cm2/sr). 
 
5.2.8.  Statistical analysis 
All results reported were statistically analysed using either an unpaired two-tailed t-test or a two-
way ANOVA with post-hoc tests.  A P-value of < 0.05 was considered statistically significant.   
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5.3.  Results and Discussion 
 
5.3.1.  Development of an in vitro BBB model  
 
 
 
                                      Culture Flask                          Transwell membrane 
 
 
 
HBMVEC 
 
 
 
 
 
 
Pericytes 
 
 
 
 
 
Astrocytes 
 
 
 
 
 
Figure 5.3.  Images of BBB cells in culture (left column) and following staining to confirm adherence to the 
Transwell membrane (right column).  Images are shown at x 20 000 magnification. 
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HBMVEC were cultured in Transwell inserts with different combinations of microglial BBB 
astrocytes and pericytes, integral components of the human BBB.  All three cell types used could 
successfully adhere to the Transwell membrane and proliferate under culture conditions, 
observed from the images displayed in Figure 5.3.  Seven different BBB models were constructed 
to investigate the optimal conditions for induction of endothelial barrier properties, as illustrated 
in Figure 5.4.  TEER values of all constructs were monitored over 6 days and showed a steady 
increase starting from day 2 until day 5.  After peaking at day 5, TEER values appeared to 
decrease for all combinations of cells on day 6.  It was therefore determined that 5 days of culture 
produced the optimal TEER value (Figure 5.5).   
 
 
 
 
 
Figure 5.4.  Diagrammatic representation of in vitro human BBB model constructs using human brain 
microvascular endothelial cells (HBMVEC) as the apical layer, with different combinations of 
astrocytes and pericytes in the basolateral chamber.  A monoculture model of HBMVEC only 
(E00) was developed alongside double (E0A, E0P, EA0 & EP0) and triple culture (EAP & 
EPA) models to determine the optimal composition of cells for induction of barrier properties.  
E= HBMVEC, P= human pericytes, A= human astrocytes and 0= no cells. 
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The TEER of the E00 monoculture model containing only HBMVEC peaked at 95 Ωcm2 after 5 
days of incubation.  It was evident from the results displayed in Figure 5.5 that both triple culture 
BBB models (EAP and EPA) consisting of HBMVEC, astrocytes and pericytes provided the 
highest TEER values.  Only the EPA model however, had significantly higher TEER values (P 
value <0.01) than the monoculture E00 model at days 4 and 5.  A maximum TEER value of 184 
Ωcm2 was reached in the EPA model after 5 days, shown in Figure 5.5A, where pericytes were 
in direct physical contact with the membrane and HBMVEC on the upper surface.  In Figure 5.5B, 
the EAP model had a maximum TEER of 120 Ωcm2.   In the literature, there is evidence that 
primary cell-based triple culture systems (Nakagawa et al., 2007; 2009; Wisniewska-Kruk et al., 
2012) develop better overall barrier-like properties and TEER values in comparison to 
monocultures, co-cultures and immortalised cell lines (Li et al., 2010).   
Similar to findings reported by Banks et al. (2018), there was no significant improvement in TEER 
observed with any of the double co-culture models compared to the monoculture E00 model. 
The addition of both astrocytes and pericytes to the in vitro BBB model was therefore required 
for optimal barrier conditions. It was determined from these results that the most promising in 
vitro BBB model was the EPA triple culture, as it not only reached a TEER of above 150 Ωcm2, 
but the organisation of cellular layers had significantly higher resistance across the in vitro 
membrane than the EAP model.   
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(A) 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.  Transendothelial electrical resistance (TEER) values of different BBB models over 6 days.  
The organisation of cellular layers within the in vitro BBB models were investigated for optimal 
arrangement with either no cells, (A) pericytes or (B) astrocytes in direct contact with the 
endothelial layer.  All measurements were recorded in triplicate ± standard deviation (n=3).  
Statistics were carried out using a two-way ANOVA with post-hoc analysis. 
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It is generally accepted that for drug transport studies, in vitro cell-based BBB models should 
have a restrictive paracellular barrier with a TEER measuring at least 150 Ωcm2 (Gaillard & de 
Boer, 2000).  In vivo, pericytes are in direct contact with up to 70% of the abluminal endothelial 
surface, all of which is then overlaid with astrocyte end-feet (Giannoni et al., 2018).  Cell 
architecture should also be as realistic to in vivo conditions as possible (Gumbleton & Audus, 
2001), further supporting the use of the EPA model.   
Pericytes are key in the establishment of the BBB from embryogenesis (Daneman et al., 2010).  
They are associated with tight junction formation, differentiation of endothelial cells, regulation of 
microvascular permeability and provide structural support from the early stages of development 
(Balabanov & Dore-Duffy, 1998; Armulik et al., 2010).  Astrocytes, produced at a later stage, are 
believed to have a complex role in barrier maintenance and regulation of endothelial cell 
physiology and permeability via chemical signalling (Abbott, 2002).  It is the cross-communication 
between these cells and others of the NVU, such as neurons and microglia (Banks et al., 2018), 
which induce the unique characteristics of BBB endothelial cells (Hawkins & Davis, 2005).  
Chemo-modulators such as cytokines and prostaglandins have been identified in vitro as 
mediators of NVU communication (Kovac et al., 2011), the highest levels of which have been 
found in triple culture in vitro models (Banks et al., 2018).  Indeed, the generation of a functional 
BBB in vivo is dependent on multi-cellular interactions, which has been reflected by in vitro 
investigations. 
Only endothelial cells can adopt barrier-like properties and this was shown in Figure 5.5A when 
a monoculture of pericytes or astrocytes alone failed to show any considerable development of 
resistance across the membrane.  After 6 days of culture, TEER values reached between 5-10 
Ωcm2 for both cell types, however this can probably be attributed to an over-confluent cell layer 
rather than any true resistance.   
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Figure 5.6.  Graph showing peak TEER values of BBB models on day 5 of culture, with and without the 
addition of heparin to the culture medium.  All measurements were recorded in triplicate ± 
standard deviation (n=3).  P values from two-way ANOVA with post-hoc analysis considered 
statistically significant if < 0.05.  */ + Statistically significant difference compared to respective 
monoculture (E00) model. ++ Statistically significant difference compared to EAP model (with 
heparin).   
 
 
Figure 5.6 also shows the difference in TEER values obtained at peak day 5 when heparin is not 
included in the culture medium.  In the monoculture BBB model of HBMVEC (E00), TEER 
increased almost 4-fold from 23.8 Ωcm2 to 95.37 Ωcm2 when cultured in medium containing 
heparin (P value < 0.001).  Caldwell et al. (2004) previously reported that inclusion of heparin in 
culture medium greatly improves the in vitro stability of the mitogen, basic fibroblast growth factor 
(bFGF), improving receptor binding and hence cell growth.  The use of heparin as part of the 
BBB medium proved to be essential in obtaining a satisfactory TEER for drug transport studies, 
as it induced a more resistant endothelial layer in the EPA model to above the threshold value 
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of 150 Ωcm2.  In all cases, the use of heparin significantly increased the TEER value of each 
BBB model (P values < 0.001) and therefore it was included in further studies.   
 
5.3.2.  Detection of tight junction proteins Claudin-5 and ZO-1 
 
HBMVEC were harvested from BBB models after 5 days of culture and tested for expression of 
claudin-5 and ZO-1 proteins using western blotting, results of which are shown in Figure 5.7.  It 
is evident from Figure 5.7A, that the most visible bands for claudin-5 and ZO-1 were detected in 
the triple culture models EPA and EAP.  There appears to be a greater amount of claudin-5 
detected in HBMVEC when they are in direct contact with astrocytes (EA0) in the double culture 
model, compared to pericytes (EP0).  In contrast, ZO-1 levels are higher in the double culture 
when pericytes are in direct contact with the HBMVEC layer.  Astrocytes and pericytes may have 
different roles in the formation of tight junctions at the BBB endothelium.  It is clear from these 
results, that expression of tight junction proteins in HBMVEC is promoted when in direct contact 
with astrocytes or pericytes, and even more so when both cell types are included in the culture. 
Relative to E00, the EPA and EAP models showed significantly higher levels of claudin-5, 1.58 
and 1.47 respectively, as detected by densitometry (Figure 5.7B).  The relative levels of ZO-1 in 
the triple culture models compared to the E00 model were even greater.  Relative expression of 
ZO-1 in the EAP model was 1.80 and for the EPA model was 2.16.  It can also be observed from 
the western blot images in Figure 5.7A that actin levels were consistent, meaning that variations 
in claudin-5 or ZO-1 were not due to unfair differences in protein loaded onto the blot.  To further 
support this, actin bands were quantified using densitometry and subsequently tight junction 
protein results were normalised for ratio of actin compared to the E00 model.    
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 (A) 
 
 
 
 
 
 
 
 
 
 
 
  
(B) 
 
Figure 5.7.  (A) Western blot showing detection of tight junction proteins claudin-5 and ZO-1 alongside 
actin in human brain microvascular endothelial cells (HBMVEC) after 5 days of culture in 
different blood brain barrier (BBB) models.  HBMVEC were either cultured alone (E00), in 
double culture with either astrocytes and pericytes (E0A, EA0, E0P & EP0) or triple culture 
with both astrocytes and pericytes (EAP & EPA).  (B) Graph showing the relative expression 
of claudin-5 and ZO-1 in different BBB models detected by densitometry of the western blot.  
* Statistically significant difference compared to respective E00 model (two-tailed T-test P 
value <0.05).  Error bars ± standard deviation (n=3).   
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Claudin is a fundamental constituent of intercellular tight junctions (Chiba et al., 2008).  Claudin-
5, occludin and junctional adhesion molecule (JAM-1) are three TJ-specific transmembrane 
proteins which have been found co-localised with peripheral zonula occludens protein (ZO-1) in 
human brain microvasculature (Vorbrodt & Dobrogowska, 2004).  Claudin-5 and ZO-1 
expression are therefore key markers for detecting the induction of barrier characteristics in 
endothelial cells of in vitro BBB models.  It has been found that the combination of pericytes and 
astrocytes in triple cultures induce expression of more tight junction proteins at the inter-
endothelial cell surface (Banks et al., 2018), rather than in the cytoplasm, as has been observed 
for monocultures (Stamatovic et al., 2005).  This contributes to tight junction formation, inhibition 
of paracellular transport and increase in barrier resistance.  The EPA model reported herein 
generated the highest TEER and expression of tight junction proteins claudin-5 and ZO-1, 
comparable to the rat-based in vitro model described by Nakagawa et al. (2009).    
 
5.3.3.  Effect of neural cell targeting peptides, RDP and DAS, on in vitro BBB model 
 
PLGA NP were successfully prepared incorporating either ICG or FITC-dextran as a payload.  
Characterisation properties, including release profile of FITC-dextran NP, are previously reported 
in sections 3.3.1- 3.3.2 (Chapter 3).  Properties of ICG-loaded NP (ICG NP) are detailed in Table 
5.1, which shows an average NP size of 293.50 nm (± 1.70 SD) which is consistent with sizes 
measured previously when loaded PLGA NP are prepared by this method (chapters 2-4).  Other 
parameters such as PDI (0.36 ± 0.09 SD) and zeta potential (-7.50 mV ± 0.2 SD) also remained 
similar to results previously obtained.  Water-soluble ICG (MW 774.96) had an entrapment 
efficiency of 40% when loaded into PLGA NP (2% loading) by the double emulsion method, 
comparable to doxorubicin (MW 543.52) in section 2.3 (Chapter 2).  Both peptides were surface 
conjugated to ICG NP with coupling efficiencies of 66.9% and 87.6% for RDP and DAS 
respectively.  Both FITC-dextran and ICG-loaded NP to be tested in the BBB model were of a 
very similar size and zeta potential.   
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Table 5.1.  Characterisation of polymeric PLGA nanoparticles loaded with small molecule cyanine dye 
ICG (MW 774.96). 
 
 
 
 
 
 
 
 
 
The release profile of ICG (Figure 5.8) shows that in distilled water at 37°C, a controlled release 
is displayed under sink conditions over 7 days, at which point around 30% of the maximum 
payload is released.  The peripheral attachment of RDP or DAS to the NP surface slowed down 
ICG release which was significant in comparison to the unlabelled ICG NP by day 7 (P values < 
0.05).  This is possibly due to steric hinderance, especially as release from RDP-ICG NP is lower 
than those surface-coated with the smaller peptide, DAS, over the first three days of incubation.   
Importantly, no ICG release could be detected from RDP-ICG NP and only 1% from DAS-ICG 
NP after 24 hours.   This was desirable to ensure free drug interference with BBB assay results 
was as limited as possible, as unlike FITC-dextran, ICG is freely cell permeable. 
Characterisation Parameter ICG NP 
Size (d.nm) 293.50 ± 1.70 
Zeta potential (mV) -7.50 ± 0.20 
Polydispersity Index (PDI) 0.36 ± 0.09 
ICG content (µg/mg) 7.92 (40.0% EE) 
RDP conjugation (µg/mg) 50.15 (66.9% CE) 
DAS conjugation (µg/mg) 43.82 (87.6% CE) 
200 
 
 
 
 
Figure 5.8.  Graphs showing the release of ICG from PLGA nanoparticles (NP) at 37°C in double distilled 
water over a period of 7 days ± standard deviation (n=3).  The effect of RDP and DAS surface 
attachment on the release profile is shown.  Statistical analysis was performed using a two-
way ANOVA with post-hoc analysis. 
 
 
 
Figure 5.9 shows the result of different FITC NP treatments on the triple culture in vitro BBB 
model after 24 hours of exposure at 37°C.  Upon sampling the media in the bottom or basolateral 
compartment of the BBB model wells after 2 and 24 hours (Figure 5.9A), significantly more FITC 
fluorescence was detected in those samples treated with DAS-FITC NP than when treated with 
unlabelled FITC NP (P value <0.05).  At the 24-hour time point, this was also the case for RDP-
FITC NP. 
Astrocytes, the lowest cellular layer of the BBB model, were harvested and tested for 
fluorescence signal of FITC after 24 hours (Figure 5.9B).  Again, significantly higher emission 
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was detected in those treated with both RDP- and DAS-conjugated NP compared to FITC NP-
treated cells, where no fluorescence was detected. 
The decrease in fluorescence detected in BBB medium from 2 hours to 24 hours is probably due 
to FITC NP uptake from the medium into the astrocytes for the RDP-FITC NP and DAS-FITC NP 
treatment groups.  The detection of fluorescence after FITC NP treatment in the basolateral 
media at 2 hours incubation, but little after 24 hours and none in the astrocytes, is possibly due 
to free FITC-dextran, which perhaps leached from the NP across the barrier and then was 
removed upon sampling.   Other explanations of this anomalous result are that unlabelled NP 
may have been taken up by endothelial cells and free FITC-dextran released across the 
membrane.  Alternatively, despite the consistent TEER values, there may have been an 
intercellular gap in the endothelial layer which allowed passage of FITC NP from upper to lower 
compartment.  Any of these possibilities may explain why fluorescence was observed in the 
medium at an early stage but not in the astrocytes after unlabelled NP treatment. 
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Figure 5.9.  (A) FITC-dextran fluorescence detected in the basolateral media (bottom chamber) of the 
BBB model at 2 and 24 hours post addition of different NP preparations and (B) lysate from 
the astrocyte layer of cells of the BBB model triple culture (EPA). * Statistically significant 
difference compared to unlabelled FITC NP (two-tailed T-test P value <0.05, n=3). 
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FITC-dextran of high molecular weight (70 kDa) is largely considered cell impermeable due its 
size and presence of many hydroxyl groups.  FITC conjugates are commonly used for drug 
transport and uptake studies (Agyare et al., 2008; Gil et al., 2012; McCarthy et al., 2015).  If free 
drug is present in the cell medium it cannot be passively taken up into cells, especially over short 
periods of time.  If the FITC NP with no attached peptide remained intact and crossed the 
endothelial layer and pericytes via cell mediated transport, it is likely that fluorescence would 
have also been observed in the lowest BBB layer of astrocytes as with the two targeted NP 
preparations.  It is therefore more likely, that the fluorescence detected in the BBB media at 2 
hours (Figure 5.9A) is due to a small gap in the barrier or free FITC-dextran release.  It could be 
postulated that peptide conjugation somewhat protects the NP from intracellular degradation and 
hence a proportion of intact NP with targeting peptide can effectively pass two cellular layers 
(HBMVEC and pericytes) to accumulate in the final layer (astrocytes).  Unlabelled NP of course 
can be taken up by cells, however the difference in cellular targeting ability over 24 hours is 
evident.  The results demonstrate that peptide attachment to the NP is facilitating an 
accumulation of drug payload in the target cells, in comparison to the untargeted delivery vehicle.  
The BBB retained integrity after addition of NP as TEER values were measured at 2 and 24 
hours post treatment (Figure 5.10).  The triple culture (EPA) BBB model showed not only 
maintenance, but improvement in TEER after 24 hours with all values greater than 200 Ωcm2 
irrespective of treatment group (P values < 0.001).  The observed increase in TEER 4 to 5 days 
post preparation of the triple culture, is typical of an untreated BBB model, as was shown in 
Figure 5.5A.  The addition of NP treatment therefore had no adverse effect on the integrity of this 
BBB model (P values > 0.05 comparing treatment groups to control at all time points) and 
endorses both RDP and DAS as active facilitators of safe NP transport across neural cell layers. 
Freese et al. (2013) also reported an increase in TEER after surface-modified NP treatment in a 
porcine in vitro BBB model.  Freese and colleagues attributed this to the use of primary cells, 
which express more favourable barrier properties than immortalised cell lines as previously 
mentioned.  
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Figure 5.10.  Graph showing monitored TEER values of in vitro BBB model before addition of NP followed 
by 2 and 24 hours post NP treatment.  Measurements were recorded in triplicate (n=3) and 
reported as average TEER with error bars representing ± standard deviation.  Statistical 
analysis was performed using a two-way ANOVA with post-hoc tests. 
 
 
 
A similar assay to Figures 5.9 & 5.10 was carried out using ICG as the NP payload instead of 
FITC-dextran, the results of which are shown in Figures 5.11-5.14.  This time, ICG fluorescence 
was measured semi-quantitatively in the middle pericyte layer, the basolateral BBB medium and 
the astrocytes at the same time points as for the FITC NP BBB assay.  Additionally, the two 
peptide-conjugated NP preparations were co-incubated with corresponding free peptide to 
assess the effect, if any, on NP transport across the in vitro BBB model. 
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Due to the capability of the instrumentation to image BBB model cell layers in situ, ICG 
fluorescence emission was detected in the middle pericyte layer on the bottom of the Transwell 
insert (Figure 5.11).  Images in Figure 5.11A and subsequent quantification of signal intensity in 
Figure 5.11B show that more ICG is present following treatment with RDP-ICG NP and DAS-
ICG NP than untargeted ICG NP.  It was demonstrated that the use of free peptide alongside 
peptide-targeted ICG NP has a profound negative effect on the amount of NP payload detected 
in cells.  The signal pattern imaged for the ICG NP group in Figure 5.11A is suggestive of non-
specific uptake into pericytes around the circumference of the Transwell membrane.  The 
endothelial layer may be susceptible to gaps where the membrane attaches to the inserts, 
leading to leakage of NP through the membrane, as little fluorescence is seen in the centre of 
the well. 
Assessment of BBB media at 2 hours post addition of NP treatment (Figure 5.12) show 
significantly higher detection of ICG fluorescence in the RDP-ICG NP and DAS-ICG NP groups 
than untargeted ICG NP.  The amount of ICG fluorescence however, again significantly reduced 
on co-incubation with free peptide.  At 24 hours, no significant ICG fluorescence could be 
detected in the media for any group (results not shown). 
Figure 5.13 shows ICG fluorescence detected from astrocytes in the bottom of the BBB model 
well after 24 hours of incubation at 37°C.  Upon imaging of these cells, there was considerably 
more ICG detected in astrocytes when NP were conjugated to new peptide, DAS, even compared 
with RDP.  No ICG could be detected in the unlabelled NP treatment group (ICG NP), supporting 
the findings from Figure 5.9B.  This was also the case for RDP-ICG NP when incubated with free 
RDP.  Although there was still some evidence of ICG uptake in astrocytes when DAS-ICG NP 
were co-incubated with free DAS, the signal intensity was significantly diminished.  The use of 
free peptide to compete with peptide-conjugated NP at potential binding sites displayed 
substantial inhibition of NP movement through the BBB model and hence the importance of RDP 
and DAS as targeting moieties is evident. 
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Figure 5.11.  (A) Images and (B) graph showing ICG fluorescence detected from pericytes on the 
underside of Transwell inserts 24 hours post exposure to different NP treatments.  
*Statistically significant increase in fluorescence compared to all other treatment groups 
except DAS-ICG NP.  α Statistically significant increase in fluorescence compared to all 
other treatment groups except RDP-ICG NP.  Two-tailed P value < 0.05 (n=3 ± SD). 
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Figure 5.12.  (A) Images and (B) graph of ICG fluorescence signal detected in the BBB model basolateral 
chamber media 2 hours post addition of different NP preparations to the Transwell insert 
(apical chamber).  *Statistically significant increase in fluorescence compared to all other 
treatment groups except DAS-ICG NP. ** Statistically significant increase in fluorescence 
compared to all other treatment groups.  Two-tailed P value < 0.05 (n=3 ± SD). 
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Figure 5.13.  (A) Images and (B) graph of ICG fluorescence signal detected in astrocytes, the bottom layer 
of cells in the BBB model 24 hours post NP exposure. *Statistically significant increase in 
fluorescence compared to all other treatment groups except DAS-ICG NP. ** Statistically 
significant increase in fluorescence compared to all other treatment groups.  Two-tailed P 
value < 0.05 (n=3 ± SD). 
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Table 5.2.  Representation of ICG fluorescence detected in pericytes and astrocytes of in vitro BBB model 
after 24 hours of NP treatment.   
 
 
 
 
 
It appears that DAS may facilitate NP transport through the BBB model more effectively than 
RDP, due to higher levels of ICG being detected in the astrocyte layer when DAS is the targeting 
ligand.  This is generally summarised in Table 5.2, which shows the location of ICG payload after 
24 hours of NP treatment.  Interestingly, no ICG fluorescence detected in the basolateral medium 
after 24 hours, suggests that the targeted NP preferentially accumulate in cells rather than in the 
medium.  This could be a positive effect for prospective in vivo studies, as the peptide ligand 
might confer the ability of the payload to enter cells rather than remain in interstitial fluid.  It could 
be postulated that further studies observing a period of time longer than 24 hours, might show a 
shift in accumulated payload from predominantly pericytes to astrocytes. 
The fact there is no ICG detected in the astrocytes following ICG NP exposure, confirms the 
findings from Figure 5.8 that the NP do not leach payload over the time course observed.  
Furthermore, both peptides effectively facilitate NP transport in these neural cell types, most 
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likely by receptor-mediated mechanisms, due to the inhibition caused by competing free 
peptides.  Song et al. (2017) reported on a triple culture rat brain-derived model of comparable 
TEER (200 Ωcm2), where lactoferrin-targeted fluorescent payload was detected in the bottom 
cell layer.  Similar to results from Figures 5.11-5.13, free ligand out-competed the conjugate 
leading Song and colleagues to propose a receptor-mediated endocytosis mechanism of 
transport.  
 
 
Figure 5.14.  TEER values of BBB triple culture model (EPA) before, then at both 2 and 24 hours after 
addition of various ICG-loaded NP treatments.  Measurements were recorded in triplicate 
(n=3) and reported as average TEER with error bars representing ± standard deviation.  
Statistical analysis was performed using a two-way ANOVA with post-hoc tests.  * P- value 
< 0.001 compared to 0 hours. 
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The integrity of the in vitro BBB model remained unaffected by the addition of NP as TEER was 
higher by the end of the 24-hour period, than the beginning, for every treatment group (Figure 
5.14).  Addition of a fibronectin coating to the Transwell insert upper surface prior to seeding of 
HBMVEC improved TEER values in comparison to poly-L-lysine, which was used as a coating 
up until this point.  It can be seen in Figure 5.14, that 24 hours after treatment (day 5 after 
assembly of the BBB model) some TEER values reach 300 Ωcm2.  This is a 66.7% increase in 
the maximum TEER value (180 Ωcm2) recorded for the EPA model at day 5 in the initial work 
carried out in Figure 5.5.   
Fibronectin is an essential component of the BBB basal membrane alongside collagen, laminin 
and proteoglycans (Krizbai et al., 2011).  Mainly adhesive in function, fibronectin assists in 
adherence of brain endothelial cells to each other and to the basement membrane.  The 
basement membrane is a special extracellular matrix which is important for proper barrier 
formation at the blood-brain interface.  This is due to the self-association of matrix proteins which 
form a scaffold to allow cellular interactions promoting adhesion, differentiation and proliferation 
of endothelial cells (Daneman and Prat, 2015).  In fact, cultured brain endothelial cells show an 
elevated TEER when grown on any of the extracellular matrix proteins; fibronectin, collagen or 
laminin (Tilling et al., 2002).   
Many in vitro BBB models have been constructed over the past two decades either containing a 
single monolayer of endothelial cells (Franke et al., 2000; Qiao et al., 2012; Clark & Davis, 2015; 
Yang et al., 2018) or in co-culture with glial cells (Megard et al., 2002; Omidi et al., 2003; Veszelka 
et al., 2007; Hutamekalin et al., 2008; Xu et al., 2008).  These models, derived from varying 
species, display a range of TEER values (30-800 Ωcm2) and do not contain pericytes, which are 
important in the arrangement of in vivo BBB cells.  Multi-cellular models, like the EPA model 
described in this work, are necessary for considering the complex dynamic of NVU cross-talk 
and thus drawing strong conclusions about nano-carrier transport across multiple cell layers 
(Gidwani & Singh, 2013).  Furthermore, the model described herein is of human origin, an 
attractive property for a biomimetic system given the potential differences in the BBB amongst 
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species (Modarres et al., 2018). Indeed, the commercially available PharmaCo-Cell model by 
Nakagawa et al. (2009) was based on primary rat tissue, which is known to naturally express 
higher levels of Claudin-5 (Hoshi et al., 2013).  
Finally, it is evident from the results that DAS is at least equally as effective as RDP in targeting 
a NP payload across an in vitro BBB model and subsequently is superior to untargeted NP in 
neural cell-targeting.  
 
5.4.  Conclusion 
 
In conclusion, an in vitro human BBB model was developed from a triple culture of HBMVEC, 
pericytes and astrocytes which produced acceptable TEER values (>150 Ωcm2) and expression 
of TJ protein for drug transport studies.  Using this model, it was demonstrated that RDP and the 
new derivative, DAS, could successfully facilitate the passage of two different NP payloads 
across the endothelial-pericyte membrane after 24 hours.  Unlabelled NP did not exhibit this 
targeting ability; therefore, it can be concluded that the effect observed was due to the action of 
RDP and DAS ligands.  Finally, the TEER value of the in vitro BBB model was not adversely 
affected by NP treatment, providing useful insight firstly into the safety of the delivery vehicles, 
and secondly, the ability of the BBB model to retain a strong TEER value over an experimental 
period. 
To this end, the findings communicated from this work support the continued development of 
DAS and potentially other RDP derivatives, which can be easily screened in vitro for potential 
BBB targeting properties. 
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Chapter 6 
Concluding remarks and future work 
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6.1.  General conclusion 
 
In this work it was shown that the effective brain targeting ligand RDP, derived from the rabies 
virus, preferentially interacts with neural cell types via the neuronal nicotinic acetylcholine 
receptor.  The expression of this receptor at the BBB and throughout the CNS presents a 
relatively specific endogenous target that can be exploited for the delivery of promising PD 
therapeutics such as neurotrophic factors.  This thesis described the optimisation of RDP to a 
more proteolytically resistant ligand termed DAS, which maintained neural-specific activity 
when conjugated to drug-loaded polymeric NP.  DAS, like RDP, did not show any significant 
targeting effect in non-neural cell types.   
A triple culture in vitro BBB model was developed from human-derived cell types which 
displayed fundamental barrier characteristics for transport studies.  Both RDP and DAS ligands 
facilitated the transport of loaded NP through this BBB model more efficiently than unlabelled 
NP.  Neither ligand had an adverse impact on barrier properties nor caused significant 
cytotoxicity, suggesting RDP and DAS would be safe for future in vivo investigations.  
 
 
6.2. Study limitations 
 
The residual solvent remaining in PLGA NP following formulation was not tested during these 
studies.  In chapter 2, it was discussed how washing may reduce residual DCM in NP to below 
the acceptable limit of 600 ppm set by the International Committee for Harmonisation.  Despite 
this, it would be preferable to test the level of residual solvent remaining in NP using 
headspace gas chromatography, especially for future in vivo work. 
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An MTT assay was used to assess cell viability in these studies, which is a metabolic test 
measuring cell respiration.  Metabolic rate may vary amongst cells types and also will depend 
on the cellular environment.  MTT assay as the sole measurement of cell viability therefore 
may not be the most accurate reflection of cell death, requiring a second non-metabolic test 
such as dye exclusion to provide robust results for in vitro cell assays.  
Confocal studies in Chapters 3 & 4 were able to show preferential peptide-facilitated uptake of 
a fluorescent payload in neural cells; however, this was not quantified.  Furthermore, peptide 
conjugation studies throughout the thesis were limited in sample number due to the expense of 
the peptide.  Statistical analysis was therefore not possible in these studies.   
Finally, although SH-SY5Y cells are a commonly used cell type in PD research and other 
neural drug delivery studies, they were not differentiated to their neuronal phenotype in this 
work.  Further studies using RDP and DAS on differentiated cells expressing neuronal 
characteristics would be appropriate for assessing the targeting ability of these peptides 
amongst neuronal populations for PD treatment.  Despite this limitation, the nAChRs required 
for peptide uptake are still present on undifferentiated SH-SY5Y cells. 
 
 
6.3.  Future impact 
 
Progress in PD research has been slow over recent decades due to the difficulties presented 
by the BBB and the lack of understanding surrounding PD pathology.  Many promising drug 
candidates have failed to achieve success in preclinical and clinical trials for varying reasons, 
however the inability to achieve effective drug delivery to the brain remains the biggest 
obstacle.  Ongoing studies contributing to our knowledge and understanding of PD will 
undoubtedly give rise to more therapeutic agents with the potential to target the cascade of 
detrimental oxidative stress within dopaminergic neurons, in addition to neurorestorative 
approaches with the use of neurotrophic growth factors.  The role of peptides such as RDP and 
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DAS within a drug delivery system to target the brain may crucially enhance the possibility of 
clinical success for new therapeutic agents. 
The derivation of DAS from RDP creates a neural-specific targeting ligand which can be easily 
incorporated into nanoparticulate drug delivery systems, affording a higher level of serum 
stability than the parent peptide.  Additionally, the development of an in vitro human-derived 
BBB model as presented in these studies, is useful for the early assessment of the targeting 
potential of such peptide-conjugated systems prior to in vivo testing.  This model is 
advantageous because, unlike the commercially available Pharmaco-Cell model from 
Nakagawa et al. (2009), it is isogenic in nature comprised only of non-immortalised human cell 
lines.  Although inter-species models have been successfully used in drug transport studies, it 
is advantageous to have an all human-derived model. The differences between interspecies 
BBB cells is not well known, however use of human cells may more accurately predict human 
in vivo responses to drugs and their delivery vehicles.     
RDP or derivatives such as DAS may prove beneficial in the pursuit of effective regenerative 
treatments for PD, providing a means of delivery for new therapeutics with curative potential.  
The in situ regeneration of dopaminergic neurons in the SNpc of the brain through non-invasive 
means is an attractive prospect for the treatment of PD.  To slow or indeed reverse the disease 
process would delay the gradual worsening of symptoms which patients endure during 
progression of the disease, improving the quality of life of those affected   Furthermore, these 
targeting ligands may also be useful in other brain-related disorders, as they ultimately provide 
a means of overcoming the restrictions of the BBB. 
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6.4.  Future work 
 
DAS is only one derivative from RDP which was shown to be effective from the results reported 
in this thesis.  In continued molecular modelling studies of RDP and DAS at the nicotinic 
acetylcholine receptor, identification of different RDP analogues and further optimisation of 
DAS may be possible.  Given the apparent safety and efficacy of DAS in vitro, progression to in 
vivo studies in an appropriate animal model is the next rational stage in the development of this 
ligand.  Firstly, assessment of the BBB transport efficacy of DAS in vivo using easily visualised 
NP payloads such as fluorescent dyes, would be necessary before commencing work in a PD 
model rodent.  Following satisfactory results from this work, DAS or other newly designed 
analogues of RDP could then be analysed for utility within neurotrophic factor-loaded 
nanoparticulate systems in PD model rodents.  NP loaded with therapeutic agents such as 
basic fibroblast growth factor could be functionalised with RDP-derived peptide ligands for 
delivery to Parkinsonian brain models in vivo.   
The in vitro BBB model developed in this work could also be optimised further, including 
detailed transport studies and expression of key BBB markers such as efflux transporters and 
other tight junction proteins from the claudin and occludin families.  
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Appendix 1  
 
1.5 M Tris Buffer pH 6.8 
18.17 g Tris base 
70 mL double distilled water 
Adjust to pH 6.8 with HCl 
Make up to 100 mL 
 
Laemmli sample treatment buffer (5x) 
2 mL Tris buffer pH 6.8 (1.5 M) 
5 mL glycerol 
2.5 mL mercaptoethanol 
1 g sodium dodecyl sulphate  
0.5 mL bromophenol blue (1%) 
 
Gel Stain 
 0.25 g Coomassie Brilliiant Blue  
10 mL glacial acetic acid 
45 mL methanol 
45 mL water 
 
Gel Destain 
25 mL glacial acetic acid 
150 mL methanol 
325 mL water 
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Appendix 2 
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Figure A2.1.  Zero order plot showing release kinetics of (A) myoglobin and (B) doxorubicin from PLGA 
NP at 37°C in PBS. 
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Figure A2.2.  First order plot showing release kinetics of (A) myoglobin and (B) doxorubicin from PLGA 
NP at 37°C in PBS. 
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Abstract 
In recent years, rabies virus-derived peptide (RDP) has shown promise as a specific 
neural cell targeting ligand, however stability of the peptide in human serum was 
unknown.  Herein, we report the molecular modelling and design of an optimised 
peptide sequence based on interactions of RDP with the 7 subunit of the nicotinic 
acetylcholine receptor (nAChR).  The new sequence, named DAS, designed around a 5-
mer sequence which demonstrated optimal nAChR binding in silico, showed greatly 
improved stability for up to 8 hours in human serum in comparison to RDP, which 
degraded within 2 hours at 37 °C.  In vitro analysis using SH-SY5Y neuroblastoma cells 
showed that DAS-conjugated nanoparticles containing the cytotoxic drug doxorubicin 
(DAS-Dox-NP) displayed significantly enhanced cytotoxicity compared with untargeted 
doxorubicin-loaded nanoparticles (Dox-NP).  DAS-Dox-NP had no significant effect on 
non-neural cell types, confirming its neural-specific targeting properties.  
 In this manuscript, we report the design and testing of an optimised peptide ligand, 
conjugated to a nanoparticulate delivery vehicle and specifically targeted to neural 
cells.. Future impact of an innovative targeting peptide ligand combining the ability to 
selectively identify the target and facilitate cellular internalisation could enable the 
successful treatment of many neural cell disorders. 
 
 
Key words: peptide targeting, nanoparticle, drug delivery, neural cell, RDP 
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Abbreviations 
DAS – newly designed targeting peptide 
DOX- doxorubicin 
DOX-NP – unlabelled doxorubicin-loaded nanoparticles 
α7 nAChR - nicotinic acetylcholine receptor alpha 7 subunit 
NP- nanoparticles 
PLGA- poly (lactic-co-glycolic) acid 
RDP- rabies virus derived peptide 
RDP-DOX-NP – RDP-labelled doxorubicin-loaded nanoparticles 
DAS-DOX-NP – DAS-labelled doxorubicin-loaded nanoparticles 
sc-DAS – scrambled version of the newly designed targeting peptide 
sc-DAS-DOX-NP – scrambled DAS-labelled doxorubicin-loaded nanoparticles 
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Introduction 
Specific targeting of therapeutics is a growing area of research for a number of different 
disease states.  The benefits of this over conventional drug delivery are numerous, 
including improved bioavailability of the drug at the target organ, reduction of 
unwanted side effects and smaller dosages required for therapeutic effect.  Cell 
penetrating peptides (CPPs) can greatly enhance the intracellular uptake of conjugated 
cargo across biological membranes in a non-invasive, non-disruptive manner.  
However, due to lack of tissue specificity, CPPs such as TAT (transactivating 
transcriptional activator) peptide, penetratin and polyarginine are not as efficient when 
aiming to deliver expensive or toxic drugs [1].  One group of diseases which are 
difficult to treat and may benefit from targeted delivery methods are neural cell 
disorders such as neuroblastoma [2-4] and neurosarcoma [5]. 
Neural cell-specific peptide targeting ligands have been explored in the past decade to 
deliver therapeutic agents in animal studies with success [6-10].  Many promising neural 
cell-specific targeting peptides take advantage of native receptors, transporters or 
enzymes to deliver therapeutic cargoes.  Derivatives from natural neurotoxic agents 
have been utilised due to their highly efficient transport abilities to nervous systems, 
such as tetanus toxin fragment C [11], neurotropic virus glycoproteins and fragments of 
snake, scorpion and bee venoms [10].  Thus far, promising results with these ligands are 
still surrounded with concerns of immune reactions and true specificity for neural cells 
only.  Kumar et al. [6] first showed that a derivative of rabies virus glycoprotein (RVG), 
RVG-29, utilised nicotinic acetylcholine receptor (nAChR) transport to safely and non-
invasively deliver siRNA to neuro-2a cells and mouse brain.  Following this success, 
derivatives of RVG have since been utilised to take advantage of this property for drug 
delivery to the CNS to treat a range of brain disorders [12-14].   
RVG found in the rabies virus envelope, is responsible for viral entry into the nervous 
system [15]. Rabies virus-derived peptide (RDP) is a 39-amino acid derivative of RVG, 
which has shown early success as a neural cell-targeting ligand both in vitro and in vivo 
[16-19].  In previous work [20], we reported that RDP is dependent upon interaction 
with the nAChR and activity was inhibited by blocking the homomeric α7 subtype of 
this receptor, commonly found throughout the nervous systems.  An obstacle in the 
development of many peptide targeting ligands is the issue of serum instability due to 
proteolysis, hence breakdown of the peptide upon systemic administration.  This is 
particularly true for larger sequences of amino acids, which may be more susceptible to 
enzymatic degradation in vivo.  Fu et al. [16] reported that the approximate in vivo half-
life of an RDP fusion protein in mice is only one hour.  The stability of RDP ligand 
alone in human serum has not yet been reported, however given its relatively large size 
it could be subject to stability issues in future studies.   
In this study, we report  the molecular modelling, design and development of an 
optimised neural cell-targeting sequence, which we have termed DAS, based on 
interactions of RDP with the neural 7 nAChR subunit.  Furthermore, we report the 
enhanced stability of DAS in human serum compared to RDP and highlight its ability to 
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specifically target neural cells with concomitant release of active nanoparticulate 
payloads.  
Materials and Methods  
 
Materials 
Resomer® RG 502 H, Poly(D,L-lactide-co-glycolide)-PLGA, acid terminated (MW 
7,000-17,000), dichloromethane (DCM), poly(vinyl) alcohol (PVA) 87-89% 
hydrolysed- MW  85,000-124,000, MES hydrate, 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC), N-hydroxysuccinimide (NHS), trichloroacetic acid (TCA), 
human serum from male AB plasma (USA origin), α-cyano-4-hydroxycinnamic acid 
(CHCA) matrix, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT), 
hexamethonium and mecamylamine were all purchased from Sigma-Aldrich (UK).  
RDP, DAS and scrambled DAS (sc-DAS) peptides were synthesised by GL Biochem 
(Shanghai) Ltd.  Nicotinic acetylcholine receptor-α7 antibody was purchased from 
Santa Cruz Biotechnology, Inc. (USA).  Doxorubicin hydrochloride was obtained from 
VWR International (Pennsylvania, USA). Tissue culture reagents and media were 
purchased from Gibco®/ Life Technologies.  Human cancer cell lines, SH-SY5Y 
(human neuroblastoma) and HeLa (human cervical cancer), were cultured in RPMI 
1640 medium as were the normal CHO (Chinese hamster ovary) cell line.  MDA-MB-
231 (human breast cancer) cells were cultured in DMEM medium.  Both RPMI 1640 
and DMEM media were supplemented with 10% foetal bovine serum and 1% 
penicillin-streptomycin (5,000U ml-1/5,000 µg ml-1).  All other chemicals were of 
analytical grade. 
 
Design of novel targeting peptide 
Step 1 Protein-ligand docking 
Potential interactions between RDP and the α7 homomeric nAChR were explored, using 
α-subunit residues 173-204 as a starting point in this study.  Original rabies virus 
glycoprotein (RVG) is reported to bind to these residues of the α1 nAChR subunit found 
at the neuromuscular junction (NMJ), hence facilitating the entry of the rabies virus into 
the nervous system [21, 22].  The coordinates of the neuronal nAChR α7 subunit, 
acetylcholine-binding protein were obtained from the Protein Databank entry 3SQ6, 
chain A [23].  This was imported into CACHe Worksystem Pro (version 7.5.0.85; 
Fujitsu Ltd).  Hydrogen atoms were added using the default settings in line with 
presumed protonation states for ionisable amino acid side-chains.  The positions of the 
added hydrogen atoms were optimised by locking the coordinates of all the non-
hydrogen atoms and subjecting the system to a molecular mechanics (MM2) geometry 
optimisation. The 30-mer of RDP, KSVRTWNEIIPSKGCLRVGGRCHPHVNGGG, 
was divided into all possible contiguous ten amino acid fragments (residues 1-10; 2-11; 
3-12 etc.) and each docked four times, using CACHe Worksystem Pro, into the 
303 
 
 
 
prepared protein structure from 3SQ6 where the potential active site was defined as 
residues 173 – 204.  The amino acid side-chains in the defined active site were allowed 
to be flexible as were all rotatable bonds in the 10-mer proteins.  The genetic algorithm 
settings for the docking protocol included population size 50, maximum generations 
3000, crossover rate 0.8, mutation rate 0.2 and convergence when the RMSD population 
fitness was less than 1.  
 
Step 2 Molecular dynamics simulations 
The input files for molecular dynamics simulations of the docked protein-ligand 
complexes were prepared using the Antechamber module of the AMBER Tools package 
(Version 14) [24], implementing the ff14SB force field.  Disulphide bonds were 
enforced between the receptor residue pairs 125 & 138 and 186 & 187.  The system was 
neutralised by addition of sodium ions and then solvated within a truncated octahedron 
of TIP3P water molecules extending 8 Å from the surface of the protein.  Using the 
Amber 14 molecular dynamics package CUDA version [25-27], the system was energy-
minimised for 2,000 cycles using a non-bonded cut-off of 12 Å and then heated under 
constant volume to 300 K over 25 ps under Langevin dynamics (time step = 1 fs).  The 
heating was continued at 300 K for a specified period under constant pressure also using 
Langevin dynamics (SHAKE on, time step = 2 fs) using the Particle–Mesh–Ewald 
(PME) method to treat the long range electrostatic interactions with a 12 Å non-bonded 
cut-off.  
 
Step 3 Peptide design 
Residues of interest from RDP (GCLRV) were identified from the work carried out in 
section 2.2.1- 2.2.2 and were subsequently incorporated into the design of a new 
peptide.  A widely used flexible linking sequence -GGGGS- was subsequently added to 
the GCLRV sequence as a spacer in the design of a new peptide [28], to allow freedom 
of movement once conjugated to PLGA NP.  Finally, two glycine residues followed by 
an arginine tail consisting of 6 alternating L- and D- arginine residues –GGRrRrRr- 
were also added to the sequence for enhanced stability and resistance to metabolic 
processes [29].  The new D-arginine-containing 18-amino acid sequence, which we 
have termed DAS, was NH2-GGGGSGCLRVGGRrRrRr-COOH. 
 
Serum stability of RDP and DAS peptides 
Peptide stability testing in human serum was carried out according to a previously 
detailed method [30].  Briefly, human serum was diluted to 25% with phosphate 
buffered saline (PBS) and subsequently centrifuged at 18809 g for 10 minutes to 
remove lipids, before incubating at 37°C.  RDP and newly derived peptide, DAS, were 
prepared so that final serum peptide concentration was 10 µM prior to incubation at 
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37°C.  A 200 µL aliquot was removed from each serum-peptide mixture at various time 
points and reacted with 40 µL of 15% TCA for 15 minutes at 4°C to remove larger 
serum proteins.  The collected samples were centrifuged at 18809 g to remove 
precipitated serum proteins for 10 minutes and supernatant collected for storage at -
20°C.  Samples were analysed by MALDI-TOF mass spectrometry (PerSeptive 
Biosystems Voyager-DE Biospectrometer, Herefordshire UK).  A 10 µL aliquot of 
serum sample was mixed with 10 µL of CHCA matrix (10 mg/mL fully dissolved), 1.5 
µL of which was used for analysis.  The mass/charge ratio (m/z) was plotted against 
relative abundance. 
 
Preparation of nanoparticles and conjugation of peptide to nanoparticles 
Doxorubicin-loaded PLGA nanoparticles (Dox-NP) were prepared by a double 
emulsion technique and characterised according to methods previously described by this 
group [20].  FITC-Dextran-loaded PLGA nanoparticles (FITC-NP) for confocal 
fluorescence imaging were also prepared and characterized using the method previously 
described in [20] using 4 mg of FITC-Dextran per 100 mg of PLGA polymer.  
Entrapment efficiency (EE) of FITC-Dextran and doxorubicin in NP was determined 
using fluorescence spectroscopy (excitation 485 nm, emission 520 nm) and UV-Vis 
absorbance (480 nm) respectively, on a FLUOstar Omega microwell plate reader (BMG 
Labtech, Germany).  
𝐸𝐸 =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑁𝑃 
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑
 𝑥 100% 
 
Peptides were conjugated to nanoparticles according to methods previously described 
by this group [20].   
 
In vitro assays 
Initial studies suggested that the presence of serum in the cell-based assay medium had 
minimal influence on the results of DAS-conjugated NP treatment (see Appendix 3). 
Therefore all assays were carried out in serum free medium to minimise possible 
interference associated with serum proteins in in vitro assays. 
 
 
In vitro cellular uptake study 
Cellular uptake of FITC-NP preparations were evaluated in SH-SY5Y and HeLa cell 
lines using a Leica SP5 confocal microscope (x 63,000 magnification).  Cells were 
seeded onto 13 mm glass coverslips at a concentration of 1x105 cells/mL (500 µL) and 
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cultured in complete RPMI media at 37°C/5% CO2 overnight.  All existing media was 
aspirated and the cells were treated with 1 mg/mL (500 µL) of either FITC-NP, RDP-
FITC NP or DAS-FITC NP in serum free media (SFM) for 24 hours whilst incubating 
at 37°C/5% CO2.   Prior to imagining, all cells including controls were treated with 75 
nM Lysotracker red in serum free media (SFM) for 30 minutes to visualise lysosomes in 
cells and track potential co-localisation with NP along the cellular internalisation 
pathway.   FITC fluorescence emission was collected between 510- 550 nm (excitation 
wavelength 490 nm).  Lysotracker emission was collected separately between 590-650 
nm (excitation wavelength 580 nm).  
 
In vitro cytotoxicity study  
SH-SY5Y cells were plated out at a concentration of 1x105 cells/mL (96 well plate) in 
complete RPMI media and incubated at 37°C/5% CO2 for 16 hours.   A range of DAS 
Dox-NP concentrations were initially tested to determine the most effective 
concentration to use for subsequent assays.  All existing media was aspirated and the 
cells were then treated with 100 µL of serum free media (SFM) and either 60 µL of a 4 
mg/mL NP suspension (final concentration 1.5 mg/mL) or an equivalent concentration 
of free peptide.  Control wells were treated with serum-free media only.  Cell viability 
was assessed after incubating for 24 hours (37°C/5% CO2), using an MTT assay.  To 
calculate cell viability, 25 µL of MTT (5 mg/ml) in PBS was added to each well on top 
of media and incubated at 37°C/5% CO2 for 2 hours.  After this, all media was aspirated 
and cells solubilised with 70 µL of DMSO per well.  UV-Vis absorbance was read at 
570 nm and cell viability calculated.  To assess targeting specificity to neural cells, NP 
treatment was also added to non-neural cell lines CHO, HeLa and MDA-MB-231 
according to the same protocol.  The cytotoxic effect of a scrambled version of DAS 
(NH2-RVGGCSGGGGGLRrRrRr-COOH) conjugated to Dox-NP (scDAS-Dox NP) 
was also assessed in SH-SY5Y cells.   
We demonstrated previously that RDP function could be blocked with nAChR 
inhibitors [20].  To determine whether nAChR antagonists would affect the activ ity of 
DAS, SH-SY5Y cells were first preincubated for 30 minutes with either 1 mM 
hexamethonium (competitive), 1 mM mecamylamine (non-competitive) or anti- 
AChRα7 antibody (1:100 dilution), all in serum-free medium, prior to addition of Dox-
NP or DAS-Dox NP, using the method described above.  
 
Statistical Analysis 
All results reported were statistically analysed using an unpaired t-test. A p value of < 
0.05 was considered statistically significant.   
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Results 
Design of novel targeting peptide 
A model of the receptor was built using the X-ray crystal structure coordinates from the 
Protein Databank, entry 3SQ6, chain A [23].  For the purposes of the docking 
experiments the active site was defined as residues 173 – 204. The 30-mer RDP peptide 
was divided into all possible contiguous ten amino acid fragments (residues 1-10; 2-11; 
3-12 etc.) and docked into the receptor.  The 10-mer fragments were allowed full 
rotational flexibility as were the side-chains of the amino acids in the receptor active 
site.  Each fragment was docked four times using a genetic algorithm protocol and the 
complexes were scored using potential of mean force (PMF: given in kcal/mol).  Since 
the genetic algorithm uses an initial random number seed, the best (lowest energy) 
result only is reported for each 10-mer fragment in Table 1.  [Table 1 near here].  The 
10-mer fragment that gave the best binding enthalpy score (PMF energy) comprised 
residues 9-18 (IIPSKGCLRV).  The best-scoring complex from this fragment was 
subjected to molecular dynamics in explicit water for 100 ns.  After the first 50 ns of 
simulation it was noticed that not all of the 10-mer was interacting with the receptor.  
Residues 9 – 12 (IIPS) in particular were positioned on average orthogonal to the 
receptor surface and engaged with water molecules.  A snapshot at 92 ns is shown in 
Figure 1 [Figure 1 near here].  .  
Consequently, the initial receptor IIPSKGCLRV complex was cut down to a version 
containing residues 14-18 (GCLRV) and this complex was subjected to molecular 
dynamics in explicit water for 100 ns.  After a settling period of approximately 60 ns, 
the GCLRV fragment adopted a fairly stable conformation (RMSD plot shown in 
Appendix 1) on the surface of the receptor with each amino acid, except for the N-
terminal glycine, making hydrogen bonding interactions.  Hydrophobic interactions 
with the receptor were also observed for the leucine and the valine residues in this 
fragment.  A two-dimensional view of the receptor-GCLRV interactions can be found in 
Appendix 2.  A new peptide (DAS) incorporating the GCLRV fragment from RDP was 
designed accordingly, consisting of 18 amino acids (GGGGSGCLRVGGRrRrRr) as 
described earlier in this report. 
 
Serum stability of RDP and DAS peptides 
RDP and DAS were incubated in 25% human serum at 37°C and then analysed by 
MALDI-TOF mass spectrometry to determine stability (Figure 2) [Figure 2 near here].  
.  RDP with no prior incubation (Figure 2B) gave rise to a peak consistent with its 
molecular weight of 4.6 kDa.  Upon incubation in serum for 2 hours intact RDP was no 
longer detectable, however a new signal was detected between 2.7-3.2 kDa, most likely 
to be RDP breakdown fragments (Figure 2C).  A minimal trace of RDP remained in 
Figure 2D, suggesting RDP and its degradation products had continued to degrade over 
8 hours.  Fully intact DAS expectedly gave rise to a peak at around 1.9 kDa indicated in 
Figure 2E, prior to incubation at 37°C.  After 2 hours of incubation, approximately 60% 
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of the signal remained, as shown in Figure 2F.  After 8 hours in serum, a small amount 
of intact DAS remained as indicated (Figure 2G).  Over the time course observed the 
new 18-mer peptide, DAS, was more resistant to degradation by serum proteases than 
RDP. 
 
Characterisation of NP preparations 
Particle size, zeta potential, drug content and peptide conjugation efficiency of the 
formulations are shown in Table 2.  PLGA NP were successfully loaded with either 
cytotoxic doxorubicin or FITC-Dextran with entrapment efficiencies of 64% and 77% 
respectively.  [Table 2 near here]. 
 
In vitro cellular uptake 
Visualisation of FITC-NP uptake by confocal fluorescence microscopy (Figure 3) 
demonstrates the ability of both RDP and DAS to preferentially target SH-SY5Y neural 
cells and promote cellular uptake compared to the untargeted FITC-NP [Figure 3 near 
here].  .  In contrast, detected fluorescence signal was low in Hela cells and no notable 
difference in cellular uptake was observed between all formulations, indicating that 
RDP and DAS do not function as targeting peptides in this non-neural cell line.  
Furthermore, the signal detected by Lysotracker red indicates that there may be co-
localisation of lysosomes and internalised FITC-NP in SH-SY5Y cells.   
 
 
In vitro cytotoxicity study  
The IC50 of DAS Dox-NP was calculated to be 0.9 mg/mL (Figure 4) [Figure 4 near 
here]. Figure 5 A shows the effect of DAS conjugation to Dox-NP in SH-SY5Y neural 
cells. Treatment with DAS-Dox NP caused a significant enhancement in SH-SY5Y 
cytotoxicity, as cell viability decreased to 60.0% (± 6.0% SD) compared with 82.7% (± 
4.0% SD) when treated with untargeted Dox-NP.  Figure 5 A also shows that neither 
free RDP nor free DAS peptides caused any significant decrease in cell viability.  In 
addition, when a scrambled version of the DAS peptide was conjugated to Dox NP (sc-
DAS-Dox NP), there was no significant decrease in cell viability compared to 
untargeted Dox-NP treatment [Figure 5  near here].  . 
Figure 5 B shows the effect of preincubating SH-SY5Y cells with the nAChR 
antagonists hexamethonium, mecamylamine and anti- AChRα7 antibody.  Pretreatment 
with all of the antagonists inhibits the cytotoxic effects of DAS-DOX-NP.  These results 
suggest that DAS is facilitating uptake of cytotoxic NP through mechanisms involving 
the nAChR. 
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The effects of DAS-DOX-NP on the non-neural cell lines HeLa, MDA-MB-231 and 
CHO are shown in Figure 6  [Figure 6  near here].  .  The cell viabilities for the normal, 
non-neural CHO cells and the cancer cell lines HeLa and MDA-MB-231 ranged 
narrowly from 62%-75% between all NP-treated groups. In the neural cell line SHSY-
5Y however, both RDP and DAS promote susceptibility of the cells to the cytotoxic 
effects of Dox-NP showing a statistically significant decrease in cell viability for both 
RDP-Dox NP (59.7% ± 4.7% SD) and DAS-Dox NP (62.0% ± 9.8% SD) formulations 
compared to the untargeted Dox-NP (75.0% ± 7.1% SD). 
 
Discussion 
 
RDP is a peptide with a molecular weight of 4.6 kDa and, as such, its size may make it 
prone to proteolysis by serum proteases, which would severely limit its in vivo targeting 
ability and application.  Therefore, design of a smaller and more proteolytically resistant 
peptide, which retains the sequence essential for binding to the nAChR, could be very 
beneficial.  In earlier work, we reported that RDP requires the nAChR for function [20].  
In this current work we modelled for interactions between RDP and the α7 nAChR 
subunit (which is specific to neural nAChR) [31] and uncovered a 5-amino acid section 
of the RDP sequence, -GCLRV-, which displays strong interactions with the α7 nAChR 
subunit and has potential for development as a new targeting sequence.  The addition of 
poly-arginine residues to a peptide has shown to promote water solubility and confer 
highly effective cell penetrating properties to a conjugated cargo whilst prolonging 
circulation time [29,32], therefore we included six arginine residues at the C terminal of 
the new peptide and included half of them as the protease-resistant D amino acid.  In 
doing this, the whole peptide should be less vulnerable to serum proteases and 
negatively charged plasma proteins, an effect which Liu et al. reported as similar to 
pegylation [32].  We also added the linker sequence -GGGGS- to the N terminal of the 
peptide, as described in the methods section, to allow free movement of the peptide 
once conjugated to the NP. 
The reported use of RDP as a neural cell-specific targeting ligand both in vitro and in 
vivo has been a promising step towards facilitating delivery of therapeutics to neural 
cells [16-19].  However, there have been no reports on the stability of RDP in serum, 
with a previous stability study looking at RDP-conjugated nanoparticles concentrating 
on the stability of the payload and not the targeting peptide [33]. 
In this report, we have shown for the first time that RDP breaks down when incubated 
with human serum at 37°C within 2 hours (Figure 2C).  Although this may be long 
enough to demonstrate an effect in vivo, it would be desirable to optimise the peptide 
sequence to make it less prone to enzymatic degradation in serum.  If serum half-life 
could be extended then potential in vivo dosing would be lower and less frequent, which 
is preferable when utilising expensive or toxic therapeutic payloads.  Our findings show 
that the new DAS peptide displays a considerable improvement in stability 
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characteristics compared to RDP, with mass spectrometry analysis detecting intact DAS 
peptide up to 8 hours after incubation in human serum at 37°C (Figure 2G).  D-amino 
acids, such as the D-arginine residues incorporated into DAS, have been used to 
improve the proteolytic resistance of peptides successfully within the area of drug 
delivery due to their ability to avoid quick metabolism [29,34].  There have also been 
many reports in the literature on the use of D-amino acid substitutions to promote serum 
stability of targeting peptides which aligns with the results reported here [35-39].   
In a previous publication, we demonstrated the use of RDP as a targeting ligand which 
enhanced the uptake of a conjugated nanoparticulate payload to induce cytotoxic effects 
in SH-SY5Y cells [20].  These findings are further supported by the confocal 
fluorescence images presented in Figure 3, which show RDP and DAS both facilitate 
NP uptake into neural cells specifically.  It has been suggested by Fu et al. [17], that the 
cellular uptake mechanism of RDP may involve energy-dependent internalisation 
pathways such as clathrin-dependent endocytosis.  Indeed, observations of co-
localisation between RDP and DAS conjugates with lysosomes in our findings support 
this idea (Figure 3).  In addition, we have also demonstrated that, like RDP, DAS 
significantly enhances cytotoxicity of Dox-NP in SH-SY5Y cells compared to 
untargeted DOX-NP and both free RDP and DAS peptides, which are non-toxic (Figure 
5 A).  When a scrambled version of DAS was conjugated to Dox NP (sc-DAS-Dox NP), 
there was no enhancement in cytotoxicity compared to untargeted Dox-NP treatment 
(Figure 5 A) demonstrating the necessity to retain the original –GCLRV- targeting 
sequence derived from RDP. 
We also reported previously that nAChR antagonists prevented RDP action in SH-
SY5Y cells [20] and the same inhibitors were employed to observe their effect on DAS 
peptide action.  Mecamylamine, hexamethonium and antibody against 7 subunit of 
homomeric neuronal nAChR were able to block the effects of DAS-DOX-NP 
confirming that DAS does indeed bind to neuronal nAChR in the same way as RDP 
(Figure 5 B).     
The results displayed in Figure 6 confirm the specific action of DAS as a neural cell-
targeting ligand as it had no significant effect in three non-neural cell lines (HeLa, 
MDA-MB-231 and CHO).    
In conclusion, the results described herein demonstrate that using molecular modelling 
and peptide design we have created a novel, bespoke neural cell nAChR targeting 
peptide, which we have termed DAS.  This peptide displays an enhancement in serum 
stability whilst retaining neural cell specificity, and aids efficient cellular uptake and 
release of nanoparticle payloads.  This targeted delivery system has potential for use in 
delivering therapeutics in a more specific manner to neural cells.  
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Table 1. PMF docking scores for the 10-mer fragments ranked in order of score. 
 
Fragment 
PMF Docking 
Score 
(kcal/mol) 
9_18 -815.10 
17_26 -804.66 
10_19 -791.05 
12_21 -779.10 
16_25 -767.22 
11_20 -763.91 
14_23 -754.99 
8_17 -753.55 
4_13 -752.98 
21_30 -742.21 
1_10 -728.43 
18_27 -728.35 
7_16 -723.68 
13_22 -723.66 
2_11 -721.83 
6_15 -712.65 
19_28 -703.93 
20_29 -702.34 
5_14 -693.11 
3_12 -682.99 
15_24 -639.01 
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Table 2. PLGA nanoparticle characterisation parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Snapshot at 92 ns from the molecular dynamics simulation of fragment IIPSKGCLRV (stick 
form) with the nicotinic acetylcholine receptor (ribbon form). Residues IIPS are not in contact with the 
receptor surface.   
NP sample Sizea 
(d.nm) 
 ZPa 
(mV) 
DCb 
(µg/mg) 
RDPc 
(µg/mg) 
DASd 
(µg/mg) 
 
Dox-NP 
 
242.7 ± 18.6 
 
-14.6 ± 1.3 
 
12.8 
 
53.6 
 
23.2 
 
 
 
FITC-NP 
 
286.5 ± 11.3 -10.3 ± 1.0 30.8 97.2 43.9 
aSize and zeta potential (ZP) reported as average of three measurements ± standard 
deviation. bDC= drug content per 1 mg of NP based on entrapment efficiencies of 
64% (Dox) and 77% (FITC); cRDP content per 1 mg of NP based on conjugation 
efficiency of 54% to Dox-NP and 73% to FITC-NP.  dDAS content per 1 mg of NP 
based on conjugation efficiency of 58% to Dox-NP and 88% to FITC-NP.   
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(A) Serum 
 
 
 
 
 
 
 
 
 
 
 
(B) RDP- T=0 
 
 
 
 
 
 
 
 
 
 
(C) RDP- T=2h 
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(D) RDP- T=8h 
 
 
 
 
 
 
 
 
 
 
 
(E) DAS- T=0 
 
  
 
 
 
 
 
 
 
 
 
(F) DAS- T=2h 
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(G) DAS- T=8h 
 
 
 
 
 
 
 
 
 
 
Figure 2.  MALDI-TOF mass spectrometry analysis of peptide stability in 25% human serum at 37°C for 
various periods of time.  (A) Human serum with no peptide.  Profile detected for RDP (MW approx. 
4.8kDa) in serum at time zero (B), 2 hours (C) and 8 hours (D) post incubation.  Peaks for intact peptide 
are indicated by a circle on the intensity/mass traces.  DAS peaks (MW approx. 1.9kDa) for the same time 
points are shown (E)-(G) respectively.   
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Figure 3. Confocal images showing the effect of RDP and DAS labelling on the cellular uptake of FITC-
NP (green) in (A) SH-SY5Y cells and (B) HeLa cells.   
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Figure 4.  Determination of IC50 of DAS-DOX-NP on SHSY-5Y cells. 
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(A) 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
Figure 5. SH-SY5Y human neuroblastoma cell viability following treatment with (A) DAS-conjugated 
doxorubicin-loaded NP (DAS-Dox NP) compared to free peptide and unlabelled doxorubicin NP (Dox-
NP) and scrambled DAS NP.  Control samples were treated with serum-free media only.  (B) Effect of 
nAChR antagonists hexamethonium (Hex) and mecamylamine (Mec) and antibody directed against 
alpha-7 subunit of homomeric neuronal nAChR (7-AB) on DAS ligand activity on SH-SY5Y neural 
cells.  * Statistically significant difference compared to Dox-NP (P value < 0.05).  
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Figure 6. Effect of peptide targeting ligands RDP and DAS on doxorubicin-loaded NP toxicity towards 
non-neural cell lines HeLa, CHO and MDA-MB-231 compared to SH-SY5Y neural cells. Control groups 
were treated with serum-free media only.  * Statistically significant difference compared to Dox-NP (P 
value < 0.05). 
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Appendix 1 
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RMSD (Å) of the fragment GCLRV throughout a 100 ns molecular dynamics 
simulation in complex with the receptor, referenced to the simulation frame at 
75 ns. 
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Appendix 2 
 
 
 
 
 
 
Two-dimensional view of the receptor-ligand interactions for GCLRV at 74 ns in the 
molecular dynamics simulation 
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Appendix 3 
 
Cell viability of SH-SY5Y neuroblastoma cells following NP treatment in either serum-free medium 
(SFM) or with medium containing foetal bovine serum (complete).  Control groups were treated with 
either SFM or complete media only.  Cell toxicity was assessed by MTT assay following 24 hours of 
treatment at 37°C.  *Statistically significant difference compared to Dox NP treatment (P value <0.05, 
n=6). 
 
 
